

Federal Office of Public Health FOPH Health and Accident Insurance Directorate Section Health Technology Assessment

Health Technology Assessment (HTA)

Scoping Report

Title	Long-term physiotherapy in patients after stroke, with multiple sclerosis, or with Parkinson's disease
Authors	Alvin Atlas ¹ , Konstance Nicolopoulos ¹ , Anna Ali ^{1,2} , Ross McLeod ^{1,3} , Thomas Vreugdenburg ¹ ¹ The Royal Australasian College of Surgeons ² The University of Adelaide ³ eSys Development

Bundesamt für Gesundheit Sektion Health Technology Assessment Schwarzenburgstrasse 157 CH-3003 Bern Schweiz

Tel.: +41 58 462 92 30 E-mail: hta@bag.admin.ch

Technology	Long-term physiotherapy
Date	29 April 2021
Type of Technology	Medical procedure (Allied health)

Executive Summary

The Swiss Federal Office of Public Health is re-evaluating the reimbursement of long-term physiotherapy, defined as more than 36 physiotherapy sessions (4 bouts of 9 sessions each). This report aims to determine the feasibility of conducting a health technology assessment (HTA) of long-term physiotherapy in patients after stroke, with multiple sclerosis (MS), or with Parkinson's disease (PD) based on clinical, economic, legal, social, ethical and organisational data identified during the scoping phase. The comparison of interest to the policy question is long-term physiotherapy compared to short-term physiotherapy. Supplementary comparisons between long-term physiotherapy and other comparators (i.e. placebo, sham, usual care and best possible care) were also sought.

A literature search was conducted in seven biomedical databases and supplemented with searches of HTA databases and specialty websites. From the 14,878 search results, no systematic reviews or randomised controlled trials were identified that investigated the policy question (i.e. long versus short-term physiotherapy). Twelve systematic reviews comparing long-term physiotherapy to any other long-term comparator were identified, of which 10 were conducted in stroke and 2 were in PD; no reviews on long-term physiotherapy for MS were identified. The searches also identified 13 social, 2 ethical and 3 organisational-related studies. Thirteen existing economic evaluations broadly matching the PICO criteria were identified; however, their applicability to the Swiss context was limited. No legal studies were identified.

There is currently no available data to undertake an HTA on the effectiveness, safety and costeffectiveness of long-term physiotherapy compared to short-term physiotherapy in patients after stroke, with MS or PD.

Zusammenfassung

Das Schweizer Bundesamt für Gesundheit überprüft die Rückerstattung von Langzeit-Physiotherapien mit mehr als 36 Physiotherapie-Sitzungen (4 Zyklen zu je 9 Sitzungen). Der Bericht soll die Machbarkeit einer Gesundheitstechnologiebewertung (Health Technology Assessment HTA) der Langzeit-Physiotherapie bei Patientinnen und Patienten nach einem Schlaganfall, mit Multipler Sklerose (MS) oder mit Parkinson-Erkrankung (PD) prüfen. In der Scoping-Phase werden dazu die klinischen, wirtschaftlichen, rechtlichen, sozialen, ethischen und organisatorischen Daten erhoben. Der vorliegende Bericht vergleicht Langzeit-Physiotherapie mit Kurzzeit-Physiotherapie. Ergänzende Vergleiche zwischen Langzeit-Physiotherapie und andere Komparatoren (d. h. Placebo, Scheinbehandlung, übliche Versorgung und bestmögliche Versorgung) wurden ebenfalls einbezogen.

Es wurde eine Literaturrecherche in sieben biomedizinischen Datenbanken durchgeführt und durch Recherchen in HTA-Datenbanken und auf fachspezifischen Websites ergänzt. Bei den 14 878 Suchergebnissen wurden keine systematischen Übersichten oder randomisierte kontrollierte Studien gefunden, die die politische Fragestellung (d. h. Langzeit- versus Kurzzeit-Physiotherapie) untersuchten. In 12 systematischen Übersichtsarbeiten wurde eine Langzeit-Physiotherapie mit anderen Langzeit-Therapien verglichen, von denen 10 bei Schlaganfall und 2 bei Parkinson-Erkrankung durchgeführt wurden; zur Langzeit-Physiotherapie bei MS wurden keine Übersichtsarbeiten gefunden. Weiter wurden 13 soziale, 2 ethische und 3 organisationsbezogene Studien gefunden. Zudem konnten 13 bestehende ökonomische Evaluationen identifiziert werden, die weitgehend den PICO-Kriterien entsprachen; ihre Übertragbarkeit auf den Schweizer Kontext war jedoch begrenzt. Es wurden keine juristischen Studien gefunden.

Derzeit sind keine Daten verfügbar, um ein HTA zur Wirksamkeit, Sicherheit und Wirtschaftlichkeit von Langzeit-Physiotherapien im Vergleich zu Kurzzeit-Physiotherapien bei Patientinnen und Patienten nach Schlaganfall, mit MS oder Parkinson durchzuführen.

Résumé

L'Office fédéral de la santé publique (OFSP) réévalue actuellement le remboursement de la physiothérapie de longue durée, soit au-delà de 36 séances (quatre séries de neuf séances). Sur la base de données liées aux aspects cliniques, économiques, juridiques, sociaux, éthiques et organisationnels recueillies lors de la phase de *scoping*, le présent rapport vise à déterminer s'il est possible ou non de procéder à une évaluation des technologies de la santé (ETS ou HTA pour *health technology assessment*) sur la physiothérapie de longue durée de personnes qui ont eu une attaque cérébrale ou qui sont atteintes d'une sclérose en plaques ou de la maladie de Parkinson. Il s'agit de comparer la physiothérapie de longue durée au traitement de courte durée. Des recherches sur la physiothérapie de longue durée en parallèle à d'autres comparateurs (p. ex. placebo, traitement fictif, traitement habituel et meilleur traitement possible) ont également été effectuées.

Des recherches documentaires ont été menées dans sept bases de données biomédicales, en conjonction avec des bases de données dédiées aux ETS et des sites Internet spécialisés. Parmi les 14 878 résultats de la recherche n'ont identifié aucune revue systématique et aucun essai randomisé contrôlé portant sur la politique en la matière (p. ex. comparaison entre la physiothérapie de longue durée et le traitement de courte durée). Douze revues systématiques qui comparaient la physiothérapie de longue durée à d'autres comparateurs de longue durée ont été identifiées. Parmi ces revues, dix traitaient des attaques cérébrales et deux abordaient la maladie de Parkinson. Aucune revue sur la physiothérapie de longue durée chez les personnes atteintes d'une sclérose en plaques n'a été identifiée. Par ailleurs, les recherches ont permis de repérer treize études portant sur les aspects sociaux, deux études sur les aspects éthiques et trois études sur les questions organisationnelles. Treize évaluations sur l'aspect économique répondant généralement aux critères de PICO (*Patient Intervention Comparison Outcome*) ont été identifiées. Toutefois, leur applicabilité au contexte suisse était limitée. Aucune étude traitant des aspects juridiques n'a été repérée.

Il n'existe actuellement aucune donnée qui permettrait de mener une ETS pour étudier l'efficacité, la sécurité et le rapport coût-efficacité de la physiothérapie de longue durée comparée à la physiothérapie de courte durée chez les personnes qui ont eu une attaque cérébrale ou qui sont atteintes d'une sclérose en plaques ou de la maladie de Parkinson.

Executive Summary

L'Ufficio federale della sanità pubblica sta rivalutando la rimunerazione della fisioterapia di lunga durata, ossia quella oltre le 36 sedute (4 prescrizioni di 9 sedute ciascuna). Il presente rapporto ha lo scopo di verificare la fattibilità di condurre valutazioni delle tecnologie sanitarie (HTA) concernenti la fisioterapia di lunga durata in pazienti colpiti da ictus, da sclerosi multipla o dal morbo di Parkinson, sulla base di dati clinici, economici, legali, sociali, etici od organizzativi identificati durante la fase di scoping. Per quanto riguarda i fattori relativi alla rimunerazione, si tratta di comparare la fisioterapia di lunga durata con quella di breve durata. Sono stati inoltre effettuati ulteriori paragoni tra la fisioterapia di lunga durata ed altri elementi (p. es. placebo, un trattamento simulato, il trattamento usuale e il trattamento migliore possibile).

Una ricerca bibliografica è stata condotta in sette banche dati di biomedicina ed ulteriori ricerche sono state effettuate nelle banche dati HTA e in siti web specialistici. Dai 14 878 risultati di ricerca non emergono revisioni sistematiche o studi controllati randomizzati che indagano la questione della rimunerazione (p. es. fisioterapia di lunga durata vs. fisioterapia di breve durata). Sono state ritrovate 12 revisioni sistematiche che confrontano la fisioterapia di lunga durata con ogni elemento di lunga durata, 10 delle quali condotte su pazienti colpiti da ictus e due in pazienti con il morbo di Parkinson; non sono state riscontrate revisioni sulla fisioterapia di lunga durata in malati di sclerosi multipla. Dalle ricerche sono inoltre risultati 13 studi vertenti su aspetti sociali, 2 studi su aspetti etici e 3 su aspetti organizzativi. Sono state reperite 13 valutazioni economiche che rispondono ampiamente ai criteri del modello PICO (*Patient Intervention Comparison Outcome*), ma che si applicano solo limitatamente al contesto svizzero. Non sono stati reperiti studi su aspetti legali.

Al momento non esistono sufficienti dati per effettuare una HTA sull'efficacia, la sicurezza e l'economicità della fisioterapia di lunga durata comparata a quella di breve durata in pazienti colpiti da ictus, da sclerosi multipla o dal morbo di Parkinson.

Table of contents

1	Policy question and context			
2	Research question			
3	Med	ical background	2	
	3.1	Medical context and disease description	2	
4	Tecl	nnology	7	
	4.1	Technology description	7	
	4.2	Alternative technologies	10	
5	PIC	D	11	
	5.1	Population	11	
	5.2	Intervention	11	
	5.3	Comparator	11	
	5.4	Outcomes	11	
6	НТА	key questions	18	
7	Meth	nodology literature search	19	
	7.1	Databases and search strategy	19	
	7.2	Study selection	19	
8	Synt	hesis of evidence base	21	
	8.1	Overall search results	21	
	8.2	Evidence base pertaining to efficacy, effectiveness and safety	21	
	8.3	Evidence base pertaining to costs, cost-effectiveness and budget impact	25	
	8.4	Evidence base pertaining to legal, social and ethical issues	29	
	8.5	Evidence base pertaining to organisational issues	31	
9	Feas	sibility HTA	32	
10	Refe	erences	33	

11	Appendix A: Search results (databases)	. 43
	11.1 Search results	. 43
	11.2 Search strings	. 43
12	Appendix B: Characteristics of included trials	. 64
	12.1 Efficacy studies	. 64
	12.2 Safety studies	. 70
13	Appendix C: Economic evaluation study extraction	. 71
14	Appendix D: List of excluded trials at full text	. 76

Abbreviations and acronyms

ADL	Activities of daily living	
BBS	Berg's Balance Scale	
CHF	Swiss francs	
CIS	Clinically isolated syndrome	
CNS	Central nervous system	
СТ	Computed tomography	
EAE	Effectiveness, appropriateness, economic efficiency	
EQ-5D	EuroQol-5D	
FOPH	Federal Office of Public Health	
НТА	Health technology assessment	
HRQoL	Health-related quality of life	
MS	Multiple sclerosis	
MRI	Magnetic resonance imaging	
PD	Parkinson's disease	
PEDro	Physiotherapy Evidence Database	
PICO (EO)	Population, intervention, comparator, outcome, (economic outcomes)	
PPMS	Primary progressive multiple sclerosis	
QALY	Quality-adjusted life years	
QoL	Quality of life	
RCT	Randomised controlled trial	
RRMS	Relapsing-remitting multiple sclerosis	
SF-6/-12/-36	Short Form-6/-12/-36	
SPMS	Secondary progressive multiple sclerosis	
SR	Systematic review	
TIA	Transient ischaemic attack	
UK	United Kingdom	
USA	United States of America	
WHO	World Health Organization	

Figures

Figure 1	PRISMA flow chart for study inclusion
Tables	
Γable 1	Risk factors for ischaemic and haemorrhagic stroke2
Γable 2	Common signs and symptoms of stroke
Γable 3	Description of MS disease course
Γable 4	Physiotherapy interventions for stroke impairments8
Γable 5	Physiotherapy interventions for MS9
Γable 6	Physiotherapy interventions for PD
Γable 7	Study selection for stroke
Γable 8	Study selection criteria for MS
Γable 9	Study selection criteria for PD
Γable 10	Outcomes reported in SRs of physiotherapy interventions in patients after stroke, with MS or PD
Γable 11	List of included studies evaluating social and ethical issues
Γable 12	List of included studies evaluating organisational issues
Γable 13	Summary of database search results for SRs and economic studies (27 September 2020)
Γable 14	Summary of database search results RCTs (from inception to 22 October 2020)
Table 15	Embase and Medline search for SRs and economic analyses (from inception to 27 September 2020)
Γable 16	Cochrane library search strategy (from inception to 27 September 2020) 47
Γable 17	PEDro search strategy (from inception to 27 Sep 2020)
Γable 18	York CRD search strategy (from inception to 27 Sep 2020)
Γable 19	International HTA database search strategy (2015 up to 27 Sep 2020) 51
Γable 20	EconLit search strategy (from inception to 27 Sep 2020)
Γable 21	Search strings for RCTs (from inception to 22 October 2020)

Table 22	The Cochrane Library searches for RCTs (from inception 22 October 2020)	55
Table 23	PEDro searches for RCTs (from inception to 22 October 2020)	56
Table 24	Search strings for legal considerations (PubMed and Embase) [from inception to November 2020]	
Table 25	Search strings for organisational issues (PubMed and Embase) [from inception to November 2020]	
Table 26	Search strings for ethical considerations (PubMed and Embase) [from inception to November 2020]	
Table 27	Search string for social considerations (PubMed and Embase) [from inception to November 2020]	
Table 28	Specialty websites literature search (18 November 2020)	60
Table 29	HTA agency websites literature search (18 November 2020)	61
Table 30	List of included systematic reviews for effectiveness outcomes	64
Table 31	List of included systematic reviews for safety outcomes	70
Table 32	Evidence table for included studies on health economic evaluations	71

Objective of the HTA scoping report

The objective of the scoping report is to conduct a systematic literature search and to synthesize the available evidence base addressing the main health technology assessment (HTA) domains, i.e., clinical effectiveness/safety, costs/budget impact/cost-effectiveness, legal/social/ethical and organisational issues. In the report the analytical methods that are to be used when a HTA is pursued are described. Based on quantity and quality of the extracted evidence the feasibility of pursuing a HTA is judged. Analysis of the individual study outcomes is not the objective of the scoping report.

1 Policy question and context

For patients after stroke, with multiple sclerosis (MS), or with Parkinson's disease (PD), best supportive care often includes long-term physiotherapy. In Switzerland, physiotherapy is covered via mandatory health insurance for up to 36 sessions. For any patient wishing to continue physiotherapy beyond 36 sessions at the expense of mandatory health insurance, the treating physician must make a formal request for reimbursement to the medical officer of the patient's insurance company. According to the medical officers, these requests have been increasing in recent years.

Studies investigating the additional benefit of extending physiotherapy from acute and subacute care into long-term care are rare, and thus evidence about the efficacy and effectiveness for the treatment of patients after stroke or with MS or PD, is scarce. The planned HTA aims to give an overview of the existing evidence to determine whether long-term physiotherapy meets the effectiveness, appropriateness, economic efficiency (EAE) criteria required for reimbursement via mandatory health insurance in Switzerland.

2 Research question(s)

The scoping report aims to estimate the quantity and quality of relevant literature addressing the following research questions:

- 1) What is the clinical effectiveness, safety and cost-effectiveness of long-term physiotherapy compared to short-term physiotherapy in patients after stroke, with MS or PD?
- 2) What is the clinical effectiveness, safety and cost-effectiveness of long-term physiotherapy compared to best supportive care, no care, interval therapy, and unsupervised home-based therapy in patients after stroke, with MS or PD?
- 3) Are there any social, legal, ethical or organisational issues associated with long-term physiotherapy in patients after stroke, with MS or PD?

1

3 Medical background

3.1 Medical context and disease description

3.1.1 Stroke

3.1.1.1 Disease description

According to the World Health Organization (WHO), stroke is defined as: "rapidly developing clinical signs of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours or longer or leading to death, with no apparent cause other than of vascular origin and includes cerebral infarction, intracerebral haemorrhage and subarachnoid haemorrhage." Stroke is classified into two major types based on aetiology: ischaemic and haemorrhagic. Ischaemic stroke is a neurological dysfunction episode caused by focal cerebral, spinal or retinal infarction, with symptoms persisting for more than 24 hours. Ischaemic cerebral infarction is commonly caused by atherosclerotic obstruction (i.e. main atherosclerotic lesion/thrombosis and embolism) of large cerebral and cervical arteries. Ischaemia can occur in all or part of the brain supplied by the occluded artery. Haemorrhagic stroke is caused by a rupture in the wall of blood vessels in the brain commonly caused by aneurysm and arteriovenous malformation.

Stroke is a heterogenous condition and establishing its risk factors and treatment depends on its pathogenesis. A comprehensive list of risk factors for stroke is presented in *Table 1*.

Table 1 Risk factors for ischaemic and haemorrhagic stroke

Ischemic stroke	Haemorrhagic stroke	
Modifiable risk factors*		
Alcohol consumption	Anticoagulation	
Cardiac disease	Diet	
Cigarette smoking	Heavy drinking	
Diabetes	Hypertension	
Diet	Illegal drug use (especially cocaine and crystal methamphetamine)	
Hypercholesterolaemia	Thrombolytic therapy	
Mitral stenosis		
Obesity and low physical activity		
Non-modifiable risk factors*		
Age/Sex	Age/Sex	
Geographic location	Amyloid angiopathy	
Race/ethnicity	Race/ethnicity	
Hereditary/familial factors		

Source: Boehme 2017³; Parmar 2011²

Note: *Genetics is increasingly recognised as potentially modifiable either directly or through gene-environment modification

3.1.1.2 Incidence or prevalence of stroke

The lifetime risk of stroke is higher among females (20–21%) than males (14–17%).⁴ As the elderly population continues to grow, it is postulated that the incidence of stroke will increase significantly.⁵ Data showing the global burden of disease indicates that 24.9% of individuals aged 25 years and older carry a lifetime risk of stroke, with 18.3% at risk of ischaemic stroke and 8.2% at risk of haemorrhagic stroke.⁶ A representative population survey of 19,123 households in Switzerland conducted in 2005 reported that in the previous one to two years, 6.9% were affected by stroke.⁷ This imposes a high burden on health care costs, with the average cost of inpatient hospitalisation and rehabilitation estimated at CHF 62,139.⁷

3.1.1.3 Symptoms and diagnostic pathway

The most common signs and symptoms associated with ischaemic stroke are presented in *Table 2*. Acute onset of symptoms upon waking, or otherwise, is the most common feature of ischaemic stroke, with unilateral weakness and speech disturbance the most common physical findings.⁸ Sudden onset of focal neurologic deficit is likely to worsen during the first 24 hours of the event, due to increased intracranial pressure.

The diagnostic pathway for stroke typically involves neuroimaging with computed tomography (CT) scan or magnetic resonance imaging (MRI) to differentiate ischaemic stroke from intracerebral haemorrhage.⁸

Table 2 Common signs and symptoms of stroke

Symptoms	Signs	
Acute onset	Arm paresis	
Subjective arm weakness	Leg paresis	
Subjective leg weakness	Dysphasia or dysarthria	
Self-reported speech disturbance	Hemiparetic or ataxic gait	
Subjective facial weakness	Facial paresis	
Arm paraesthesia	Eye movement abnormality	
Leg paraesthesia	Visual field defect	
Headache	Dysphagia	
Non-orthostatic dizziness		

Source: Yew et al. 20158

3.1.2 MS

3.1.2.1 Disease description

MS is a demyelinating, inflammatory, autoimmune disease of the central nervous system (CNS) that is a major cause of chronic neurological disability in young and middle-aged adults from 18 to 50 years old. The pathological process in the development and progression of MS is the damage or loss of axons due to immune-mediated destruction of the myelin sheath. Based on the new phenotypic classification for MS there are four main disease courses: clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS). The updated MS disease course description is presented in *Table 3*.

Table 3 Description of MS disease course

Disease Course	Description	
Clinically isolated syndrome (CIS)	The first episode of CNS inflammatory demyelination that may become MS if additional activity occurs	
Relapsing-remitting MS (RRMS)		ogic functioning (new symptoms or worsening of covery and no apparent progression of disease
gadolinium enhancing lesions and/or new or enlarging T2 lesions on MRI		increased disability confirmed over a specified period following a relapse Stable no evidence of increasing disability over a specified
Primary progressive MS (PPMS)	Steadily worsening neurologic function from onset of symptoms without initial relapses or remissions	
PPMS subtypes	Active evidence of new relapses, new gadolinium enhancing lesions and/or new or enlarging T2 lesions on MRI over a specified period Inactive no evidence of disease activity	With progression evidence of disease worsening on an objective measure of change confirmed over a specified period, with or without relapses Without progression no evidence of disease worsening on an objective measure of change over a specified period
Secondary progressive MS (SPMS)	SPMS refers to the disease progressing steadily, with or without relapses, following an initial relapsing-remitting course	
SPMS subtypes	Active evidence of new relapses, new gadolinium enhancing lesions and/or new or enlarging T2 lesions on MRI over a specified period Inactive no evidence of disease activity	With progression evidence of disease worsening on an objective measure of change, confirmed over a specified period, with or without relapses Without progression no evidence of disease worsening on an objective measure of change over a specified period

Abbreviations: **CNS** = central nervous system, **MRI** = magnetic resonance imaging, **MS** = multiple sclerosis, **PPMS** = primary progressive multiple sclerosis, **RRMS** = relapsing-remitting multiple sclerosis, **SPMS** = secondary progressive multiple sclerosis.

Source: Lublin 2014¹²

3.1.2.2 Incidence or prevalence of MS

MS is the most common neuroimmunological disorder seen in young adults (average age of onset 30 years). The estimated number of people with MS increased from 2.1 million in 2008 to 2.3 million in 2013, with the global median prevalence increasing from 30 per 100,000 in 2008 to 33 per 100,000 in 2013. The overall prevalence of MS in Switzerland was estimated to be 150 per 100,000 in 2011 rising to 190 per 100,000 in 2015, which translates to an estimated 10,000 individuals with MS in 2011 and 12.600 in 2015. The overall prevalence of MS in Switzerland was estimated 10,000 individuals with MS in 2011 and 12.600 in 2015. The overall prevalence of MS in Switzerland was estimated 10,000 individuals with MS in 2011 and 12.600 in 2015.

3.1.2.3 Symptoms and diagnostic pathway

Symptoms of MS are highly variable and unpredictable depending on the degree and location of demyelination in the CNS. Common symptoms experienced by MS patients include discrete episodes of numbness, tingling, weakness, vision loss, gait impairment, loss of coordination, imbalance, and bowel and bladder dysfunction. Patients may be stable between attacks but may experience fatigue and heat sensitivity.¹⁵

No single test can determine if a person has MS. The diagnosis process involves gathering evidence from clinical examination, medical history, lab tests and MRI of the brain and spinal cord. ¹⁶ Diagnosis of MS relies on evidence of CNS lesions showing the twin tenets of dissemination in time, signifying that damage has occurred more than once, and dissemination in space, suggesting damage in more than one location in the nervous system. The lack of precision in diagnosing MS led to the development of the McDonald Criteria by the International Panel on MS Diagnosis, which involves clinical, radiographic and laboratory data to diagnose MS. ¹⁷

3.1.3 PD

3.1.3.1 Disease description

PD is a complex neurodegenerative condition characterised by the loss of dopaminergic neurons in the substantia nigra located in the basal ganglia, and the presence of Lewy bodies.¹⁸

The risk factors associated with PD include elevated cholesterol, environmental toxins (carbon disulfide, cyanide, herbicides, methanol and organic solvents, pesticides), head trauma, high caloric intake, increased body mass index, inflammation associated with activation of microglia, methcathinone (manganese content), methamphetamine/amphetamine abuse, mitochondrial dysfunction, nitric oxide toxicity, oxidative stress (potent neurotoxins and formation of free radicals), post-infection state and signal mediated apoptosis.¹⁸

3.1.3.2 Incidence or prevalence of PD

The prevalence of PD is 100 to 200 per 100,000 people, with an annual incidence of 15 per 100,000. The disease is more common in males than females, with disease onset usually occurring between 65 to 70 years of age.¹⁹ In Europe, the estimated prevalence of PD is 108 to 257 per 100,000, and the estimated incidence is 11 to 19 per 100,000 inhabitants per year.²⁰ According to a Swiss population-based epidemiological study, PD in the canton of Geneva showed an age-adjusted prevalence of 114 (105.8–122.2) per 100,000, while the age-adjusted incidence was 20.1 (16–24.3) per 100,000 inhabitants between 2009 and 2012.²⁰ From 1990 to 2016, deaths, prevalence and disability-adjusted life years increased in Switzerland by 13.9%, 10.3% and 10.8%, respectively.²¹

3.1.3.3 Symptoms and diagnostic pathway

The cardinal features of PD such as bradykinesia, rigidity and resting tremor are often reported as the first clinical findings of the disease and are classified as motor symptoms.²² Postural instability affects 50% of PD patients within five years of diagnosis. Other symptoms include freezing of gait, sialorrhea (drooling or excessive salivation), amimia (inability to express ideas through gestures or signs), depression, loss of taste and sense of smell, sleep disturbance, gastrointestinal complications, constipation, anxiety, pain, fatigue, sexual dysfunction, hallucinations and psychosis, impulse control disorder, cognitive impairment and dementia.²³ ²⁴

Parkinsonism is defined as bradykinesia in combination with either resting tremor, rigidity or both.²⁵ Parkinsonism must be established before criteria from the Movement Disorder Society²⁵ can be applied to determine whether the patient meets the criteria for PD as the cause. However, there is no reliable test to diagnose PD, making it difficult to distinguish from other conditions with similar presentations. Therefore, this condition is mainly diagnosed by a range of classical presentations only related to PD, such as hypokinesia, bradykinesia, postural instability, rigidity and sometimes a rest tremor.²⁶ ²⁷

4 Technology

4.1 Technology description

Physiotherapy is a mode of therapy that uses physical techniques to develop, maintain and restore movement and functional ability.²⁸ In patients after stroke, or with MS or PD, physiotherapy is commonly performed over a long-term basis to assist in the treatment and management of these diseases through movement and exercise, manual therapy, and education. Due to the complexity of neurological diseases, physiotherapists often require additional training to specialise in the rehabilitation of patients after stroke, with MS or PD.

4.1.1 Physiotherapy for patients after stroke

The care pathway for stroke patients often includes a multidisciplinary rehabilitation team with clearly documented roles and duties. This team should work closely with the patient and the family/caregiver so that all important information can be gathered and full support to the patient and family can be provided.²⁹ At the time of admission, patients should be screened across the following domains: orientation, positioning, mobility level (incl. risk of fall), pressure area risk, swallowing, continence, communication, nutritional status and hydration.

The National Institutes of Health Stroke Scale,³⁰ and the Barthel Index³¹ or Extended Barthel Index³² are commonly used to assess functional abilities, psychological function, pain, activity restriction and other environmental factors at admission, and again at discharge.

Physiotherapy can be implemented in the acute setting, at a rehabilitation centre, in an out-patient setting, and at home or in primary care centres.

The recommended timing for physiotherapy is at the very early stage of recovery, ideally within 24 hours of stroke onset, especially for patients who are unable to maintain or change posture on their own.³³ **Table 4** lists physiotherapy interventions used to treat various stroke impairments.

 Table 4
 Physiotherapy interventions for stroke impairments

Stroke impairment	Physiotherapy intervention
Gait, balance, mobility and	Gait-oriented physical fitness training
movement	Balance training
	Repetitive task training
	Muscle strength training
	Electrical stimulation
	Electromechanical-assisted gait training
	Hydrotherapy
	Ankle foot orthoses
	Cardiorespiratory training
	Resistance training
	Circuit class training
Upper limb function	Constraint induced movement therapy
	Electromechanical-/robotic-assisted training
	Repetitive task training
	Splinting
	Mirror therapy
	Electrostimulation
	Electromyographic biofeedback
	Virtual reality
	Bilateral training
Post-stroke spasticity	Routine resting splint of upper limb
	Routine functional electrical stimulation
	Electromyographic biofeedback
	Robot-mediated passive therapy
Dysphagia	Muscle strengthening exercises
	Electrical stimulation
	Biofeedback
Pain	Electrical stimulation
	Exercise
	Position and supportive devices
Fatigue	Graded aerobic exercise
	Cognitive intervention
Other	Mental practice
	Motor imagery
	Patient and caregiver education

Source: Adapted from various guidelines³⁴⁻³⁸

4.1.2 Physiotherapy for patients with MS

Along with pharmacological management, physiotherapy plays an important role in the management of MS and helps to improve and maintain functional performance. Patients with MS may have problems with balance, strength, mobility and fatigue.

The optimal type of physiotherapy intervention will vary according to an individual patient's needs, depending on the stage of MS and specific functional deficits. *Table 5* shows the physiotherapy interventions used to treat functional defects in MS.

Table 5 Physiotherapy interventions for MS

Functional deficit	Physiotherapy intervention
Gait	Exercise interventions
	Functional electrical stimulation
	Ankle foot orthosis
Balance	Balance exercises
	Aquatic therapy
	Core strength training
	Vestibular exercises
	Dual-task training
Spasticity and flexibility	Stretching exercises
	Muscle strength training
	Electrical stimulation
Weakness	Resistance training
Coordination	Weight training
	Bracing/splinting
Aerobic endurance	Aerobic training
	Aquatic therapy
Respiratory function	Respiratory muscle training

Source: Rohrig 2018³⁹

4.1.3 Physiotherapy for patients with PD

Non-pharmacological management of patients with PD targets specific areas, mainly physical capacity, transfers, manual activities, balance and falls, and gait, as well as patient-centeredness and self-management support.⁴⁰ *Table 6* shows the physiotherapy interventions used to treat functional deficits in PD.

Table 6 Physiotherapy interventions for PD

Functional deficit	Physiotherapy intervention
Functional mobility	Conventional physiotherapy
	Treadmill
	Tai Chi
	Dance
Hypokinesia	Lee Silverman voice treatment
Reciprocal movements	Recumbent bicycle
	Elliptical machine
Gait	Exercise
	Gait training
Stiffness	Stretching and flexibility
Weakness	Weight training
	Water resistance training
Motor disability	Aerobic training
	Aquatic therapy
	Martial arts
Respiratory function	Respiratory muscle training
Pain	Exercise
	Peripheral desensitisation technique
	Mirror therapy
	Cognitive strategies
Motor learning	Visual and auditory cues
	Cognitive strategies

Source: Adapted from European Physiotherapy Guidelines for PD⁴⁰

4.2 Alternative technologies

Within the context of this scoping report, an alternative technology can be described as an intervention or modality of therapy, other than conventional/standard physiotherapy, that may be offered to stroke, PD and MS patients.

Various technologies can be offered as alternative or parallel treatment to physiotherapy, irrespective the length of physiotherapy treatment. For stroke, PD and MS patients, such therapies include biological therapies (e.g. stem cell treatments), acupuncture, massage, herbal therapies, Alexander technique, aromatherapy, Ayurveda, biofeedback, chiropractic treatment, diet, magnetic therapy, and yoga.⁴¹⁻⁴⁹

5 PICO

5.1 Population

The eligible patient population is defined as patients diagnosed with stroke, MS or PD. Patients with transient ischemic attack (TIA), clinically and radiologically isolated MS syndrome, or juvenile onset PD were excluded.

5.2 Intervention

Long-term physiotherapy is the intervention under investigation. No definition of what constitutes "long-term" physiotherapy could be identified from existing literature and clinical practice guidelines. In Switzerland, physiotherapy is covered under mandatory health insurance for up to 36 sessions (four bouts of nine sessions each). If a patient's condition requires more than 36 sessions at the expense of mandatory health insurance, the treating physician must make a formal request for reimbursement to the medical officer of the patient's insurance company. Based on this information, long-term physiotherapy has been defined in this scoping report as continual or regular physiotherapy beyond 36 sessions for patients diagnosed with stroke, MS or PD, which translates to continuous or regular physiotherapy sessions >2 months in patients after stroke, and >6 months in patients with MS or PD. These thresholds were informed by a survey of Swiss physiotherapy practices. To allow for a degree of clinical variation, and due to the lack of certainty around this definition, these cut-offs were used as a quide rather than strict inclusion criteria.

5.3 Comparator

The primary comparison of relevance to the policy question is short-term physiotherapy compared top long-term physiotherapy. In addition, long-term physiotherapy was compared to unsupervised home-based physiotherapy, no intervention, placebo/sham, usual care and treatments other than physiotherapy (i.e. best supportive care) including pharmacological treatments, cannabis, botulinum toxin, yoga and Pilates, in patients after stroke, with MS or PD.

5.4 Outcomes

Limitations in **functional capacity and mobility** are primary concerns of patients after stroke, with MS or PD and their families. Mobility disability has a profound impact on everyday life and can affect emotional wellbeing, activities of daily living (ADL), quality of life (QoL) and autonomy. Some of the tools used to measure balance and mobility in stroke patients include the Berg's Balance Scale (BBS),⁵⁰ the Activities-Specific Balance Confidence (ABC) Scale,⁵¹ the Functional Ambulation Classification (FAC),⁵²

the Motor Assessment Scale (MAS),⁵³ the Rivermead Mobility Index (RMI),⁵⁴ and the Stroke Rehabilitation Assessment of Movement (STREAM).⁵⁵⁻⁵⁸ Assessment tools used to measure functional mobility and balance in PD include the Timed Up and Go (TUG) Test,⁵⁹ the Functional Reach Test (FRT),⁶⁰ the BBS,⁵⁰ ABC Scale,⁵¹ Mini-Balance Evaluation System Test (Mini-BEST),⁶¹ Functional Gait Assessment (FGA),⁶² and 5 Times Sit to Stand (5TST).⁶³ ⁶⁴ As disease progresses, the ability to perform ADLs is profoundly affected.⁶⁵ ADLs are classified into personal, which includes toileting, dressing, eating, grooming, ambulation and bathing, and instrumental, which involves more complex task such as communication, shopping, transportation and domestic activities (cooking, housekeeping, laundry). Validated tools used to measure ADL include the Functional Independence Measure (FIM),⁶⁶ the Barthel Index (BI),³¹ and the PD ADL Scale.⁶⁷ ⁶⁸ Commonly used tools in assessing mobility disability among patients with MS include the Expanded Disability Status Scale (EDSS),⁶⁹ and the MS Functional Composite (MSFC).⁷⁰ ⁷¹ Assessment tools used to measure dexterity include the Nine-Hole Peg Test (9HPT),⁷² and the Box and Block Test (BBT),⁷³ which are crucial to determine finger, hand and arm function.

Walking ability is a key component of mobility, which is routinely assessed by standardised tests and scales to observe the progression of neurological conditions.⁷⁴ Walking impairment places a great burden on patients after stroke, or with MS or PD. Validated clinician- and patient-driven instruments are available to evaluate walking performance (i.e., Timed 25 Foot Walk Test (T25FW),⁷⁵ 10 Metre Walk Test (10MWT),⁷⁶ and patient self-reported 12-Item MS Walking Scale(MSWS-12)⁷⁷) and speed (i.e., assessment of velocity in metres per second, cadence in steps per minute, stride length in metres), and to test other aspects of mobility including balance (i.e., Dynamic Gait Index (DGI),⁷⁸ Timed Up and Go (TUG) Test,⁵⁹ and Functional Gait Assessment (FGA)⁶²), endurance or motor fatigue (i.e., 2- or 6-Minute Walk Test⁷⁹). The Freezing of Gait Questionnaire (FOGQ)⁸⁰ is an additional tool for PD (scores range from 0–24 with higher scores indicating more severe freezing of gait).

Clinician-rated impairment and disability measures describe disease progression over time as observed and rated by clinicians. This includes assessment on disability, disease severity and motor and clinical impairment. For stroke patients, Modified Rankin Scale (MRS)⁸¹ and the Glasgow Outcome Scale (GOS)⁸² are considered as the gold standard for stroke outcome assessment. MRS⁸¹ is a 6-point ordinal scale that measures global disability (0=no symptoms to 6=Dead).⁸³ GOS⁸² is an ordinal rating scale describing disability and handicap in patients with brain injury with scores ranging from 1 (death) to 5 (good recovery).⁸⁴ The Expanded Disability Status Scale (EDSS)⁶⁹ is considered the gold standard in the clinician rated comprehensive assessment of MS related disability.⁸⁵ The clinician-rated comprehensive assessment of PD-related disability include the following: Hoehn and Yahr (H&Y)

Scale,⁸⁶ Unified PD Rating Scale (UPDRS),⁸⁷ Webster Rating Scale,⁸⁸ and the Columbia University Rating Scale (CURS)⁸⁹ (higher scores indicate greater disability).⁶⁴

Health-related QoL (HRQoL) is critical in patients after stroke, with MS or PD to provide information on the progression of the disease, effectiveness of treatment and the management of care provided. HRQoL can be measured using a patient-reported assessment of physical, social, emotional and mental health. It also refers to the way health influences a person's ability to function, as well as their perceived physical, mental and social well-being.90 Examples of tools used to measure HRQoL in stroke patients include the Short Form-36 and -12 (SF-36/12),91 92 Short Form 6-Dimensions (SF-6D),93 EuroQol-5D (EQ-5D),94 the Stroke-Specific QoL Scale (SS-QoL),95 the Sickness Impact Profile (SIP),96 and the Quality of Wellbeing Scale (QWS).97-100 HRQoL is commonly assessed using self-reported questionnaires validated for MS patients such as the MS 54-Item QoL Questionnaire (MSQoL-54),101 the Functional Assessment of MS (FAMS)102 Questionnaire, the Hamburg QoL Questionnaire in MS (HAQUAMS),¹⁰³ the QoL Index – MS (QLI-MS),¹⁰⁴ the Leeds MS QoL Scale,¹⁰⁵ the 29-Item MS Impact Scale (MSIS-29),106 the Disability and Impact Profile (DIP),107 the extension of measures of Qualityadjusted Time Without Symptoms of Disease and Toxicity of Treatment,108 and the MS International QoL¹⁰⁹ Questionnaire.^{10 110} In PD, QoL is commonly measured using the 39-Item PD Questionnaire (PDQ-39),111 the PD QoL Questionnaire (PDQoL),112 the PD Impact Scale (PIMS),113 and the SF-3691 or SF-12.64 92

Pain is a subjective experience and is often reported using the Visual Analogue Scale (VAS)¹¹⁴ and the Numerical Rating Scale (NRS)¹¹⁵ presented as mean differences across included patients. The VAS¹¹⁴ and NRS¹¹⁵ are recommended to assess pain in both stroke and MS patients. For patients with PD, the King's PD Pain Scale (KPPS)¹¹⁶ is recommended for rating pain intensity, due to the insufficient validation of the VAS¹¹⁵ and NRS¹¹⁵ in patients with PD.¹¹⁷ The KPPS Scale¹¹⁶ has 14 questions that investigate the frequency and severity of different pain syndromes frequently observed in PD patients.¹¹⁷ Items are scored by severity (0–3) multiplied by frequency (0–4), resulting in a subscore of 0–12, with a total possible score of 0–168.¹¹⁶ 117

Fatigue is one of the most common and debilitating manifestation of MS that can significantly affect a person's functional ability at home and at work. 118 It can have socioeconomic consequences involving loss of work hours and loss of employment. 119 120 Fatigue in MS is not clearly understood. Common definition of fatigue includes: 'a sense of exhaustion, lack of energy or tiredness', and 'subjective lack of physical and/or mental energy that is perceived by the individual or caregiver to interfere with usual or desired activity. 119 121 122 The definition is open to a wide range of interpretation depending on the patient's cultural or educational background. Patient-reported questionnaires to quantify the severity of fatigue are commonly used for MS patients. However, this outcome can be confounded by other

conditions associated with MS, such as depression and sleep disorders.¹²³ Fatigue rating scales used are the Chalder Fatigue Scale (CFQ11),¹²⁴ the Krupps Fatigue Severity Scale (FSS),¹²⁵ the Modified Fatigue Impact Scale (MFIS),¹²⁶ and the Neurological Fatigue Index for MS (NFI-MS).¹¹⁹ ¹²⁷

Impaired cognition, muscle strength, muscle tone, sensation, coordination and gait, predispose patients after stroke, with MS or PD to increased risk of **falls**. ¹²⁸⁻¹³⁰ The falls per person year, or the standardised measure of fall occurrence, is determined by dividing the falls rate by the length of follow-up. ¹³¹⁻¹³³ For patients after stroke, with MS or PD, the Falls Efficacy Scale-International (FES-I)¹³⁴ has been used to measure the patient's confidence in performing ADL (scores ranging from 1 to 10 with higher scores signifying lower levels of confidence and a total score of 70 or more denoting that the patient has a fear of falling). ⁶⁴ ¹³⁵ ¹³⁶

Poor **compliance** to physiotherapy and rehabilitation intervention can have a negative effect on overall health outcomes and on the long-term healthcare cost. ¹³⁷ Compliance with physiotherapy intervention, like adherence to physical activity, might be difficult since the symptoms and impairment in patients after stroke, with MS or PD change over time. ¹³⁸ ¹³⁹ Compliance can be measured using adherence. ¹⁴⁰ Adherence is defined as: 'the degree to which the person's behavior corresponds with the agreed recommendation from a healthcare provider,' and is calculated as the number of sessions the patient attended over the expected number of treatment sessions in a specific time period or duration. ¹³⁸ ¹⁴¹ The concept of adherence in physiotherapy is multidimensional and could include appointment attendance, treatment fidelity and performance of the prescribed exercises (frequency and duration). ¹⁴² The most frequently used adherence measurement methods were diaries and logbooks. ¹³⁹

Adverse events are critical safety outcomes in the management of patients after stroke, with MS or PD. An adverse event is defined as: 'an unexpected and undesired incident directly associated with the care or services provided to the patient.' ¹⁴³ Events that result in death, life threatening adverse experience, inpatient hospitalisation or prolongation of existing hospitalisation, disability, or permanent damage are categorised as serious adverse events. ¹⁰ Adverse events recorded include fracture, pain, muscle soreness, dizziness, and adverse reaction to exercise interventions such as pallor (skin becoming pale); excessive sweating or clamminess; sudden or excessive shortness of breath unrelated to increased activity; increased cough or wheeze; nausea or vomiting; confusion; chest heaviness, pain or tightness; angina and rapid heart rate; palpitations or irregular heartbeat. ⁶⁴ 144 145

Table 7 Study selection for stroke

- P: Patients diagnosed with stroke Exclusion criteria:
 - Patients with transient ischaemic attack
 - Patients in the acute (1 to 7 days post-stroke) or sub-acute stage (7 days to 6 months post-stroke) of the disease¹⁴⁶
- I: Any long-term physiotherapy interventions given to chronic stroke patients, which includes:
 - Physiotherapeutic interventions: active and passive movement therapy, manual therapy, pelvic floor exercises, medical exercise therapy, movement therapy in water, cardiovascular physiotherapy, pelvic floor physiotherapy
 - Physical methods/modalities: heat and cold therapy, muscle and connective tissue massage, electrotherapy, hydrotherapy
 - Other interventions: breathing (respiratory) and lymphological physiotherapy, light and ultrasound therapy
- C: Best supportive care, including pharmacologic, cannabis, botulinum toxin, yoga, Pilates
 - Interval therapy including short-term physiotherapy
 - Unsupervised home-based physiotherapy
 - No intervention
 - Placebo/sham procedure
- O: Critical clinical outcomes
 - Functional capacity and mobility (including activities of daily living, balance, gait)
 - Walking
 - Clinician-rated impairment and disability measures
 - Health-related quality of life

Important clinical outcomes

- Pain
- Falls
- Compliance

Safety outcomes

Adverse events

Table 8 Study selection criteria for MS

P: Patients with MS (relapsing-remitting MS, which may convert to secondary-progressive MS, primary progressive MS, and progressive relapsing MS)

Exclusion criteria:

- Study population with possible MS such as:
 - Clinically isolated syndrome
 - Radiologically isolated syndrome
- 1: Any long-term physiotherapy interventions given to MS patients, which includes:
 - Physiotherapeutic interventions: active and passive movement therapy, manual therapy, pelvic floor exercises, medical exercise therapy, movement therapy in water, cardiovascular physiotherapy, pelvic floor physiotherapy, hippotherapy
 - Physical methods/modalities: heat and cold therapy, muscle and connective tissue massage, electrotherapy, hydrotherapy
 - Other interventions: breathing (respiratory) and lymphological physiotherapy, light and ultrasound therapy
- C: Best supportive care, including pharmacologic, cannabis, botulinum toxin, yoga, Pilates
 - Interval therapy including short-term physiotherapy
 - Unsupervised home-based physiotherapy
 - No intervention
 - Placebo/sham procedure
- O: Critical clinical outcomes
 - Functional capacity and mobility (including activities of daily living, balance, gait)
 - Walking
 - Clinician-rated impairment and disability measures
 - · Health-related quality of life

Important clinical outcomes

- Pain
- Fatigue
- Falls
- Compliance

Safety outcomes

Adverse events

Abbreviations: MS = multiple sclerosis.

Table 9 Study selection criteria for PD

P: • Patients with PD

Exclusion criteria:

• Juvenile onset PD age <18 years old

l: • Any long-term physiotherapy interventions given to PD patients, which includes:

- Physiotherapeutic interventions: active and passive movement therapy, manual therapy, pelvic floor exercises, medical exercise therapy, movement therapy in water, cardiovascular physiotherapy, pelvic floor physiotherapy
- Physical methods/modalities: heat and cold therapy, muscle and connective tissue massage, electrotherapy, hydrotherapy
- Other interventions: breathing (respiratory) and lymphological physiotherapy, light and ultrasound therapy
- C: Best supportive care including pharmacologic, cannabis, botulinum toxin, yoga, Pilates
 - Interval therapy including short-term physiotherapy
 - Unsupervised home-based physiotherapy
 - No intervention
 - Placebo/sham procedure
- O: Critical clinical outcomes
 - Functional capacity and mobility (including activities of daily living, balance, gait)
 - Walking
 - Clinician-rated impairment and disability measures
 - · Health-related quality of life

Important clinical outcomes

- Pain
- Falls
- Compliance

Safety outcome

Adverse events

Abbreviations: PD = Parkinson's disease.

6 HTA key questions

For the evaluation of the technology the following key questions covering the central HTA domains, as designated by the EUnetHTA Core Model (clinical effectiveness, safety, costs, cost-effectiveness, budget impact, legal, social, ethical and organisational aspects), are addressed:

- 1. Is long-term physiotherapy effective/efficacious compared to short-term physiotherapy in patients after stroke, with MS, or with PD?
 - a) Is long-term physiotherapy effective/efficacious compared to no treatment, placebo/sham, best supportive care, unsupervised home-based physiotherapy and interval therapy in patients after stroke, with MS, or with PD?
- 2. Is long-term physiotherapy safe compared to short-term physiotherapy in patients after stroke, with MS, or with PD?
 - a) Is long-term physiotherapy safe compared to no treatment, placebo/sham, best supportive care, unsupervised home-based physiotherapy and interval therapy in patients after stroke, with MS, or with PD?
- 3. What are the costs associated with long-term physiotherapy in patients after stroke, with MS, or with PD?
- 4. How cost-effective is long-term physiotherapy compared to other treatments in patients after stroke, with MS, or with PD?
- 5. What is the budget impact of limiting the indication of physiotherapy to 36 treatment sessions in patients after stroke, with MS, or with PD?
- 6. Are there legal, social or ethical issues related to limiting physiotherapy treatments to 36 sessions in patients after stroke, with MS, or with PD?
- 7. Are there organisational issues related to limiting physiotherapy treatments to 36 sessions in patients after stroke, with MS, or with PD?

7 Methodology literature search

7.1 Databases and search strategy

A scoping search strategy was created to identify published literature that addresses the research questions. Literature searches were conducted in seven biomedical databases (PubMed, Embase, Cochrane Library, EconLit, University of York Centre for Reviews and Dissemination (York CRD), International HTA database (date limited from 2015-2020)), Physiotherapy Evidence Database (PEDro)). Separate searches were conducted to identify systematic reviews (SRs) and economic evaluations up to 27 September 2020, randomised control trials (RCTs) up to 22 October 2020, and evidence for the social, legal, ethical, and organisational auxiliary domains up to 13 November 2020. Details about the bibliographic database searches are available in *Appendix A*. Additionally, the websites of HTA agencies were searched to identify relevant HTA reports that included cost-effectiveness analyses (*Table 29*). The search strings for RCTs and SRs were verified using known publications identified through targeted searches and were peer-reviewed by an independent reviewer not affiliated with the authors prior to the searches being conducted.

The key search terms related to the population and intervention were combined with various methodological and topical search filters (SR and HTA, RCTs, cost-effectiveness, etc.), depending on the database and research question being addressed.¹⁴⁷ The full search strategies for each database are reported in *Appendix A*.

Owing to the broad nature of the intervention keywords, clinical trials databases were not searched as the volume of hits could not be screened within the available time to produce this scoping report. Grey literature searches were conducted on specialty websites (*Table 28*) to highlight any relevant literature that may not have been otherwise identified.

7.2 Study selection

Results from the literature search were imported into Rayyan (bibliographic management software). Rayyan functions similarly to EndNote but allows for easy blinding of reviewers and management of study inclusion conflicts. 148 Study selection was limited to studies in English, French, German and Italian. French, German, and Italian are three of the four official languages of Switzerland. The fourth language of Romansh was not included because of the limited number of publications available. 149 150 Only studies that met the population, intervention, comparator and outcome (PICO) criteria were considered eligible for inclusion. SRs and RCTs were considered as eligible study designs to address the policy question comparing long- versus short-term physiotherapy. In addition, SRs were also included to identify

literature for the supplementary comparison of long-term physiotherapy versus other long-term comparators. As this comparison was not the focus of the policy question, but can provide some indication of the benefit of long-term physiotherapy, only SR evidence was considered to be eligible for inclusion.

Studies based in countries outside of WHO Mortality Stratum A were excluded during full-text screening because burdens of disease in these countries are not comparable to Switzerland. The following countries comprise WHO Mortality Stratum A: Andorra, Australia, Belgium, Brunei, Canada, Croatia, Cuba, Cyprus, Czech Republic (Czechia), Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Japan, Luxembourg, Malta, Monaco, The Netherlands, New Zealand, Norway, Portugal, San Marino, Singapore, Slovenia, Spain, Sweden, Switzerland, United Kingdom (UK) and United States of America (USA).¹⁵¹

Study selection was conducted independently by two reviewers in duplicate, in two phases. All records were screened by title and abstract. Conflicts between reviewers on study inclusion were settled via consensus. If consensus could not be reached, a third reviewer decided whether to include or exclude the study. Articles deemed potentially relevant were then reviewed in full text by both reviewers independently, with disagreements settled via the same procedure of consensus.

Study characteristics (e.g. author details, country of publication, year, setting, length of follow-up, population, intervention, comparator, outcomes, sample size) were extracted for the included studies using piloted extraction templates. All data extractions were completed by one reviewer, then checked by a second reviewer for accuracy.

8 Synthesis of evidence base

8.1 Overall search results

The results of the systematic literature searches are presented in *Figure 1*. Database searches (Medline, Embase, the Cochrane Library, York CRD, International HTA Database, PEDro, and EconLit) identified 14,878 studies. After the removal of duplicates, 10,309 studies were reviewed by title and abstract, of which 401 were reviewed by full text. No publications were identified that compared long-term physiotherapy to short-term physiotherapy.

Twelve publications¹⁵²⁻¹⁶³ were included which compared long-term physiotherapy to any other long-term comparator. The searches also identified 13 social, 2 ethical and 3 organisational-related studies. Thirteen existing economic evaluations¹⁶⁴⁻¹⁷⁶ broadly matching the PICO criteria were identified. No legal studies were identified. A complete list of articles excluded at full text review is presented in *Appendix D*.

8.2 Evidence base pertaining to efficacy, effectiveness and safety

8.2.1 Search results

No systematic reviews or RCTs were identified that investigated the policy question of long-term physiotherapy compared to short-term physiotherapy in patients after stroke, with MS or with PD.

Due to the absence of information addressing the policy question, supplementary research questions were included comparing long-term physiotherapy to other alternative therapies. As this was not a focus of the scoping report, relevant evidence for these supplementary questions was limited to existing systematic reviews. For the supplementary comparison of long-term physiotherapy versus any other long-term comparators, 12 systematic reviews were identified, 152-163 of which 10 were conducted in stroke and 2 were in PD; no reviews on long-term physiotherapy for MS were identified.

The included studies are as follows:

Effectiveness

- 0 SRs or RCTs compared long-term physiotherapy to short-term physiotherapy.
- 12 SRs compared long-term physiotherapy interventions to sham, placebo or no intervention. 152-163

Safety

- 0 SRs or RCTs compared long-term physiotherapy to short-term physiotherapy.
- 2 SRs compared long-term physiotherapy to sham, placebo or no intervention. 161 162




Figure 1 PRISMA flow chart for study inclusion

Abbreviations: **RCT** = randomised control trial, **SR** = systematic review.

Note: a = A total of 12 SRs were included: 10 studies considered effectiveness outcomes, two studies reported both safety and effectiveness data.

8.2.2 Evidence table

Detailed extraction tables reporting the characteristics of identified studies are outlined in *Appendix B*, *Table 30* and *Table 31*.

8.2.3 Findings regarding efficacy, effectiveness and safety

The 12 SRs¹⁵²⁻¹⁶³ comparing long-term physiotherapy to any other long-term comparators included RCTs conducted across various countries, with many performed in non-stratum A countries (see *Appendix B* for the countries of included RCTs).

The long-term physiotherapy interventions included electrical stimulation (k=4), constrained induced movement therapy (k=1), motor rehabilitation physiotherapy interventions (k=1), cardiorespiratory and resistance training (k=1), overground physiotherapy (k=1), exercise therapy (k=2), ergometer training (k=1), and general physiotherapy interventions (k=1) compared with placebo or no intervention (k=10), sham (k=1), usual care (k=2) and treatments other than physiotherapy (k=3).

Physiotherapy in stroke is aimed to maintain functional capacity and performance in ADL. Electrical stimulation, which includes functional electrical stimulation, was the most commonly studied physiotherapy intervention (k=4) specific to patients diagnosed with stroke among the SRs included in this scoping report.

The stroke population most commonly studied included adults over 18 years of age, diagnosed at least 6 months prior to the study (k=4) with arm function of the hemiparetic/hemiplegic status after stroke (k=3). One SR included studies with participants ≥65 years of age (or mean age of participants required to be ≥65 years) regardless of stroke aetiology, type or severity.¹⁵⁷

The number of studies included in the SRs ranged from 9 to 75, with sample sizes ranging from 168 to 3,617. It should be noted, however, that in the study by Stewart et al.,¹⁵⁷ only two of the 28 included RCTs compared electrical stimulation to sham, acupuncture or other physiotherapy interventions. There was considerable variability in the characteristics of the included SRs in terms of the type of stroke, age of the patients, and type and duration of physiotherapy interventions.

For PD, the primary goal of providing physiotherapy interventions is to enable patients to maintain the utmost level of mobility, activity and independence. This will enhance their quality of life and may prevent problems associated with the progressive nature of the disease. The number of studies included in the SRs was 25¹⁶¹ and 76¹⁶², respectively, with sample sizes of 1,181 and 1,827, respectively. The included SRs did not discriminate on duration or severity of PD, medications, falls risk, age or any duration of physiotherapy intervention.

No SRs were found that investigated the effect of long-term physiotherapy in patients with MS.

Physiotherapy interventions were most frequently compared with placebo or no intervention (k=10). Other comparators included usual care, sham and other physiotherapy interventions. It should be noted that not all of the studies included in the SRs had treatment durations greater than 2 months for stroke, or greater than 6 months for MS or PD. The duration of physiotherapy intervention ranged from 1 day to 12 months. Treatment duration, the presence of multiple physiotherapy interventions covered by the SRs and the restriction on physiotherapy intervention comparators, all limited the ability to include studies for this scoping report.

Functional capacity and mobility were the most frequently studied effectiveness outcomes (k=8 for stroke and k=2 for PD). Five studies reported on HRQoL, four studies reported on walking and ambulation, three studies investigated falls, and one study explored the clinician-rated impairment and disability measure.

In terms of safety, two SRs (one each for stroke and PD) reported on adverse events¹⁶² and mortality/death.¹⁶³ Reported adverse events included recurrent non-fatal cardiovascular or cerebrovascular events, altered muscle tone, training induced injury, pain, incidence of falls and incidence of fractures. Compliance was measured by one study on PD.¹⁶²

A summary of the studies reporting the effectiveness and safety outcomes per population is provided in *Table 10*.

8.2.4 Quality of evidence assessment

The methodological quality of the studies included in the SRs were assessed using the PEDro scale for rating quality of RCTs and the Cochrane Collaboration's tool for assessing risk of bias. The risk of bias of the included studies varied from low to high. Two SRs only included RCTs with moderate to high quality. One reason for the relatively low methodological quality scores relates to the difficulty in blinding the therapist providing the treatment and, to some extent, blinding of the participants on the interventions they are receiving.

Table 10 Outcomes reported in SRs of physiotherapy interventions in patients after stroke, with MS or PD

Author	Effectiveness						Safety		Compliance
	Clinician- rated impairment /disability	Falls	Functional capacity and mobility	Walking	HRQoL	Pain	Adverse events	Mortality	
Stroke									
Ferrarello 2011 ¹⁵²			✓						
Hakkennes 2005 ¹⁵³			√		✓				
Howlett 2015 ¹⁵⁴			✓						
Pomeroy 2006 ¹⁵⁵			✓						
Saunders 2020 ¹⁶³			✓		✓		✓	✓	
States 2009 ¹⁵⁶				✓					
Stewart 2019 ¹⁵⁷					✓				
Van der Lee 2001 ¹⁵⁸			✓						
Veldema 2020 ¹⁵⁹		✓	✓	✓	✓				
Yang 2019 ¹⁶⁰			✓						
Parkinson's	disease								
Shen 2016 ¹⁶¹		✓	✓	✓					
Tomlinson 2013 ¹⁶²	✓ VID0.1 -	✓	✓ VIII 6116	✓	√		✓		✓

Abbreviations: **HRQoL** = health-related quality of life.

8.3 Evidence base pertaining to costs, cost-effectiveness and budget impact

8.3.1 Search results

A total of 78 studies identified in the systematic literature searches (see **Section 8.1**) were reviewed by full text for relevancy in relation to the economic section. The study selection focused on costs and economic evaluations in line with the PICO. For inclusion, the intervention needed to be delivered or supervised by a physiotherapist. Studies comparing physiotherapy interventions to usual care, no treatment placebo or relaxation were included. No restriction was placed on the duration of physiotherapy (long- or short-term), as economic approaches relevant to the PICO could include short-

term physiotherapy interventions. Studies were excluded if they were protocols, SRs and conference abstracts, or if the intervention included robotics or electronic games (i.e. exergaming). Following full text study selection, 13 studies were considered relevant and the remaining 65 studies were excluded.

8.3.2 Evidence table

A detailed extraction table reporting the characteristics of the thirteen included studies are outlined in Appendix C, Table 32.

8.3.3 Findings regarding costs, cost-effectiveness, and budget impact

Physiotherapy intervention variations

The thirteen economic studies¹⁶⁴⁻¹⁷⁶ identified in this review involved varying types of physiotherapy interventions. Ten of the studies involved physiotherapy intervention for less than three months.^{164 166-168 170-174 176} Among the included studies, 11 tested the cost-effectiveness of physiotherapy against usual care, ^{164 165 167 169-176} one against no care, ¹⁶⁶ and one against relaxation.¹⁶⁸

Two of the studies included three physiotherapy sessions per week over 10 to 12 weeks.¹⁶⁸ ¹⁷⁴ One study compared higher- to lower-intensity physiotherapy.¹⁶⁵, the more intensive intervention involved 23 hours of treatment for stroke rehabilitation, versus a lower intensity regimen of 9 hours.

The physiotherapy interventions included a range of individual and group exercises. The longer-term study of Farag et al.¹⁶⁹ had varying intensities of treatments, with the intervention group receiving between 2 and 4 home visits from a physical therapist over 6 months. In the study by Chan¹⁶⁵ the clinical trial used for the analysis involved increased intensities of physiotherapy for stroke rehabilitation compared to the standard level of physiotherapy. The Clarke et al.¹⁶⁶ intervention was delivered by a therapist in 4 sessions of 58 minutes each over 8 weeks. The study by Collins et al.¹⁶⁸ involved fitness classes of 1 hour and 15 minutes, held 3 times per week for 12 weeks.

The interventions were delivered in many different settings including community care, ¹⁶⁴ ¹⁶⁸ ¹⁶⁹ ¹⁷¹ ¹⁷⁵ ¹⁷⁶ acute care and inpatient delivery, ¹⁶⁵ outpatient clinics, ¹⁶⁶ ¹⁷³ ¹⁷⁴ and primary care facilities. ¹⁷²

Economic evaluation: populations and perspectives in the studies

Six studies were associated with stroke rehabilitation, ¹⁶⁴ ¹⁶⁵ ¹⁶⁷ ¹⁶⁸ ¹⁷⁰ ¹⁷¹ one with MS, ¹⁷⁶ and the remainder with PD. ¹⁶⁶ ¹⁶⁹ ¹⁷² ¹⁷⁵ Most of the stroke studies included participants aged 70–75 years. The MS study ¹⁷⁶ included participants aged 45–46 years and the PD study included participants aged around 70–71 years.

Most of the included studies were conducted in the UK,¹⁶⁴ ¹⁶⁶⁻¹⁶⁸ ¹⁷¹⁻¹⁷³ ¹⁷⁵ ¹⁷⁶ and the remainder took place in Canada,¹⁶⁵ Sweden,¹⁷⁴ Australia,¹⁶⁹ and New Zealand.¹⁷⁰ Many of the UK studies used a National Health Service government perspective. The Australian study¹⁶⁹ took a health system perspective, and the Swedish study¹⁷⁴ a societal perspective for cost-effectiveness calculations, while the New Zealand study¹⁷⁰ appeared to use hospital costs.

Economic evaluation: approaches

Seven of the included studies were trial-based cost-utility analyses.¹⁶⁶ ¹⁶⁷ ¹⁶⁹ ¹⁷² ¹⁷⁴⁻¹⁷⁶ Four were cost analyses, ¹⁶⁴ ¹⁷⁰ ¹⁷¹ ¹⁷³ and one a decision model. ¹⁶⁸

Chan¹⁶⁵ developed a Markov state transition model as part of the Ontario Health Technology Assessment Series. The model had a lifelong duration and employed alive and dead states for recent stroke patients. Patients transitioned from one state to another using assumptions derived from peer-reviewed journals, government reports and expert opinion from members of the Canadian Stroke Network.

Economic evaluation: costs

Costs captured in the economic evaluations generally included physiotherapist time (i.e. duration costs) and hospital cost outcomes. The studies by Beech et al., ¹⁶⁴ Hunter et al., ¹⁶⁷ Fletcher et al., ¹⁷² Farag et al., ¹⁶⁹ Xin et al., ¹⁷⁵ Joseph et al., ¹⁷⁴ Tosh et al., ¹⁷⁶ and Clarke et al., ¹⁶⁶ collected costs during trials. Fletcher et al. ¹⁷² included resource use for physiotherapists involved in the delivery of the exercise. Costs of venue hire, equipment costs and travel costs incurred by physiotherapists and participants were also documented. Collins et al. ¹⁶⁸ used costs sourced from a local community group fitness provider. In the Chan study, ¹⁶⁵ conventional and high-intensity hours of physiotherapy duration for each arm of the model were estimated using expert opinion and the literature.

Economic evaluation: outcomes

Incremental cost per quality-adjusted life year (QALY) was reported in nine studies. Five of the studies ¹⁶⁶ ¹⁶⁷ ¹⁷² ¹⁷⁵ ¹⁷⁶ derived EQ-5D estimates of patient utility from questionnaires administered during trials, one study ¹⁷⁴ used the SF-36 questionnaire, and one study ¹⁶⁹ used the SF-6D questionnaire. One study ¹⁷¹ used a WHO QoL Index approach to estimate QoL outcomes. The Markov model study of Chan ¹⁶⁵ sourced utility estimates from the literature, and the decision model of Collins et al. ¹⁶⁸ used the results of a previously conducted trial. Four studies ¹⁶⁴ ¹⁷⁰ ¹⁷¹ ¹⁷³ were cost-per-patient analyses.

Economic evaluation: sensitivity analysis

The Markov modelling analysis of Chan¹⁶⁵ included a probabilistic sensitivity analysis, and included uncertainty of model inputs as confidence intervals or standard deviations. Univariate analyses were

conducted for duration of effect, physiotherapist wage, physiotherapy assistant cost, mortality rate, discount rate, utility value and length of inpatient stay. There were some sensitivity analyses included with trial-based studies. Tosh et al.¹⁷⁶ examined the impacts of differing costs of settings (private gyms or by third-party providers), disability sub-groups and wage costs, Hunter et al.¹⁶⁷ presented scenarios where carer costs were included and training costs excluded, Farag et al.¹⁶⁹ outlined scenarios for a group based program and no hospital costs, and Xin et al.¹⁷⁵ varied the time horizon, physiotherapist visits and numbers of sessions. The decision model of Collins et al.¹⁶⁸ included scenarios of different comparators, classes for 12 months and less than 7 attendees per class.

Existing systematic reviews

Two SRs undertaken to support physiotherapy HTA and economic modelling studies were identified.¹⁷⁷
¹⁷⁸ Although they were not formally included in this review, their key findings are presented as background prior to presenting results. The overarching conclusions of these two reviews were that there were limited studies that have evaluated the cost-effectiveness of physiotherapy interventions for treating neurological disorders.

- One study was conducted in Canada to support an HTA examining the effectiveness of continual long-term physiotherapy (more than 12 weeks) for patients after stroke.¹⁷⁷ The authors searched major databases in October 2018 and were unable to find published evidence on the clinical effectiveness of continual long-term physiotherapy for recovery post-stroke. They concluded there was a lack of available information, which prevented an assessment of costeffectiveness.
- The review by Winser et al.¹⁷⁸ undertook a broader systematic search of existing evidence to identify studies examining the cost-effectiveness of physiotherapy interventions for people with neurological disorders including PD, stroke and MS. Major database searches up to July 2018 yielded 225 articles, of which 51 were duplicated studies. Following the full text screening, 10 studies were included. Three of these are included in this scoping report.¹⁶⁷ ¹⁶⁹ ¹⁷⁶ The other seven were not applicable as they related to other conditions such as complex regional pain syndrome, reflex sympathetic dystrophy, Alzheimer's disease or cerebral palsy, and interventions such as WiiTM sports games or robot-assisted therapy.

Summary

Only a limited number of economic studies were identified to assess the cost-effectiveness of physiotherapy to treat patients after stroke, with MS or PD. Most were related to stroke, and only one assessed an intervention of longer than six months. Most economic analyses were trial based. One Markov model was developed to evaluate the long-term benefit of physiotherapy; however, key

assumptions were based on limited literature which may not be relevant to Switzerland. No included study examined the cost-effectiveness of long- versus short-term physiotherapy, so assumptions are of limited applicability. Swiss cost data sourced using DRG and TARMED positions could be included in a simple decision model in the event relevant clinical outcome data were to be identified in the future.

8.4 Evidence base pertaining to legal, social and ethical issues

Searches identified 13 social and 2 ethical studies associated with physiotherapy in patients after stroke, with MS or PD. Searches did not identify any literature related to the legal implications associated with physiotherapy in patients after stroke, with MS or PD.

8.4.1 Evidence table

Relevant studies are summarised in Table 11.

Table 11 List of included studies evaluating social and ethical issues

Author year Location	Condition	Study type	Outcomes
Patient and social issues			
Asplund 2009 ¹⁷⁹ Sweden	Stroke	Data from the Swedish Stroke Register (Riks-Stroke)	Patient characteristics and stroke services as determinants of patient dissatisfaction
Bulley 2011 ¹⁸⁰ UK	Stroke	Phenomenological approach using semi-structured interviews	User experiences, preferences and choices on the use of FES and AFO for foot drop
Hubbard 2012 ¹⁸¹ Australia	Stroke	Data from the Australian audit of stroke rehabilitation practice	Adherence to recommended management and good recovery outcomes from clinical guidelines for patients after stroke
Karingen 2011 ¹⁸² Norway	Stroke	Phenomenological perspective focusing on experiences of stroke survivors in rehabilitation	Long-term adherence to physiotherapy home exercise
McInnes 2008 ¹⁸³ UK	Stroke	Analysis of a subset of data from the Scottish Stroke Care Audit	Gender discrepancy in the use of stroke interventions
Miller 2016 ¹⁸⁴ USA	Stroke	Cross-sectional survey	Patient adherence on home exercise program as provided by physiotherapist after discharge from rehabilitation
Salbach 2009 ¹⁸⁵ Canada	Stroke	In-depth telephone interviews	Use of research evidence by physiotherapist to update clinical management of stroke patients
Skolarus 2017 ¹⁸⁶ USA	Stroke	Analysis of 2011 Medicare data for hospitalised patients diagnosed with stroke	Racial differences in rehabilitation utilisation
Wottrich 2004 ¹⁸⁷ Sweden	Stroke	Qualitative descriptive comparative study	Perspectives of patients and physiotherapist on physiotherapy session characteristics in relation to the observed behaviour

Author year Location	Condition	Study type	Outcomes
Martinkova 2018 ¹⁸⁸ Czech Republic, UK, USA, Italy, Belgium, Portugal, Norway, Croatia., Germany, Spain, Greece, Turkey, FYROM	MS	Online cross-sectional survey	Factors affecting differences in physiotherapeutic intervention application in Europe
Finlayson 2010 ¹⁸⁹ USA	MS	Cross-sectional descriptive study	Use of and need for physiotherapy services among middle-aged and older adults with MS
Allen 2015 ¹⁹⁰ Australia	PD	RCT	Predictors of adherence to fall prevention exercise program
Keus 2004 ¹⁹¹ The Netherlands	PD	Two postal questionnaires for patients and physiotherapists	Utilisation and patient satisfaction on quality and quantity of physiotherapy care
Ethical issues			
Cherney 2006 ¹⁹² USA	Stroke	Case study	Highlights the ethical issues involving the treatment of right hemisphere stroke patients
Sharp 2006 ¹⁹³ USA	Stroke	Case study	Highlights the ethical issues in the management of dysphagia after stroke

Abbreviations: AFO = ankle foot orthosis, FES = functional electrical stimulation, FYRM = former Yugoslav Republic of Macedonia, MS = multiple sclerosis, PD = Parkinson's disease, RCT = randomised control trial, UK = United Kingdom, USA = United States of America.

8.4.2 Legal results

No legal issues were identified from systematic and non-systematic searches related to physiotherapy interventions for patients after stroke, with MS or PD.

8.4.3 Social results

Thirteen studies (9 studies for stroke, 2 for MS, 2 for PD) evaluating patient, therapist or social perspectives were identified. 179-191 Most of the studies were from European countries such as UK, Norway, The Netherlands and Sweden. One study on MS examined differences in physiotherapy intervention application in the USA and Europe (Czech Republic, UK, Italy, Belgium, Portugal, Norway, Croatia, Germany, Spain, Greece, Turkey and the former Yugoslav Republic of Macedonia). 188 Eight studies sought to determine the influence of patient and physiotherapist factors on physiotherapy utilization, 179 180 183 185-189 four studies reported on adherence to physiotherapy management, 181 182 184 190 and one study described the factors influencing patient satisfaction of physiotherapy services. 191

8.4.4 Ethical results

Two case studies highlighting the ethical issues involved in therapeutic intervention in people after stroke in the right hemisphere, and the management of dysphagia in people after stroke were identified.¹⁹² ¹⁹³ While this occurred in an American context, many of the issues discussed are likely relevant to the Swiss context.

8.5 Evidence base pertaining to organisational issues

The literature search identified three studies regarding organisational issues associated with physiotherapy management.

8.5.1 Evidence table

Relevant studies are summarised in Table 12.

Table 12 List of included studies evaluating organisational issues

Author year Location	Condition	Study type	Outcomes
Johnstone 2013 ¹⁹⁴ New Zealand	Stroke	Retrospective audit	Alignment of stroke management in the inpatient setting with the physiotherapy guidelines
Norris 2014 ¹⁹⁵ UK	Stroke	Qualitative methodology using semi-structured interviews	Rehabilitation ownership and the barriers in implementing self-management post-stroke
Salbach 2007 ¹⁹⁶ Canada	Stroke	Cross-sectional mail survey	Practitioner and organisational barriers to EBP among physiotherapists

Abbreviations: EBP = evidence-based practice, UK = United Kingdom.

8.5.2 Findings regarding organisational issues

Two studies identified the barriers in implementing a post-stroke management program and evidence-based practice among patients and physiotherapists. 194 195 One study reported on management issues associated with the alignment of physiotherapy interventions with clinical guidelines. 196

9 Feasibility HTA

Clinical evidence

The focus of the policy question was to quantify any additional benefit of extending physiotherapy for patients after stroke, with MS or PD beyond the number of sessions currently covered under mandatory health insurance (36 sessions). The searches conducted in this scoping report did not identify any SRs or RCTs that have investigated this question directly.

The absence of direct evidence comparing long- and short-term physiotherapy was anticipated, based on the pre-scoping report and preliminary scoping searches. As such, the PICO criteria in this scoping report were broadened to include evidence comparing any long-term physiotherapy regime—where long-term was defined according to the 36-session limit covered under mandatory health insurance—to any other relevant long-term comparator. A total of 12 SRs were identified that measured the effects of long-term physiotherapy, of which 10 were on stroke and two were on PD. There were no reviews of long-term physiotherapy for MS. While this evidence provides some indication of the benefit of long-term physiotherapy, it does not inform the policy question directly. Furthermore, there is considerable heterogeneity in the type and duration of interventions reported in the existing SRs. Overall, the existing reviews can be considered to offer evidence supporting specific long-term physiotherapy subtypes, but do not cover the breadth of physiotherapy practice covered under mandatory health insurance in Switzerland.

Economic evaluation

In the absence of clinical evidence addressing the policy question, an economic evaluation of the policy question is not feasible at this time. It is technically feasible to undertake an economic analysis of long-term physiotherapy compared to other relevant long-term comparators in stroke and PD, noting that evidence exists for a range of heterogenous interventions and populations. Existing models could be used to inform the evaluation structure (most likely a decision model), but are not directly applicable to the Swiss context. In order to conduct an evaluation within the scope of the HTA program, specific physiotherapy interventions and populations with adequate clinical data would need to be prioritised.

Conclusion

No SRs or RCTs were found that compared long-term physiotherapy to short-term physiotherapy in patients after stroke, with MS, or with PD. As the primary focus of the policy question is the comparison of long-term physiotherapy versus short-term physiotherapy in patients after stroke, with MS or PD, a full HTA report on this topic is not feasible. There is currently no available data to undertake an HTA on the effectiveness, safety and cost-effectiveness of long-term physiotherapy compared to short-term physiotherapy in patients after stroke, with MS or PD.

10 References

- 1. Truelsen T, Begg S. The Global Burden of Cerebrovascular Disease. *World Health Organization* 2006.
- 2. Parmar P, Sumaria S, Hashi S. Stroke: classification and diagnosis. *The Pharmaceutical Journal* 2011;3:200-04.
- 3. Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention. *J Circulation research* 2017;120(3):472-95.
- 4. Seshadri S, Beiser A, Kelly-Hayes M, et al. The lifetime risk of stroke: estimates from the Framingham Study. *Stroke* 2006;37(2):345-50.
- 5. Gorelick PB. The global burden of stroke: persistent and disabling. *The Lancet Neurology* 2019;18(5):417-18.
- 6. Collaborators GLRoS. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. New England Journal of Medicine 2018;379(25):2429-37.
- 7. Snozzi P, Blank PR, Szucs TD. Stroke in Switzerland: social determinants of treatment access and cost of illness. *Journal of Stroke and Cerebrovascular Diseases* 2014;23(5):926-32.
- 8. Yew KS, Cheng EM. Diagnosis of acute stroke. American family physician 2015;91(8):528-36.
- 9. Barten LJ, Allington DR, Procacci KA, et al. New approaches in the management of multiple sclerosis. *J Drug design, development therapy* 2010;4:343.
- Amatya B, Khan F, Galea M. Effectiveness of rehabilitation interventions for people with multiple sclerosis-A Cochrane Review summary with commentary. *NeuroRehabilitation* 2019;45(3):429-31.
- 11. Kennedy P. Impact of delayed diagnosis and treatment in clinically isolated syndrome and multiple sclerosis. *Journal of Neuroscience Nursing* 2013;45(6):S3-S13.
- 12. Lublin FD. New Multiple Sclerosis Phenotypic Classification. European Neurology 2014;72:1-5.
- 13. Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. *Neurology* 2014;83(11):1022-24.
- Blozik E, Rapold R, Eichler K, et al. epidemiology and costs of multiple sclerosis in switzerland: an analysis of health-care claims data, 2011–2015. Neuropsychiatric Disease Treatment 2017;13:2737.
- 15. Gelfand JM. Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. Handbook of clinical neurology: Elsevier 2014:269-90.
- 16. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *The Lancet Neurology* 2018;17(2):162-73.
- 17. Carroll WM. 2017 McDonald MS diagnostic criteria: Evidence-based revisions. *Multiple Sclerosis Journal* 2018
- 18. DeMaagd G, Philip A. Parkinson's disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. *Pharmacy therapeutics* 2015;40(8):504.
- 19. Tysnes O-B, Storstein A. Epidemiology of Parkinson's disease. *Journal of Neural Transmission* 2017;124(8):901-05.
- 20. Fleury V, Brindel P, Nicastro N, et al. Descriptive epidemiology of parkinsonism in the Canton of Geneva, Switzerland. *Parkinsonism related disorders* 2018;54:30-39.
- 21. Dorsey ER, Elbaz A, Nichols E, et al. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Neurology* 2018;17(11):939-53.

- 22. Fernandez-Gonzalez P, Carratala-Tejada M, Monge-Pereira E, et al. Leap motion controlled video game-based therapy for upper limb rehabilitation in patients with Parkinson's disease: A feasibility study. *Journal of NeuroEngineering and Rehabilitation* 2019;16(1).
- Hidalgo-Agudo RD, Lucena-Anton D, Luque-Moreno C, et al. Additional physical interventions to conventional physical therapy in parkinson's disease: A systematic review and meta-analysis of randomized clinical trials. *Journal of Clinical Medicine* 2020;9(4).
- 24. Butt A, Rovini E, Dolciotti C, et al. Objective and automatic classification of Parkinson disease with Leap Motion controller. *Biomedical engineering online* 2018;17(1):168.
- 25. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Movement disorders* 2015;30(12):1591-601.
- 26. NICE Guidelines. Parkinson's disease in adults: diagnosis and management: Developed by the National Institute for Health and Care Excellence, 2017.
- 27. Rogers G, Davies D, Pink J, et al. Parkinson's disease: summary of updated NICE guidance. *Bmj* 2017;358:j1951.
- 28. World Confederation for Physical Therapy, Policy statement: Description of physical therapy, 2019.
- 29. National Institute for Health and Care Excellence. Stroke rehabilitation, 2020.
- 30. National Institute of Neurological Disorders and Stroke. NIH stroke scale: National Institute of Neurological Disorders and Stroke, Dept. of Health and Human Services, USA, 2011.
- 31. Mahoney FI, Barthel DW. Functional evaluation: The Barthel Index: A simple index of independence useful in scoring improvement in the rehabilitation of the chronically ill. *Maryland State Medical Journal* 1965;14:61-65.
- 32. Prosiegel M, Böttger S, Schenk T, et al. Der erweiterte Barthel-Index (EBI)–eine neue Skala zur Erfassung von Fähigkeitsstörungen bei neurologischen Patienten. *Neurol Rehabil* 1996;1:7-13.
- 33. Bernhardt J, Churilov L, Ellery F, et al. Prespecified dose-response analysis for a very early rehabilitation trial (AVERT). *Neurology* 2016;86(23):2138-45.
- Scottish Intercollegiate Guidelines Network. Management of patients with stroke: Rehabilitation, prevention and management of complications, and discharge planning- A national clinical guideline, 2010.
- 35. National Institute of Health and Care Excellence. Stroke Rehabilitation: Long Term Rehabilitation After Stroke, 2013.
- 36. National Institute of Health and Care Excellence. National Clinical Guideline for Stroke, 2016.
- 37. National Stroke Foundation. Clinical Guidelines for Stroke Management 2010, 2010.
- 38. Stroke Foundation of New Zealand. Clinical Guidelines for Stroke Management 2010.: Wellington: Stroke Foundation of New Zealand, 2010.
- 39. Rohrig M. Physical therapy in multiple sclerosis. Clin Bull Natl Mult Scler Soc 2018:1-16.
- 40. Keus SHJ, Munneke M, Graziano M, et al. European physiotherapy guidelines for people with Parkinson's disease. *Journal of Parkinson's Disease* 2013;1):147.
- 41. Horie N, Pereira MP, Niizuma K, et al. Transplanted stem cell-secreted vascular endothelial growth factor effects poststroke recovery, inflammation, and vascular repair. *Stem cells* 2011;29(2):274-85.
- 42. Wu P, Mills E, Moher D, et al. Acupuncture in poststroke rehabilitation: a systematic review and meta-analysis of randomized trials. *Stroke* 2010;41(4):e171-e79.
- 43. Yue Z, Zhang X, Wang J. Hand rehabilitation robotics on poststroke motor recovery. *Behavioural neurology* 2017.
- 44. Shi B, Chen X, Yue Z, et al. Wearable ankle robots in post-stroke rehabilitation of gait: A systematic review. *Frontiers in neurorobotics* 2019;13:63.

- 45. Sormani MP, Muraro PA, Schiavetti I, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis. *Neurology* 2017;88(22):2115-22.
- 46. Ng JY, Kishimoto V. Multiple Sclerosis Clinical Practice Guidelines Provide Few Complementary and Alternative Medicine Recommendations: A Systematic Review. *Complementary Therapies in Medicine* 2020:102595.
- 47. Rajendran PR, Thompson RE, Reich SG. The use of alternative therapies by patients with Parkinson's disease. *Neurology* 2001;57(5):790-94.
- 48. Kabra A, Sharma R, Kabra R, et al. Emerging and alternative therapies for Parkinson disease: an updated review. *Current Pharmaceutical Design* 2018;24(22):2573-82.
- 49. F Lévesque M, Neuman T, Rezak M. Therapeutic microinjection of autologous adult human neural stem cells and differentiated neurons for Parkinson's disease: five-year post-operative outcome. *The Open Stem Cell Journal* 2009;1(1).
- 50. Berg K, Wood-Dauphine S, Williams JI, et al. Measuring balance in the elderly: preliminary development of an instrument. *Physiotherapy Canada* 1989;41(6):304-11.
- 51. Powell LE, Myers AM. The Activities-specific Balance Confidence (ABC) Scale. *J Gerontol A Biol Sci Med Sci* 1995;50a(1):M28-34.
- 52. Holden MK, Gill KM, Magliozzi MR. Gait assessment for neurologically impaired patients. Standards for outcome assessment. *Phys Ther* 1986;66(10):1530-9.
- 53. Carr JH, Shepherd RB, Nordholm L, et al. Investigation of a new motor assessment scale for stroke patients. *Phys Ther* 1985;65(2):175-80.
- 54. Collen FM, Wade DT, Robb GF, et al. The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment. *Int Disabil Stud* 1991;13(2):50-4.
- 55. Daley K, Mayo N, Wood-Dauphinée S. Reliability of Scores on the Stroke Rehabilitation Assessment of Movement (STREAM) Measure. *Physical Therapy* 1999;79(1):8-23.
- 56. Hill K, Ellis P, Bernhardt J, et al. Balance and mobility outcomes for stroke patients: a comprehensive audit. *Australian Journal of Physiotherapy* 1997;43(3):173-80.
- 57. Johnson L, Selfe J. Measurement of mobility following stroke: a comparison of the Modified Rivermead Mobility Index and the Motor Assessment Scale. *Physiotherapy* 2004;90(3):132-38.
- 58. Moore JL, Potter K, Blankshain K, et al. A Core Set of Outcome Measures for Adults With Neurologic Conditions Undergoing Rehabilitation: A Clinical Practice Guideline. *Journal of Neurologic Physical Therapy* 2018;42(3):174-220.
- 59. Mathias S, Nayak US, Isaacs B. Balance in elderly patients: the "get-up and go" test. *Arch Phys Med Rehabil* 1986;67(6):387-9.
- 60. Duncan PW, Weiner DK, Chandler J, et al. Functional reach: a new clinical measure of balance. *J Gerontol* 1990;45(6):M192-7.
- 61. Horak FB, Wrisley DM, Frank J. The Balance Evaluation Systems Test (BESTest) to differentiate balance deficits. *Physical therapy* 2009;89(5):484-98.
- 62. Wrisley DM, Marchetti GF, Kuharsky DK, et al. Reliability, internal consistency, and validity of data obtained with the functional gait assessment. *Phys Ther* 2004;84(10):906-18.
- 63. Whitney SL, Wrisley DM, Marchetti GF, et al. Clinical Measurement of Sit-to-Stand Performance in People With Balance Disorders: Validity of Data for the Five-Times-Sit-to-Stand Test. *Physical Therapy* 2005;85(10):1034-45.
- 64. Tomlinson CL, Herd CP, Clarke CE, et al. Physiotherapy for Parkinson's disease: a comparison of techniques. *Cochrane Database of Systematic Reviews* 2014(6).
- 65. Månsson E, Lexell J. Performance of activities of daily living in multiple sclerosis. *Disability Rehabilitation* 2004;26(10):576-85.
- 66. Granger CV, Hamilton BB, Keith RA, et al. Advances in functional assessment for medical rehabilitation. *Topics in Geriatric Rehabilitation* 1986;1(3).

- 67. Hobson JP, Edwards NI, Meara RJ. The Parkinson's Disease Activities of Daily Living Scale: a new simple and brief subjective measure of disability in Parkinson's disease. *Clinical Rehabilitation* 2001;15(3):241-46.
- 68. Jonasson SB, Hagell P, Hariz G-M, et al. Psychometric evaluation of the Parkinson's disease activities of daily living scale. *Parkinson's Disease* 2017.
- 69. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology* 1983;33(11):1444-52.
- Fischer JS, Rudick RA, Cutter GR, et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5(4):244-50.
- 71. Lord JP, Hall K. Neuromuscular reeducation versus traditional programs for stroke rehabilitation. *Archives of Physical Medicine and Rehabilitation* 1986;67(2):88-91.
- 72. Mathiowetz V, Weber K, Kashman N, et al. Adult Norms for the Nine Hole Peg Test of Finger Dexterity. *The Occupational Therapy Journal of Research* 1985;5(1):24-38.
- 73. Mathiowetz V, Volland G, Kashman N, et al. Adult norms for the Box and Block Test of manual dexterity. *Am J Occup Ther* 1985;39(6):386-91.
- 74. Bethoux F, Bennett S. Introduction: enhancing mobility in multiple sclerosis. *International Journal of MS Care* 2011;13(1):1-3.
- 75. Schwid SR, Goodman AD, Mattson DH, et al. The measurement of ambulatory impairment in multiple sclerosis. *Neurology* 1997;49(5):1419-24.
- Scivoletto G, Tamburella F, Laurenza L, et al. Validity and reliability of the 10-m walk test and the 6-min walk test in spinal cord injury patients. Spinal Cord 2011;49(6):736-40.
- 77. Hobart JC, Riazi A, Lamping DL, et al. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). *Neurology* 2003;60(1):31-6.
- 78. Shumway-Cook A, Woollacott MH. Motor control: theory and practical applications: Baltimore (Md.): Williams and Wilkins 1995.
- Scalzitti DA, Harwood KJ, Maring JR, et al. Validation of the 2-Minute Walk Test with the 6-Minute Walk Test and Other Functional Measures in Persons with Multiple Sclerosis. *International journal of MS care* 2018;20(4):158-63.
- 80. Giladi N, Shabtai H, Simon ES, et al. Construction of freezing of gait questionnaire for patients with Parkinsonism. *Parkinsonism Relat Disord* 2000;6(3):165-70.
- 81. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. *Stroke* 1988;19(5):604-07.
- 82. Jennett B, Bond M. Assessment of outcome after severe brain damage. *Lancet* 1975;1(7905):480-4.
- 83. Harrison JK, McArthur KS, Quinn TJ. Assessment scales in stroke: clinimetric and clinical considerations. *Clinical interventions in aging* 2013;8:201.
- 84. Lees KR, Bath PM, Schellinger PD, et al. Contemporary outcome measures in acute stroke research: choice of primary outcome measure. *Stroke* 2012;43(4):1163-70.
- 85. Collins CD, Ivry B, Bowen JD, et al. A comparative analysis of patient-reported expanded disability status scale tools. *Multiple Sclerosis Journal* 2016;22(10):1349-58.
- 86. Hoehn MM, Yahr MD. Parkinsonism. Neurology 1967;17(5):427.
- 87. Fahn S. Unified Parkinson's disease rating scale. Recent development in Parkinson's disease 1987.
- 88. Webster DD. Critical analysis of the disability in Parkinson's disease. Mod Treat 1968;5(2):257-82.
- 89. Hely MA, Chey T, Wilson A, et al. Reliability of the columbia scale for assessing signs of parkinson's disease. *Movement Disorders* 1993;8(4):466-72.

- 90. Golomb BA, Vickrey BG, Hays RD. A review of health-related quality-of-life measures in stroke. *Pharmacoeconomics* 2001;19(2):155-85.
- 91. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30(6):473-83.
- 92. Ware Jr JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Medical care* 1996:220-33.
- 93. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. *Journal of Health Economics* 2002;21(2):271-92.
- 94. EuroQol. A new facility for the measurement of health-related quality of life. *Health Policy* 1990;16(3):199-208.
- 95. Williams LS, Weinberger M, Harris LE, et al. Development of a stroke-specific quality of life scale. *Stroke* 1999;30(7):1362-69.
- 96. Gilson BS, Gilson JS, Bergner M, et al. The sickness impact profile. Development of an outcome measure of health care. *Am J Public Health* 1975;65(12):1304-10.
- 97. Kaplan RM, Bush JW, Berry CC. Health status index: category rating versus magnitude estimation for measuring levels of well-being. *Medical care* 1979:501-25.
- 98. Albers GW, Goldstein LB, Hess DC, et al. Stroke treatment academic industry roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. *Stroke* 2011;42(9):2645-50.
- 99. Pinedo S, SanMartin V, Zaldibar B, et al. Quality of life of stroke patients and their caregivers. *Int J Phys Med Rehabil* 2017;5(386):2.
- 100. de Haan R, Limburg M, van der Meulen J, et al. Use of health care services after stroke. *Quality in health care : QHC* 1993;2(4):222-27.
- 101. Vickrey BG, Hays RD, Harooni R, et al. A health-related quality of life measure for multiple sclerosis. *Qual Life Res* 1995;4(3):187-206.
- 102. Cella DF, Dineen K, Arnason B, et al. Validation of the Functional Assessment of Multiple Sclerosis quality of life instrument. *Neurology* 1996;47(1):129.
- 103. Gold SM, Heesen C, Schulz H, et al. Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). Mult Scler 2001;7(2):119-30.
- 104. Ferrans CE, Powers MJ. Psychometric assessment of the Quality of Life Index. *Research in nursing* & health 1992;15(1):29-38.
- 105. Ford H, Gerry E, Tennant A, et al. Developing a disease-specific quality of life measure for people with multiple sclerosis. *Clinical Rehabilitation* 2001;15(3):247-58.
- 106. McGuigan C, Hutchinson M. The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure. *Journal of Neurology, Neurosurgery & Psychiatry* 2004;75(2):266-69.
- 107. Lankhorst GJ, Jelles F, Smits RC, et al. Quality of life in multiple sclerosis: the disability and impact profile (DIP). *Journal of neurology* 1996;243(6):469-74.
- 108. Schwartz CE, Cole BF, Gelber RD. Measuring patient-centered outcomes in neurologic disease: extending the Q-TWiST method. *Archives of neurology* 1995;52(8):754-62.
- 109. Simeoni M, Auquier P, Fernandez O, et al. Validation of the multiple sclerosis international quality of life questionnaire. *Multiple Sclerosis Journal* 2008;14(2):219-30.
- 110. Baumstarck K, Boyer L, Boucekine M, et al. Measuring the quality of life in patients with multiple sclerosis in clinical practice: a necessary challenge. *Multiple sclerosis international* 2013.
- 111. Peto V, Jenkinson C, Fitzpatrick R, et al. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995;4(3):241-8.

- 112. de Boer AG, Wijker W, Speelman JD, et al. Quality of life in patients with Parkinson's disease: development of a questionnaire. *J Neurol Neurosurg Psychiatry* 1996;61(1):70-4.
- 113. Calne S, Schulzer M, Mak E, et al. Validating a quality of life rating scale for idiopathic parkinsonism: Parkinson's Impact Scale (PIMS). *Parkinsonism Relat Disord* 1996;2(2):55-61.
- 114. Hayes M, Patterson D. Experimental Development of the Graphic Rating Method. *Psychological Bulletin* 1921;18:98-99.
- 115. Thong ISK, Jensen M, Miró J, et al. The validity of pain intensity measures: what do the NRS, VAS, VRS, and FPS-R measure? *Scandinavian Journal of Pain* 2018;18.
- 116. Chaudhuri KR, Rizos A, Trenkwalder C, et al. King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. *Movement Disorders* 2015;30(12):1623-31.
- 117. Perez-Lloret S, Ciampi de Andrade D, Lyons KE, et al. Rating scales for pain in Parkinson's disease: Critique and recommendations. Movement disorders clinical practice 2016;3(6):527-37.
- National MS Society. MS Symptoms: Fatigue 2020 [Available from: https://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms/Fatigue13 September 2020].
- 119. Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. *Sleep* 2010;33(8):1061-67.
- 120. Smith MM, Arnett PA. Factors related to employment status changes in individuals with multiple sclerosis. *Multiple Sclerosis Journal* 2005;11(5):602-09.
- 121. Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and Multiple Sclerosis: Evidence-based Management Strategies for Fatigue in Multiple Sclerosis: Clinical Practice Guidelines: The Council 1998.
- 122. Krupp LB, Alvarez LA, LaRocca NG, et al. Fatigue in multiple sclerosis. *Arch Neurol* 1988;45(4):435-7.
- 123. Schwid SR, Covington M, Segal BM, et al. Fatigue in multiple sclerosis: current understanding and future directions. *Journal of rehabilitation research* 2002;39(2):211-24.
- 124. Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. *J Psychosom Res* 1993;37(2):147-53.
- 125. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. *Arch Neurol* 1989;46(10):1121-3.
- 126. Miskovic A, Ehrlich-Jones L. Measurement Characteristics and Clinical Utility of the Modified Fatigue Impact Scale in Individuals With Multiple Sclerosis. Archives of Physical Medicine and Rehabilitation 2018;99(1):213-14.
- 127. Mills RJ, Young CA, Pallant JF, et al. Development of a patient reported outcome scale for fatigue in multiple sclerosis: The Neurological Fatigue Index (NFI-MS). *Health and Quality of Life Outcomes* 2010;8(1):22.
- 128. Carling A, Forsberg A, Nilsagård Y. Falls in people with multiple sclerosis: experiences of 115 fall situations. *Clinical rehabilitation* 2018;32(4):526-35.
- 129. Denissen S, Staring W, Kunkel D, et al. Interventions for preventing falls in people after stroke. *Cochrane database of systematic reviews* 2019(10).
- 130. Farombi TH, Owolabi MO, Ogunniyi A. Falls and their associated risks in Parkinson's disease patients in Nigeria. *Journal of movement disorders* 2016;9(3):160.
- 131. Denissen S, Staring W, Kunkel D, et al. Interventions for preventing falls in people after stroke. *Cochrane Database of Systematic Reviews* 2019(10).
- 132. Araujo A, Lima MA, Silva MTT. Human T-lymphotropic virus 1 neurologic disease. *Current Treatment Options in Neurology* 2008;10(3):193-200.

- 133. Coote S, Sosnoff JJ, Gunn H. Fall incidence as the primary outcome in multiple sclerosis falls-prevention trials: recommendation from the International MS Falls Prevention Research Network. *International journal of MS care* 2014;16(4):178-84.
- 134. Yardley L, Beyer N, Hauer K, et al. Development and initial validation of the Falls Efficacy Scale-International (FES-I). *Age Ageing* 2005;34(6):614-9.
- 135. Hayes S, Galvin R, Kennedy C, et al. Interventions for preventing falls in people with multiple sclerosis. *Cochrane Database of Systematic Reviews* 2019 (11).
- 136. Tinetti ME, Richman D, Powell L. Falls efficacy as a measure of fear of falling. *Journal of gerontology* 1990;45(6):P239-P43.
- 137. Jack K, McLean SM, Moffett JK, et al. Barriers to treatment adherence in physiotherapy outpatient clinics: a systematic review. *Manual therapy* 2010;15(3):220-28.
- 138. Donkers SJ, Nickel D, Paul L, et al. Adherence to physiotherapy-guided web-based exercise for persons living with moderate-to-severe multiple sclerosis: a randomized-controlled pilot study. *International Journal of MS Care* 2020:0000-00.
- 139. Levy T, Laver K, Killington M, et al. A systematic review of measures of adherence to physical exercise recommendations in people with stroke. *Clinical rehabilitation* 2019;33(3):535-45.
- 140. D'Amico E, Chisari CG, Gitto L, et al. Pharmacoeconomics of synthetic therapies for multiple sclerosis. *Expert Opinion on Pharmacotherapy* 2019;20(11):1331-40.
- 141. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: WHO; 2003, 2014.
- 142. Kolt GS, Brewer BW, Pizzari T, et al. The Sport Injury Rehabilitation Adherence Scale: a reliable scale for use in clinical physiotherapy. *Physiotherapy* 2007;93(1):17-22.
- 143. World Health Organization. Conceptual framework for the international classification for patient safety version 1.1: final technical report January 2009: World Health Organization, 2010.
- 144. Allied Health Professions' Office of Queensland. Physiotherapy Learner Guide: Deliver and monitor an exercise program for mobility. In: Queensland AHPOo, ed. State of Queensland State of Queensland, 2017:71.
- 145. Glasgow Augmented Physiotherapy Study Group. Can augmented physiotherapy input enhance recovery of mobility after stroke? A randomized controlled trial. *Clinical rehabilitation* 2004;18(5):529-37.
- 146. Marzolini S, Robertson AD, Oh P, et al. Aerobic Training and Mobilization Early Post-stroke: Cautions and Considerations. 2019;10:1187.
- 147. Canadian Agency for Drugs and Technologies in Health. Strings Attached: CADTH's Database Search Filters: Canadian Agency for Drugs and Technologies in Health; 2019 [Available from: https://www.cadth.ca/resources/finding-evidence/strings-attached-cadths-database-search-filters accessed March 25 2020].
- 148. Mourad Ouzzani, Hossam Hammady, Zbys Fedorowicz, et al. Rayyan a web and mobile app for systematic reviews. *Syst Rev* 2016;5.
- 149. Swiss Broadcasting Corporation. Languages: Swiss Broadcasting Corporation; 2019 [Available from: https://www.swissinfo.ch/eng/languages/29177618 accessed March 19 2020].
- 150. Federal Chancellery. Romansh: Federal Chancellery; [Available from: https://www.bk.admin.ch/bk/en/home/regierungsunterstuetzung/languages/translation/raetoro manisch.html accessed March 19 2020].
- 151. World Health Organization. List of Member States by WHO Region and Mortality Stratum: World Health Organization; 2020 [Available from: https://www.who.int/choice/demography/mortality_strata/en/ accessed February 5 2020].
- 152. Ferrarello F, Baccini M, Rinaldi LA, et al. Efficacy of physiotherapy interventions late after stroke: A meta-analysis. *Journal of Neurology, Neurosurgery and Psychiatry* 2011;82(2):136-43.

- 153. Hakkennes S, Keating JL. Constraint-induced movement therapy following stroke: A systematic review of randomised controlled trials. *Australian Journal of Physiotherapy* 2005;51(4):221-31.
- 154. Howlett OA, Lannin NA, Ada L, et al. Functional electrical stimulation improves activity after stroke: A systematic review with meta-analysis. *Archives of Physical Medicine and Rehabilitation* 2015;96(5):934-43.
- 155. Pomeroy VM, King L, Pollock A, et al. Electrostimulation for promoting recovery of movement or functional ability after stroke. *Cochrane database of systematic reviews (Online)* 2006(2):CD003241.
- 156. States RA, Pappas E, Salem Y. Overground physical therapy gait training for chronic stroke patients with mobility deficits. *Cochrane Database of Systematic Reviews* 2009.
- 157. Stewart C, Subbarayan S, Paton P, et al. Non-pharmacological interventions for the improvement of post-stroke quality of life amongst older stroke survivors: a systematic review of systematic reviews (The SENATOR ONTOP series). *European Geriatric Medicine* 2019;10(3):359-86.
- 158. van der Lee JH, Snels IAK, Beckerman H, et al. Exercise therapy for arm function in stroke patients: A systematic review of randomized controlled trials. *Clinical Rehabilitation* 2001;15(1):20-31.
- 159. Veldema J, Jansen P. Ergometer Training in Stroke Rehabilitation: Systematic Review and Metaanalysis. *Archives of Physical Medicine and Rehabilitation* 2020;101(4):674-89.
- 160. Yang JD, Liao CD, Huang SW, et al. Effectiveness of electrical stimulation therapy in improving arm function after stroke: a systematic review and a meta-analysis of randomised controlled trials. Clinical rehabilitation 2019;33(8):1286-97.
- 161. Shen X, Wong-Yu IS, Mak MK. Effects of Exercise on Falls, Balance, and Gait Ability in Parkinson's Disease: A Meta-analysis. *Neurorehabilitation & Neural Repair* 2016;30(6):512-27.
- 162. Tomlinson CL, Patel S, Meek C, et al. Physiotherapy versus placebo or no intervention in Parkinson's disease. *Cochrane Database of Systematic Reviews* 2013(9).
- 163. Saunders DH, Sanderson M, Hayes S, et al. Physical fitness training for stroke patients. *Cochrane Database of systematic reviews* 2020(3).
- 164. Beech R, Rudd AG, Tilling K, et al. Economic consequences of early inpatient discharge to community-based rehabilitation for stroke in an inner-London teaching hospital. Stroke 1999;30(4):729-35.
- 165. Chan B. Effect of Increased Intensity of Physiotherapy on Patient Outcomes After Stroke: An Economic Literature Review and Cost-Effectiveness Analysis. Ontario Health Technology Assessment Series 2015;15(7):1-43.
- 166. Clarke CE, Patel S, Ives N, et al. Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson's disease: a large pragmatic randomised controlled trial (PD REHAB). Health technology assessment (Winchester, England) 2016;20(63):1-96.
- 167. Hunter SM, Johansen-Berg H, Ward N, et al. Functional strength training and movement performance therapy for upper limb recovery early poststroke-efficacy, Neural correlates, predictive markers, and cost-effectiveness: FAST-INdiCATE trial. Frontiers in Neurology 2018;8.
- 168. Collins M, Clifton E, Van Wijck F, et al. Cost-effectiveness of physical fitness training for stroke survivors. *Journal of the Royal College of Physicians of Edinburgh* 2018;48(1):62-68.
- 169. Farag I, Sherrington C, Hayes A, et al. Economic evaluation of a falls prevention exercise program among people With Parkinson's disease. *Movement Disorders* 2016;31(1):53-61.
- 170. Faulkner J, Stoner L, Lanford J, et al. Long-Term Effect of Participation in an Early Exercise and Education Program on Clinical Outcomes and Cost Implications, in Patients with TIA and Minor, Non-Disabling Stroke. *Translational Stroke Research* 2017;8(3):220-27.
- 171. Harrington R, Taylor G, Hollinghurst S, et al. A community-based exercise and education scheme for stroke survivors: a randomized controlled trial and economic evaluation. *Clinical rehabilitation* 2010;24(1):3-15.

- 172. Fletcher E, Goodwin VA, Richards SH, et al. An exercise intervention to prevent falls in Parkinson's: an economic evaluation. *BMC health services research* 2012;12:426.
- 173. Gage H, Kaye J, Owen C, et al. Evaluating rehabilitation using cost-consequences analysis: An example in Parkinson's disease. *Clinical Rehabilitation* 2006;20(3):232-38.
- 174. Joseph C, Brodin N, Leavy B, et al. Cost-effectiveness of the HiBalance training program for elderly with Parkinson's disease: analysis of data from a randomized controlled trial. *Clinical rehabilitation* 2019;33(2):222-32.
- 175. Xin Y, Ashburn A, Pickering RM, et al. Cost-effectiveness of the PDSAFE personalised physiotherapy intervention for fall prevention in Parkinson's: an economic evaluation alongside a randomised controlled trial. *BMC Neurology* 2020;20(1):295.
- 176. Tosh J, Dixon S, Carter A, et al. Cost effectiveness of a pragmatic exercise intervention (EXIMS) for people with multiple sclerosis: Economic evaluation of a randomised controlled trial. *Multiple Sclerosis* 2014;20(8):1123-30.
- 177. Ontario Health Quality. Continual Long-Term Physiotherapy After Stroke: A Health Technology Assessment. Ontario Health Technology Assessment Series 2020;20(7):1-70.
- 178. Winser S, Lee SH, Law HS, et al. Economic evaluations of physiotherapy interventions for neurological disorders: a systematic review. *Disability and rehabilitation* 2020;42(7):892-901.
- 179. Asplund K, Jonsson F, Eriksson M, et al. Patient dissatisfaction with acute stroke care. *Stroke* 2009;40(12):3851-6.
- 180. Bulley C, Shiels J, Wilkie K, et al. User experiences, preferences and choices relating to functional electrical stimulation and ankle foot orthoses for foot-drop after stroke. *Physiotherapy* 2011;97(3):226-33.
- 181. Hubbard IJ, Harris D, Kilkenny MF, et al. Adherence to clinical guidelines improves patient outcomes in Australian audit of stroke rehabilitation practice. *Arch Phys Med Rehabil* 2012;93(6):965-71.
- 182. Kåringen I, Dysvik E, Furnes B. The elderly stroke patient's long-term adherence to physiotherapy home exercises. *Advances in Physiotherapy* 2011;13(4):145-52.
- 183. McInnes C, McAlpine C, Walters M. Effect of gender on stroke management in Glasgow. *Age Ageing* 2008;37(2):220-2.
- 184. Miller KK, Porter RE, DeBaun-Sprague E, et al. Exercise after Stroke: Patient Adherence and Beliefs after Discharge from Rehabilitation. *Top Stroke Rehabil* 2017;24(2):142-48.
- 185. Salbach NM, Veinot P, Rappolt S, et al. Physical therapists' experiences updating the clinical management of walking rehabilitation after stroke: a qualitative study. *Phys Ther* 2009;89(6):556-68.
- 186. Skolarus LE, Feng C, Burke JF. No racial difference in rehabilitation therapy across all post-acute care settings in the year following a stroke. *Stroke* 2017;48(12):3329-35.
- 187. Wohlin Wottrich A, Stenström CH, Engardt M, et al. Characteristics of physiotherapy sessions from the patient's and therapist's perspective. *Disabil Rehabil* 2004;26(20):1198-205.
- 188. Martinková P, Freeman J, Drabinová A, et al. Physiotherapeutic interventions in multiple sclerosis across Europe: Regions and other factors that matter. *Multiple sclerosis and related disorders* 2018;22:59-67.
- 189. Finlayson M, Plow M, Cho C. Use of physical therapy services among middle-aged and older adults with multiple sclerosis. *Phys Ther* 2010;90(11):1607-18.
- 190. Allen NE, Song J, Paul SS, et al. Predictors of adherence to a falls prevention exercise program for people with Parkinson's disease. *Movement disorders clinical practice* 2015;2(4):395-401.
- 191. Keus SH, Bloem BR, Verbaan D, et al. Physiotherapy in Parkinson's disease: utilisation and patient satisfaction. *J Neurol* 2004;251(6):680-7.
- 192. Cherney LR. Ethical issues involving the right hemisphere stroke patient: to treat or not to treat? *Top Stroke Rehabil* 2006;13(4):47-53.

- 193. Sharp HM. Ethical issues in the management of dysphagia after stroke. *Topics in Stroke Rehabilitation* 2006;13(4):18-25.
- 194. Johnston J, PGDipHSc P. Physiotherapy alignment with guidelines for the management of stroke in the inpatient setting. *New Zealand Journal of Physiotherapy* 2013;41(3):102.
- 195. Norris M, Kilbride C. From dictatorship to a reluctant democracy: stroke therapists talking about self-management. *Disability and rehabilitation* 2014;36(1):32-38.
- 196. Salbach NM, Jaglal SB, Korner-Bitensky N, et al. Practitioner and organizational barriers to evidence-based practice of physical therapists for people with stroke. *Physical therapy* 2007;87(10):1284-303.

11 Appendix A: Search results (databases)

11.1 Search results

Table 13 Summary of database search results for SRs and economic studies (27 September 2020)

Source	Results
PubMed and Embase	3,716
The Cochrane Library (incl. CENTRAL)	168
York CRD	1,198
INAHTA HTA database	146
EconLit	3
PEDro	883
Total	6,114

Table 14 Summary of database search results RCTs (from inception to 22 October 2020)

Source	Results
PubMed and Embase	7,341
The Cochrane Library (incl. CENTRAL)	367
PEDro	1,056
Total	8,764

11.2 Search strings

Table 15 Embase and Medline search for SRs and economic analyses (from inception to 27 September 2020)

Database(s): Embase 1974 to 2020 October 21, OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present		
#	Searches	Results
1	exp Physical Therapy Modalities/ use ppez	154232
2	Physiotherapy/ use oemezd	85622
3	Constraint Induced Therapy/ use oemezd	564
4	Electrotherapy/ use oemezd	1499
5	Electrostimulation/ use oemezd	69540
6	Hippotherapy/ use oemezd	370
7	Home Physiotherapy/ use oemezd	325
8	exp Kinesiotherapy/ use oemezd	79299
9	Cryotherapy/	23455

10	exp Hyperthermia, Induced/ use ppez	32322
11	Thermotherapy/ use oemezd	2784
12	exp Massage/	20607
13	exp Ultrasonic Therapy/ use ppez	12161
14	exp Ultrasound Therapy/ use oemezd	16353
15	exp Phototherapy/	132230
16	(manual therap* or physiotherap* or physio-therap* or (physic* adj therap*) or CIMT or mCIMT or FES or NMES).tw,kf,kw,dv.	161647
17	((aerobic* or aquatic? or balance or bilateral or bi-lateral or breathing or cardiovascular or cardiovascular or dualtask or dual-task or electromechanical assist* or electro-mechanical assist* or endurance or equine-assisted or exercise? or exercising or fitness or gait or horseback rid* or horseback rid* or lower extremit* or lower limb* or mirror? or mobility or mobilisation or mobilization or motion? or movement? or muscle stretch* or physical or resistance or respiratory muscle? or strength or strengthening or taskoriented or task-oriented or task specific or treadmill* or tread-mill* or upper extremit* or upper limb*) adj2 (rehabilitat* or retraining or re-training or program* or therap* or training)).tw,kf,kw,dv.	299700
18	(ammotherap* or (biostimulat* adj2 laser*) or cryotherap* or cryo-therap* or cryotherm* or cryo-therm* or cryo-therm* or cryo-treatment? or ((induc* or local*) adj (hyperthermi* or hyper-thermi* or hypo-thermi*)) or (manual* adj (lymph* adj2 drain*)) or ((lowlevel? laser? or low-level? laser? or low-power* laser?) adj2 (irradiat* or therap*)) or massotherap* or massotherap* or phototherap* or photo-therap* or thermotherap* or thermo-therap* or ((cold or cryogenic* or fever* or heat or hyperthermia? or hyper-thermia? or infrared or infra-red or light? or massag* or photobiomodulat* or photo-biomodulat* or ultrasonic* or ultrasound?) adj2 (therap* or treatment?))).tw,kf,kw,dv.	157043
19	(aquatherap* or aqua-therap* or hydrotherap* or hydro-therap*).tw,kf,kw,dv.	3004
20	((electric* adj3 stimulation) or electrostimul* or electro-stimul* or electrotherap* or electro-therap* or galvanostimulation or galvano-stimulation).tw,kf,kw,dv.	146128
21	(hippotherap* or hippo-therap*).tw,kf,kw,dv.	482
22	medical training therap*.tw,kf,kw,dv.	59
23	exp Exercise/	542917
24	(rehabilitat* or retraining or re-training or program* or therap* or training).mp.	17746222
25	(exercis* adj3 (rehabilitat* or retraining or re-training or program* or therap* or training)).ti,kf,kw.	40784
26	(23 and 24) or 25	296946
27	or/1-22,26 [Physiotherapeutic Interventions]	1181329
28	*Nervous System Diseases/ use ppez	30234
29	*Neurologic Disease/ use oemezd	32999
30	((neurologic* or nervous system?) adj2 (disease? or disorder?)).ti,kf,kw.	32294
31	exp *Multiple Sclerosis/	137737
32	*Demyelinating Autoimmune Diseases, CNS/ use ppez	362
33	(multiple adj (scleros#s or scleroti*)).ti,kf,kw.	136386
34	MS.ti. and (multiple adj (scleros#s or scleroti*)).ab.	7395
35	(MS adj10 (scleros#s or scleroti*)).ti,kf,kw.	3530
36	((disseminated or insular or multiplex) adj (scleros#s or scleroti*)).ti,kf,kw.	773
37	((PPMS or PRMS or RPMS or SPMS) adj10 (progressive or relaps* or remit* or scleros#s or scleroti*)).ti,kf,kw.	137
38	((ARMS or RMS or RRMS) adj10 (relaps* or remit* or scleros#s or scleroti*)).ti,kf,kw.	535

-		
39	(encephalomyelit* adj2 disseminat*).ti,kf,kw.	2756
40	exp *Parkinson Disease/	157019
41	((Parkinson* adj disease?) or Primary Parkinsonism or Paralysis Agitans).ti,kf,kw.	157978
42	PD.ti. and Parkinson*.ab.	2709
43	*Brain Ischemia/	118294
44	exp *Intracranial Hemorrhages/ use ppez	51162
45	exp *Brain Hemorrhage/ use oemezd	54436
46	exp *Stroke/ use ppez	102506
47	exp *Cerebrovascular Accident/ use oemezd	82827
48	*Stroke Rehabilitation/	12170
49	(stroke* or poststroke? or CVA or CVAs).ti,kf,kw.	320040
50	((cerebrovascular* or cerebro-vascular* or cerebral vascular*) adj2 (apoplex* or accident* or infarct*)).ti,kf,kw.	6027
51	((brain or cerebral or intracerebral or intra-cerebral or arachnoid or subarachnoid or sub-arachnoid or intracranial* or intra-cranial* or cranial*) adj2 (infarct* or isch?emi* or h?emorrhag*)).ti,kf,kw.	147137
52	((postacute or post-acute or chronic) adj5 (stroke* or poststroke? or post-stroke?)).tw,kf,kw.	18341
53	(((postacute or post-acute or chronic) adj5 (hemipare* or paretic or paresis or phase? or stage? or state? or condition? or paraly* or spastic*)) and (stroke* or poststroke? or post-stroke?)).tw,kf,kw.	9732
54	or/28-53 [Population for SR/Econ]	985945
55	Meta-Analysis.pt.	120152
56	Meta-Analysis/ or Systematic Review/ or Meta-Analysis as Topic/ or "Meta Analysis (Topic)"/ or "Systematic Review (Topic)"/ or exp Technology Assessment, Biomedical/ or Network Meta-Analysis/	648544
57	(meta-analy* or metaanaly* or met-analy* or metanaly*).tw,kf,kw.	426047
58	(systematic review* or systematic overview* or evidence-based review* or evidence-based overview* or (evidence adj3 (review* or overview*)) or meta-review* or meta-overview* or meta-synthes* or rapid review* or "review of reviews" or umbrella review?).tw,kf,kw.	501853
59	(technology assessment* or HTA or HTAs or technology overview* or technology appraisal*).tw,kf,kw.	23569
60	((quantitative adj3 (review* or overview* or synthes*)) or (research adj3 (integrati* or overview*))).tw,kf,kw.	24650
61	((integrative adj3 (research or review* or overview*)) or (collaborative adj3 (review* or overview*)) or (pool* adj3 analy*)).tw,kf,kw.	68709
62	(meta regression* or metaregression*).tw,kf,kw.	20984
63	(systematic review* or biomedical technology assessment* or bio-medical technology assessment*).mp,hw.	560637
64	(cochrane or (health adj2 technology assessment) or evidence report or systematic review?).jw.	54282
65	((indirect or indirect treatment or mixed-treatment or bayesian) adj3 comparison*).tw,kf,kw.	9109
66	(multi* adj3 treatment adj3 comparison*).tw,kf,kw.	590
67	(multi* adj2 paramet* adj2 evidence adj2 synthesis).tw,kf,kw.	35
68	(multiparamet* adj2 evidence adj2 synthesis).tw,kf,kw.	35
69	(multi-paramet* adj2 evidence adj2 synthesis).tw,kf,kw.	29
70	or/55-69 [SR/MA/HTA filter]	1003662
71	Economics/	266491
72	exp "Costs and Cost Analysis"/	591273

73	Economics, Nursing/	35143
74	Economics, Medical/	41161
75	Economics, Pharmaceutical/	10331
76	exp Economics, Hospital/	879730
77	Economics, Dental/	34968
78	exp "Fees and Charges"/	70717
79	exp Budgets/	43183
80	Economics/	266491
81	Cost/	107552
82	exp Health Economics/	855030
83	Budget/	40783
84	budget*.tw,kf,kw.	69800
85	(economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or finance or finances or financed).ti,kf,kw.	518789
86	(economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or finance or finances or financed).ab. /freq=2	711482
87	(cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ab,kf,kw.	399910
88	(value adj2 (money or monetary)).tw,kf,kw.	5787
89	exp Models, Economic/	17421
90	Statistical Model/	253972
91	economic model*.ab,kf,kw.	8376
92	Markov Chains/	20313
93	Probability/	165068
94	markov.tw,kf,kw.	53077
95	Monte Carlo Method/	69497
96	monte carlo.tw,kf,kw.	101048
97	exp Decision Theory/	13877
98	Decision Tree/	24584
99	(decision* adj2 (tree* or analy* or model*)).tw,kf,kw.	60423
101	or/71-99 [Econ Eval filter]	2523287
102	(Case Reports/ or letter.pt.) not ((Case Reports/ or letter.pt.) and randomized controlled trial.pt.)	4147557
103	Conference Abstract/	974462
104	102 or 103 [Conference abstracts, etc not of interest]	5122017
105	27 and 54 and 70	3449
106	(27 and 54 and 70) not 104 [SRs]	3296
107	limit 106 to (english or french or german or italian)	3232
108	remove duplicates from 107 [Final SR set]	2186
109	27 and 54 and 101	2063
110	(27 and 54 and 101) not 104 [Econ Evals]	1936

111	limit 110 to (english or french or german or italian)	1908
112	remove duplicates from 111 [Final Econ Eval set]	1530

Table 16 Cochrane library search strategy (from inception to 27 September 2020)

```
Search string | CDSR | 168 results
exp Physical Therapy Modalities
Cryotherapy
exp Hyperthermia, Induced
exp Massage
exp Ultrasonic Therapy
exp Phototherapy
manual therap* OR physiotherap* OR physio-therap* OR (physic* NEXT therap*) OR CIMT OR mCIMT OR FES OR
NMES =ti,ab,kw
(aerobic* OR aquatic* OR balance OR bilateral OR bi-lateral OR breathing OR cardiovascular OR cardio-vascular OR
dualtask OR dual-task OR electromechanical assist* OR electro-mechanical assist* OR endurance OR equine-assisted
OR exercise* OR exercising OR fitness OR gait OR horseback rid* OR horse-back rid* OR lower extremit* OR lower
limb* OR mirror* OR mobility OR mobilisation OR mobilization OR motion* OR movement* OR muscle stretch* OR
physical OR resistance OR respiratory muscle* OR strength OR strengthening OR taskoriented OR task-oriented OR
task specific OR treadmill* OR tread-mill* OR upper extremit* OR upper limb*) NEAR/2 (rehabilitat* OR retraining OR re-
training OR program* OR therap* OR training) =ti,ab,kw
ammotherap* OR (biostimulat* NEAR/2 laser*) OR cryotherap* OR cryo-therap* OR cryotherm* OR cryo-therm* OR
cryotreatment* OR cryo-treatment* OR ((induc* OR local*) NEXT (hyperthermi* OR hyper-thermi* OR hyper-thermi
hypo-thermi*)) OR (manual* NEXT (lymph* NEAR/2 drain*)) OR ((lowlevel* laser* OR low-level* laser* OR lowpower*
laser* OR low-power* laser*) NEAR/2 (irradiat* OR therap*)) OR massotherap* OR masso-therap* OR phototherap* OR
photo-therap* OR thermotherap* OR thermo-therap* OR ((cold OR cryogenic* OR fever* OR heat OR hyperthermia* OR
hyper-thermia* OR infrared OR infra-red OR light* OR massag* OR photobiomodulat* OR photo-biomodulat* OR
ultrasonic* OR ultrasound*) NEAR/2 (therap* OR treatment*)) =ti,ab,kw
aguatherap* OR agua-therap* OR hydrotherap* OR hydro-therap* =ti,ab,kw
(electric* NEAR/3 stimulation) OR electrostimul* OR electro-stimul* OR electrotherap* OR electro-therap* OR
galvanostimulation OR galvano-stimulation =ti,ab,kw
hippotherap* OR hippo-therap* =ti,ab,kw
medical training therap* =ti,ab,kw
exp Exercise
rehabilitat* OR retraining OR re-training OR program* OR therap* OR training =all
exercis* NEAR/3 (rehabilitat* OR retraining OR re-training OR program* OR therap* OR training) =.ti
Nervous System Diseases
(neurologic* OR nervous system*) NEAR/2 (disease* OR disorder*) =.ti
exp Multiple Sclerosis
multiple NEXT (scleros#s OR scleroti*) =.ti
MS NEAR/10 (scleros#s OR scleroti*) =.ti
(disseminated OR insular OR multiplex) NEXT (scleros#s OR scleroti*) =.ti
(PPMS OR PRMS OR RPMS OR SPMS) NEAR/10 (progressive OR relaps* OR remit* OR scleros#s OR scleroti*) = ti
((ARMS OR RMS OR RRMS) NEAR/10 (relaps* OR remit* OR scleros#s OR scleroti*)) OR (encephalomyelit* NEAR/2
disseminat*) =.ti
exp Parkinson Disease
(Parkinson* NEXT disease*) OR Primary Parkinsonism OR Paralysis Agitans = .ti
Brain Ischemia
exp Intracranial Hemorrhages
exp Stroke
```

Stroke Rehabilitation

stroke* OR poststroke* OR post-stroke* OR CVA OR CVAs =.ti

(cerebrovascular* OR cerebro-vascular* OR cerebral vascular*) NEAR/2 (apoplex* OR accident* OR infarct*) =.ti (brain OR cerebral OR intracerebral OR intra-cerebral OR arachnoid OR sub-arachnoid OR intra-cranial* OR intra-cranial* OR cranial*) NEAR/2 (infarct* OR isch*emi* OR h*emorrhag*) =.ti (postacute OR post-acute OR chronic) NEAR/5 (stroke* OR poststroke* OR post-stroke*) =.ti,ab,kf. ((postacute OR post-acute OR chronic) NEAR/5 (hemipare* OR paretic OR paresis OR phase* OR stage* OR state* OR condition* OR paraly* OR spastic*)) and (stroke* OR poststroke* OR post-stroke*) =.ti,ab,kf.

Table 17 PEDro search strategy (from inception to 27 Sep 2020)

#	Searches	Results
1	Multiple Sclero*	123
2	Parkinson* Disease*	148
3	stroke*	520
4	poststroke*	30
5	post-stroke*	54
6	cerebrovascular* apoplex*	0
7	cerebro-vascular* apoplex*	0
8	cerebral vascular* apoplex*	0
9	cerebrovascular* accident*	4
10	cerebro-vascular* accident*	0
11	cerebral vascular* accident*	2
12	cerebrovascular* infarct*	1
13	cerebro-vascular* infarct*	0
14	cerebral vascular* infarct*	1
15	brain infarct*	6
16	brain ischaemi*	1
17	brain ischemi*	5
18	brain haemorrhag*	0
19	brain hemorrhag*	0
20	cerebral infarct*	1
21	cerebral ischaemi*	0
22	cerebral ischemi*	0
23	cerebral haemorrhag*	0
24	cerebral hemorrhag*	0
25	intracerebral infarct*	0
26	intracerebral ischaemi*	0
27	intracerebral ischemi*	0
28	intracerebral haemorrhag*	0
29	intracerebral hemorrhag*	2
30	intra-cerebral infarct*	0
31	intra-cerebral ischaemi*	0
32	intra-cerebral ischemi*	0
33	intra-cerebral haemorrhag*	0
34	intra-cerebral hemorrhag*	0

35	arachnoid infarct*	0
36	arachnoid ischaemi*	0
37	arachnoid ischemi*	0
38	arachnoid haemorrhag*	0
39	arachnoid hemorrhag*	0
40	subarachnoid infarct*	0
41	subarachnoid ischaemi*	0
42	subarachnoid ischemi*	0
43	subarachnoid haemorrhag*	1
44	subarachnoid hemorrhag*	0
45	sub-arachnoid infarct*	0
46	sub-arachnoid ischaemi*	0
47	sub-arachnoid ischemi*	0
48	sub-arachnoid haemorrhag*	0
49	sub-arachnoid hemorrhag*	0
50	intracranial* infarct*	0
51	intracranial* ischaemi*	0
52	intracranial* ischemi*	0
53	intracranial* haemorrhag*	0
54	intracranial* hemorrhag*	0
55	intra-cranial* infarct*	0
56	intra-cranial* ischaemi*	0
57	intra-cranial* ischemi*	0
58	intra-cranial* haemorrhag*	0
59	intra-cranial* hemorrhag*	0
60	cranial* infarct*	0
61	cranial* ischaemi*	0
62	cranial* ischemi*	0
63	cranial* haemorrhag*	0
64	cranial* hemorrhag*	0
65	1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43 OR 44 OR 45 OR 46 OR 47 OR 48 OR 49 OR 50 OR 51 OR 52 OR 53 OR 54 OR 55 OR 56 OR 57 OR 58 OR 59 OR 60 OR 61 OR 62 OR 63 OR 64	883

Table 18 York CRD search strategy (from inception to 27 Sep 2020)

#	Search	Results
1	MeSH DESCRIPTOR Physical Therapy Modalities EXPLODE ALL TREES	2401
2	MeSH DESCRIPTOR Cryotherapy EXPLODE ALL TREES	136
3	MeSH DESCRIPTOR Hyperthermia, Induced EXPLODE ALL TREES	226
4	MeSH DESCRIPTOR Massage EXPLODE ALL TREES	96
5	MeSH DESCRIPTOR Ultrasonic Therapy EXPLODE ALL TREES	121
6	MeSH DESCRIPTOR Phototherapy EXPLODE ALL TREES	316

7	(manual therap* OR physiotherap* OR physio-therap* OR (physic* ADJ therap*) OR CIMT OR mCIMT OR FES OR NMES):TI OR ((aerobic* OR aquatic* OR balance OR bilateral OR bi-lateral OR breathing OR cardiovascular OR cardio-vascular OR dualtask OR dual-task OR electromechanical assist* OR electro-mechanical assist* OR endurance OR equine-assisted OR exercise* OR exercising OR fitness OR gait OR horseback rid* OR horse-back rid* OR lower extremit* OR lower limb* OR mirror* OR mobility OR mobilisation OR mobilization OR motion* OR movement* OR muscle stretch* OR physical OR resistance OR respiratory muscle* OR strength OR strengthening OR taskoriented OR task-oriented OR task specific OR treadmill* OR tread-mill* OR upper extremit* OR upper limb*) ADJ2 (rehabilitat* OR retraining OR re-training OR program* OR therap* OR training)):TI OR (ammotherap* OR (biostimulat* ADJ2 laser*) OR cryotherap* OR cryo-therap* OR cryotherm* OR cryo-therm* OR cryothermi* OR hypothermi* OR hypothermi* OR ((induc* OR local*) ADJ (hyperthermi* OR hyper-thermi* OR hypothermi* OR hypothermi*)) OR (manual* ADJ (lymph* ADJ2 drain*)) OR ((lowlevel* laser* OR low-level* laser* OR lowpower* laser* OR low-power* laser*) ADJ2 (irradiat* OR therap*)) OR massotherap* OR masso-therap* OR phototherap* OR photo-therap* OR thermotherap* OR thermotherap* OR light* OR massag* OR photobiomodulat* OR photo-biomodulat* OR ultrasounic* OR ultrasound*) ADJ2 (therap* OR treatment*))):TI	
8	(aquatherap* OR aqua-therap* OR hydrotherap* OR hydro-therap*):TI OR ((electric* ADJ3 stimulation) OR electrostimul* OR electro-stimul* OR electrotherap* OR electro-therap* OR galvanostimulation OR galvano-stimulation):TI OR (hippotherap* OR hippo-therap* OR medical training therap*):TI	216
9	MeSH DESCRIPTOR Exercise EXPLODE ALL TREES	1137
10	(rehabilitat* OR retraining OR re-training OR program* OR therap* OR training)	45576
11	#9 AND #10	903
12	(exercis* ADJ3 (rehabilitat* OR retraining OR re-training OR program* OR therap* OR training)):TI	315
13	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #11 OR #12	3928
14	MeSH DESCRIPTOR Nervous System Diseases EXPLODE ALL TREES	10135
15	((neurologic* OR nervous system*) ADJ2 (disease* OR disorder*)):TI	30
16	MeSH DESCRIPTOR Multiple Sclerosis EXPLODE ALL TREES	294
17	MeSH DESCRIPTOR Demyelinating Autoimmune Diseases, CNS EXPLODE ALL TREES	299
18	(multiple ADJ (scleros* OR scleroti*)):TI OR (MS ADJ10 (scleros* OR scleroti*)):TI OR ((disseminated OR insular OR multiplex) ADJ (scleros* OR scleroti*)):TI	311
19	((ARMS OR RMS OR RRMS) ADJ10 (relaps* OR remit* OR scleros* OR scleroti*)):TI OR (encephalomyelit* ADJ2 disseminat*):TI	1
20	MeSH DESCRIPTOR Parkinson Disease EXPLODE ALL TREES	243
21	((Parkinson* ADJ disease*) OR Primary Parkinsonism OR Paralysis Agitans):TI	273
22	MeSH DESCRIPTOR Brain Ischemia EXPLODE ALL TREES	326
23	MeSH DESCRIPTOR Intracranial Hemorrhages EXPLODE ALL TREES	258
24	MeSH DESCRIPTOR Stroke EXPLODE ALL TREES	1354
25	MeSH DESCRIPTOR Stroke Rehabilitation EXPLODE ALL TREES	1
26	(stroke* OR poststroke* OR post-stroke* OR CVA OR CVAs):TI OR ((cerebrovascular* OR cerebrovascular* OR cerebral vascular*) ADJ2 (apoplex* OR accident* OR infarct*)):TI OR ((brain OR cerebral OR intracerebral OR intra-cerebral OR arachnoid OR sub-arachnoid OR intracranial* OR intra-cranial* OR cranial*) ADJ2 (infarct* OR ischaemi* OR ischemi* OR haemorrhag* OR hemorrhag*)):TI	1354
27	((postacute OR post-acute OR chronic) ADJ5 (stroke* OR poststroke* OR post-stroke*)):TI OR (((postacute OR post-acute OR chronic) ADJ5 (hemipare* OR paretic OR paresis OR phase* OR stage* OR state* OR condition* OR paraly* OR spastic*)) AND (stroke* OR poststroke* OR poststroke*)):TI	17
28	#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27	10490
29	#13 AND #28	1198

Table 19 International HTA database search strategy (2015 up to 27 Sep 2020)

#	Searches	
1	(Physical Therapy Modalities)[mh] OR (Cryotherapy)[mh] OR (Hyperthermia, Induced)[mh] OR (Massage)[mh] OR (Ultrasonic Therapy)[mh] OR (Phototherapy)[mh] OR (manual therap* OR physiotherap* OR physiotherap* OR physical therap* OR CIMT OR mCIMT OR FES OR NMES OR aerobic* OR aquatic* OR balance OR bilateral OR bi-lateral OR breathing OR cardiovascular OR cardio-vascular OR dualtask OR dual-task OR electromechanical assist* OR electro-mechanical assist* OR endurance OR equine-assisted OR exercise* OR exercising OR fitness OR gait OR horseback rid* OR horse-back rid* OR lower extremit* OR lower limb* OR mirror* OR mobility OR mobilisation OR mobilization OR motion* OR movement* OR muscle stretch* OR physical OR resistance OR respiratory muscle* OR strength OR strengthening OR taskoriented OR task-oriented OR task specific OR treadmill* OR tread-mill* OR upper extremit* OR upper limb* OR ammotherap* OR laser* OR cryotherap* OR cryo-therap* OR cryotherm* OR cryo-therm* OR cryotreatment* OR hyperthermi* OR hyper-thermi* OR hyper-thermi* OR hyper-thermi* OR hyper-thermi* OR hyper-thermi* OR thermo-therap* OR cold OR cryogenic* OR fever* OR heat OR hyperthermia* OR hyper-thermia* OR infrared OR infrared OR light* OR massag* OR photobiomodulat* OR photo-biomodulat* OR ultrasonic* OR ultrasound* OR aquatherap* OR aqua-therap* OR hydrotherap* OR hydro-therap* OR electric* stimulation OR electrostimul* OR electro-stimul* OR electrotherap* OR medical training therap*)[Title]	
2	(Nervous System Diseases)[mh] OR (Multiple Sclerosis)[mh] OR (Parkinson Disease)[mh] OR (Brain Ischemia)[mh] OR (Intracranial Hemorrhages)[mh] OR (Stroke)[mh] OR (Stroke Rehabilitation)[mh] OR (neurologic disease* OR neurologic disorder* OR nervous system disease* OR nervous system disorder* OR Multiple Sclerosis OR Parkinson* Disease* OR Brain Ischemi* OR Intracranial Hemorrhag* OR Stroke* OR Stroke Rehabilitation OR poststroke* OR post-stroke*)[Title]	-
3	1 AND 2	146

Table 20 EconLit search strategy (from inception to 27 Sep 2020)

#	Searches			
	SU (Physical Therapy Modalities OR Cryotherapy OR Hyperthermia OR Massage OR Ultrasonic			
	Therapy OR Phototherapy) OR TI (manual therap* OR physiotherap* OR physiotherap* OR (physio*			
	N1 therap*) OR CIMT OR mCIMT OR FES OR NMES) OR AB (manual therap* OR physiotherap* OR			
	physio-therap* OR (physic* N1 therap*) OR CIMT OR mCIMT OR FES OR NMES) OR TI ((aerobic*			
	OR aquatic* OR balance OR bilateral OR bi-lateral OR breathing OR cardiovascular OR cardio-vascular OR dualtask OR dual-task OR electromechanical assist* OR electro-mechanical assist* OR endurance			
	OR equine-assisted OR exercise* OR exercising OR fitness OR gait OR horseback rid* OR horse-back			
	rid* OR lower extremit* OR lower limb* OR mirror* OR mobility OR mobilisation OR mobilization OR			
	motion* OR movement* OR muscle stretch* OR physical OR resistance OR respiratory muscle* OR			
	strength OR strengthening OR taskoriented OR task-oriented OR task specific OR treadmill* OR tread-			
	mill* OR upper extremit* OR upper limb*) N2 (rehabilitat* OR retraining OR re-training OR program* OR			
	therap* OR training)) OR AB ((aerobic* OR aquatic* OR balance OR bilateral OR bi-lateral OR			
	breathing OR cardiovascular OR cardio-vascular OR dualtask OR dual-task OR electromechanical			
	assist* OR electro-mechanical assist* OR endurance OR equine-assisted OR exercise* OR exercising OR fitness OR gait OR horseback rid* OR horse-back rid* OR lower extremit* OR lower limb* OR			
	mirror* OR mobility OR mobilisation OR mobilization OR motion* OR movement* OR muscle stretch*			
	OR physical OR resistance OR respiratory muscle* OR strength OR strengthening OR taskoriented OR			
	task-oriented OR task specific OR treadmill* OR tread-mill* OR upper extremit* OR upper limb*) N2			
	(rehabilitat* OR retraining OR re-training OR program* OR therap* OR training)) OR TI (ammotherap*			
	OR (biostimulat* N2 laser*) OR cryotherap* OR cryo-therap* OR cryotherm* OR cryo-therm* OR			
	cryotreatment* OR cryo-treatment* OR ((induc* OR local*) N1 (hyperthermi* OR hyper-thermi* OR			
	hypothermi* OR hypo-thermi*)) OR (manual* N1 (lymph* N2 drain*)) OR ((lowlevel* laser* OR low-level*			
	laser* OR lowpower* laser* OR low-power* laser*) N2 (irradiat* OR therap*)) OR massotherap* OR			
	masso-therap* OR phototherap* OR photo-therap* OR thermotherap* OR thermo-therap* OR ((cold OR			
	cryogenic* OR fever* OR heat OR hyperthermia* OR hyper-thermia* OR infrared OR infra-red OR light*			
1	OR massag* OR photobiomodulat* OR photo-biomodulat* OR ultrasonic* OR ultrasound*) N2 (therap*	1,431		
	OR treatment*))) OR AB (ammotherap* OR (biostimulat* N2 laser*) OR cryotherap* OR cryo-therap*	1,43		

OR cryotherm* OR cryo-therm* OR cryotreatment* OR cryo-treatment* OR ((induc* OR local*) N1 (hyperthermi* OR hyper-thermi* OR hypothermi* OR hypo-thermi*)) OR (manual* N1 (lymph* N2 drain*)) OR ((lowlevel* laser* OR low-level* laser* OR lowpower* laser* OR low-power* laser*) N2 (irradiat* OR therap*)) OR massotherap* OR masso-therap* OR photo-therap* OR thermotherap* OR thermo-therap* OR ((cold OR cryogenic* OR fever* OR heat OR hyperthermia* OR hyper-thermia* OR infrared OR infra-red OR light* OR massag* OR photobiomodulat* OR photobiomodulat* OR ultrasonic* OR ultrasound*) N2 (therap* OR treatment*))) OR TI (aquatherap* OR agua-therap* OR hydrotherap* OR hydro-therap* OR (electric* N3 stimulation) OR electrostimul* OR electro-stimul* OR electrotherap* OR electro-therap* OR galvano-stimulation OR galvano-stimulation OR hippotherap* OR hippo-therap* OR medical training therap*) OR AB (aguatherap* OR agua-therap* OR hydrotherap* OR hydro-therap* OR (electric* N3 stimulation) OR electrostimul* OR electro-stimul* OR electrotherap* OR electro-therap* OR galvanostimulation OR galvano-stimulation OR hippotherap* OR hippo-therap* OR medical training therap*) OR TX (exercis* N3 (rehabilitat* OR retraining OR retraining OR program* OR therap* OR training)) SU (Nervous System Diseases OR Multiple Sclerosis OR Demyelinating Autoimmune Diseases, CNS OR Parkinson Disease OR Brain Ischemia OR Intracranial Hemorrhages OR Stroke OR Stroke Rehabilitation) OR TI ((neurologic* OR nervous system*) N2 (disease* OR disorder*)) OR TI (multiple N1 (scleros* OR scleroti*)) OR TI (MS N10 (scleros* OR scleroti*)) OR TI ((disseminated OR insular OR multiplex) N1 (scleros#s OR scleroti*)) OR TI ((PPMS OR PRMS OR RPMS OR SPMS) N10 (progressive OR relaps* OR remit* OR scleros* OR scleroti*)) OR TI ((ARMS OR RMS OR RRMS) N10 (relaps* OR remit* OR scleros#s OR scleroti*)) OR TI encephalomyelit* N2 disseminat* OR TI ((Parkinson* N1 disease*) OR Primary Parkinsonism OR Paralysis Agitans) OR TI (stroke* OR poststroke* OR post-stroke* OR CVA OR CVAs) OR TI ((brain OR cerebral OR intracerebral OR intracerebral OR arachnoid OR subarachnoid OR sub-arachnoid OR intracranial* OR intra-cranial* OR cranial*) N2 (infarct* OR ischaemi* OR ischemi* OR haemorrhag* OR hemorrhag*)) OR TI ((postacute 2 OR post-acute OR chronic) N5 (stroke* OR poststroke* OR post-stroke*)) 251 TI ((postacute OR post-acute OR chronic) N5 (hemipare* OR paretic OR paresis OR phase* OR stage* OR state* OR condition* OR paraly* OR spastic*)) AND (stroke* OR poststroke* OR post-stroke*) 3 0 3 1 AND 2

Table 21 Search strings for RCTs (from inception to 22 October 2020)

	Database(s): Embase 1974 to 2020 October 21, OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present				
#	# Searches				
1	exp Physical Therapy Modalities/ use ppez	154861			
2	Physiotherapy/ use oemezd	86194			
3	Constraint Induced Therapy/ use oemezd	573			
4	Electrotherapy/ use oemezd	1531			
5	Electrostimulation/ use oemezd	69790			
6	Hippotherapy/ use oemezd	378			
7	Home Physiotherapy/ use oemezd	327			
8	exp Kinesiotherapy/ use oemezd	79945			
9	Cryotherapy/ [both]	23555			
10	exp Hyperthermia, Induced/ use ppez	32436			
11	Thermotherapy/ use oemezd	2861			
12	exp Massage/ [both]	20720			
13	exp Ultrasonic Therapy/ use ppez	12213			
14	exp Ultrasound Therapy/ use oemezd	16691			
15	exp Phototherapy/ [both]	133074			

16	(manual therap* or physiotherap* or physio-therap* or (physic* adj therap*) or CIMT or mCIMT or FES or NMES).tw,kf,kw,dv.	162852
17	((aerobic* or aquatic? or balance or bilateral or bi-lateral or breathing or cardiovascular or cardio-vascular or dualtask or dual-task or electromechanical assist* or electro-mechanical assist* or endurance or equine-assisted or exercise? or exercising or fitness or gait or horseback rid* or horse-back rid* or lower extremit* or lower limb* or mirror? or mobility or mobilisation or mobilization or motion? or movement? or muscle stretch* or physical or resistance or respiratory muscle? or strength or strengthening or taskoriented or task-oriented or task specific or treadmill* or tread-mill* or upper extremit* or upper limb*) adj2 (rehabilitat* or retraining or re-training or program* or therap* or training)).tw,kf,kw,dv.	
18	(ammotherap* or (biostimulat* adj2 laser*) or cryotherap* or cryo-therap* or cryotherm* or cryo-therm* or cryotreatment? or cryo-treatment? or ((induc* or local*) adj (hyperthermi* or hyper-thermi* or hypothermi*)) or (manual* adj (lymph* adj2 drain*)) or ((lowlevel? laser? or low-level? laser? or low-power* laser?) adj2 (irradiat* or therap*)) or massotherap* or masso-therap* or phototherap* or photo-therap* or thermotherap* or thermo-therap* or ((cold or cryogenic* or fever* or heat or hyperthermia? or hyper-thermia? or infrared or infra-red or light? or massag* or photobiomodulat* or photo-biomodulat* or ultrasonic* or ultrasound?) adj2 (therap* or treatment?))).tw,kf,kw,dv.	157995
19	(aquatherap* or aqua-therap* or hydrotherap* or hydro-therap*).tw,kf,kw,dv.	3015
20	((electric* adj3 stimulation) or electrostimul* or electro-stimul* or electrotherap* or electro-therap* or galvanostimulation or galvano-stimulation).tw,kf,kw,dv.	146613
21	(hippotherap* or hippo-therap*).tw,kf,kw,dv.	486
22	medical training therap*.tw,kf,kw,dv.	59
23	exp Exercise/ [both]	
24	(rehabilitat* or retraining or re-training or program* or therap* or training).mp.	17834932
25	(exercis* adj3 (rehabilitat* or retraining or re-training or program* or therap* or training)).ti,kf,kw.	
26	(23 and 24) or 25	
27	or/1-22,26 [Physiotherapeutic Interventions]	
28	exp *Multiple Sclerosis/ [both]	
29	*Demyelinating Autoimmune Diseases, CNS/ use ppez	364
30	(multiple adj (scleros#s or scleroti*)).ti,kf,kw.	137290
31	MS.ti. and (multiple adj (scleros#s or scleroti*)).ab.	7474
32	(MS adj10 (scleros#s or scleroti*)).ti,kf,kw.	3570
33	((disseminated or insular or multiplex) adj (scleros#s or scleroti*)).ti,kf,kw.	773
34	((PPMS or PRMS or RPMS or SPMS) adj10 (progressive or relaps* or remit* or scleros#s or scleroti*)).ti,kf,kw.	140
35	((ARMS or RMS or RRMS) adj10 (relaps* or remit* or scleros#s or scleroti*)).ti,kf,kw.	541
36	(encephalomyelit* adj2 disseminat*).ti,kf,kw.	2768
37	exp *Parkinson Disease/ [both]	158007
38	((Parkinson* adj disease?) or Primary Parkinsonism or Paralysis Agitans).ti,kf,kw.	159259
39	PD.ti. and Parkinson*.ab.	
40	*Brain Ischemia/ [both]	119234
41	exp *Intracranial Hemorrhages/ use ppez	51338
42	exp *Brain Hemorrhage/ use oemezd	54944
43	exp *Stroke/ use ppez	103074
44	exp *Cerebrovascular Accident/ use oemezd	83515
45	*Stroke Rehabilitation/ [both]	12305

52 Longitudinal Studies/ use ppez 138571 53 Longitudinal Study/ use oemezd 146559 54 Time/ 334516 55 Time Factors/ use ppez 119280 56 Time Factors/ use ppez 119280 56 Time Factors/ use oemezd 36573 7 "Duration of Therapy"/ use ppez 161 58 Treatment Duration/ use oemezd 235452 59 (duration? or (long' adj term?) or long-term* or longitudinal* or time*).tw,kf,kw. 117211 60 or/52-59 [Long-term Study filter] 10 (Randomized Controlled Trial or Controlled Clinical Trial or Pragmatic Clinical Trial or Adaptive Clinical Trial or Equivalence Trial or Clinical Trial, Phase III or Clinical Trial, Phase IV).pt. 61 (Randomized Controlled Trial/ 62 Randomized Controlled Trials as Topic/ 63 exp Randomized Controlled Trial (topic)"/ 65 Controlled Clinical Trial (topic)"/ 66 exp Controlled Clinical Trial (topic)"/ 67 "Controlled Clinical Trial (topic)"/ 68 (random* or sham or placebo*) tw kf.kw. 69 ((singl* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 10 ((tirpi* or trebi*) adj (blind* or dumm* or mask*)).tw,kf,kw. 11 ((adaptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. 12 ((quasi-random* or quasirandom*).tw,kf,kw. 13 "allocated to* tw. 14 ((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw. 16 ((gragmatic or practical) adj3 trial*).tw,kf,kw. 17 ((gragmatic or practical) adj3 trial*).tw,kf,kw. 18 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 18 ((passa adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 18 (passa adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 18 (passa adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 18 (passa adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw.			
infanct"), il. kf.kw. 148033 ### (Infanct"), il. k	46	(stroke* or poststroke? or post-stroke? or CVA or CVAs).ti,kf,kw.	
19003	47		
((postacute or post-acute or chronic) adjs (hemipane* or paretic or paresis or phase? or state? or condition? or parely* or spastic*)) and (stroke* or post-stroke?)).tw,kf,kw. 9812	48		
or condition? or paraly" or spastic")) and (stroke" or poststroke? or post-stroke?)), tw, kf, kw. 1 or/28-50 [Population] 1 or/28-50 [Population] 1 or/28-50 [Population] 1 defs59 1 Longitudinal Studies/ use ppez 1 146559 1 Time / 334516 1 Time / 334516 1 Time Factors/ use ppez 1 19280 1 Time Factors / use operezd 3 6573 1 Duration of Therapy" use ppez 1 fe1 3 Treatment Duration/ use oemezd 2 35452 3 (duration? or (long" adj term?) or long-term" or longiterm" or longitudinal or time"), tw, kf, kw. 1 17211 6 or/52-59 [Long-term Study filter] 1 27864 1 (Randomized Controlled Trial or Controlled Clinical Trial or Pragmatic Clinical Trial or Adaptive Clinical Trial or Equivalence Trial or Clinical Trial, Phase III or Clinical Trial, Phase IV), pt. 2 Randomized Controlled Trials as Topic/ 3 exp Randomized Controlled Trials as Topic/ 4 "Randomized Controlled Trials as Topic/ 5 Controlled Clinical Trial (topic)"/ 5 Controlled Clinical Trial (topic)"/ 1 1168 8 (random* or sham or placebo*), tw, kf, kw. 3 ((singl" or doubl") adj (blind" or dumm" or mask")), tw, kf, kw. 4 ((pradom* or sham or placebo*), tw, kf, kw. 4 ((ingla price or outper) adj (blind" or dumm" or mask")), tw, kf, kw. 4 ((ingla price or outper) adj (blind" or dumm" or mask")), tw, kf, kw. 4 ((ingla price or outper) adj (blind" or dumm" or mask")), tw, kf, kw. 4 ((ingla price or outper) adj (blind" or dumm" or mask")), tw, kf, kw. 5 ((ingramatic study or pragmatic studies), tw, kf, kw. 4 ((ingramatic study or pragmatic studies) tw, kf, kw. 5 ((ingramatic study or pragmatic studies) tw, kf, kw. 5 ((ingramatic study or pragmatic studies) tw, kf, kw. 5 ((ingramatic study or pragmatic studies) tw, kf, kw. 6 ((ingramatic study or pragmatic studies) tw, kf, kw. 7 ((ingramatic or practical) adj3 (study or studies or trial")), tw, kf, kw. 8 ((ingramatic study or pragmatic studies) tw, kf, kw. 9 (ingramatic study or pragmatic studies) tw, kf, kw. 10 (ingramatic study or pragmatic studies) tw, kf, kw. 10 (ingramatic stud	49	((postacute or post-acute or chronic) adj5 (stroke* or poststroke? or post-stroke?)).tw,kf,kw.	18531
52 Longitudinal Studies/ use ppez 138571 53 Longitudinal Study/ use oemezd 146559 54 Time/ 334516 55 Time Factors/ use ppez 119280 56 Time Factors/ use ppez 119280 56 Time Factors/ use oemezd 36573 7 "Duration of Therapy"/ use ppez 161 58 Treatment Duration/ use oemezd 235452 59 (duration? or (long' adj term?) or long-term* or longitudinal* or time*).tw,kf,kw. 117211 60 or/52-59 [Long-term Study filter] 10 (Randomized Controlled Trial or Controlled Clinical Trial or Pragmatic Clinical Trial or Adaptive Clinical Trial or Equivalence Trial or Clinical Trial, Phase III or Clinical Trial, Phase IV).pt. 61 (Randomized Controlled Trial/ 62 Randomized Controlled Trials as Topic/ 63 exp Randomized Controlled Trial (topic)"/ 65 Controlled Clinical Trial (topic)"/ 66 exp Controlled Clinical Trial (topic)"/ 67 "Controlled Clinical Trial (topic)"/ 68 (random* or sham or placebo*) tw kf.kw. 69 ((singl* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 10 ((tirpi* or trebi*) adj (blind* or dumm* or mask*)).tw,kf,kw. 11 ((adaptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. 12 ((quasi-random* or quasirandom*).tw,kf,kw. 13 "allocated to* tw. 14 ((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw. 16 ((gragmatic or practical) adj3 trial*).tw,kf,kw. 17 ((gragmatic or practical) adj3 trial*).tw,kf,kw. 18 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 18 ((passa adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 18 (passa adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 18 (passa adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 18 (passa adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw.	50	(((postacute or post-acute or chronic) adj5 (hemipare* or paretic or paresis or phase? or stage? or state? or condition? or paraly* or spastic*)) and (stroke* or poststroke? or post-stroke?)).tw,kf,kw.	9812
53 Long/fuldrial Study/ use oemezd 146559 54 Time/ 334516 55 Time Factors/ use pepz 119280 56 Time Factor/ use oemezd 36573 57 "Duration of Therapy"/ use pepz 161 58 Treatment Duration/ use oemezd 235452 59 (duration? or (long* adj term?) or long-term* or longitudinal* or time*).tw,kf,kw. 117211 60 or/52-59 [Long-term Study filter] 127864 61 (Randomized Controlled Trial or Controlled Clinical Trial or Pragmatic Clinical Trial or Adaptive Clinical Trial or Equivalence Trial or Clinical Trial, Phase III or Clinical Trial, Phase IV).pt. 609009 62 Randomized Controlled Trials as Topic/ 329993 63 exp Randomized Controlled Trial (topic)*/ 189427 65 Controlled Clinical Trial (topic)*/ 189427 66 exp Controlled Clinical Trial (topic)*/ 343002 67 "Controlled Clinical Trial (topic)*/ 11168 68 (random* or sham or placebo*).tw,kf,kw. 310537 69 ((singl* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 417514	51	or/28-50 [Population]	917276
54 Time/ 334516 55 Time Factors/ use ppez 119280 56 Time Factor/ use oemezd 36573 57 "Duration of Therapy"/ use ppez 161 58 Treatment Duration/ use oemezd 235452 59 (duration? or (long* adj term?) or long-term* or longiterm* or longitudinal* or time*).tw,kf,kw. 117211 60 or/52-59 [Long-term Study filter] 127864 61 (Randomized Controlled Trial or Controlled Clinical Trial or Pragmatic Clinical Trial or Adaptive Clinical Trial or Equivalence Trial or Clinical Trial, Phase III or Clinical Trial, Phase IV).pt. 609009 62 Randomized Controlled Trial as a Topic/ 329993 63 *Randomized Controlled Trial (topic)*/ 189427 65 Controlled Clinical Trial (topic)*/ 189427 66 exp Controlled Clinical Trial (topic)*/ 343002 67 *Controlled Clinical Trial (topic)*/ 310537 69 ((singl* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 417514 70 ((itripl* or trebl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 417514 71 ((dadaptive or control* or equivalence) adj3 (s	52	Longitudinal Studies/ use ppez	138571
55 Time Factors/ use pepez 119280 56 Time Factor/ use oemezd 36573 57 "Duration of Therapy"/ use ppez 161 58 Treatment Duration/ use oemezd 235452 59 (duration? or (long* adj term?) or long-term* or longiterm* or longitudinal* or time*).tw,kf,kw. 117211 60 or/52-59 [Long-term Study filter] 127864 61 (Randomized Controlled Trial or Controlled Clinical Trial or Pragmatic Clinical Trial or Adaptive Clinical Trial or Equivalence Trial or Clinical Trial, Phase III or Clinical Trial, Phase IV).pt. 609009 62 Randomized Controlled Trials as Topic/ 329993 63 exp Randomized Controlled Trials as Topic/ 329993 64 "Randomized Controlled Trial (topic)"/ 189427 65 Controlled Clinical Trial (topic)"/ 11188 66 exp Controlled Clinical Trial (topic)"/ 11168 67 "Controlled Clinical Trial (topic)"/ 11168 68 (random* or sham or placebo*).tw,kf,kw. 310537 69 ((singl* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 417514 70 ((udaptive or control* or equivalenc	53	Longitudinal Study/ use oemezd	146559
56 Time Factor/ use oemezd 36573 57 "Duration of Therapy"/ use ppez 161 58 Treatment Duration/ use oemezd 235452 59 (duration? or (long* adj term?) or long-term* or longitudinal* or time*).tw,kf,kw. 117211 60 or/52-59 [Long-term Study filter] 127864 61 (Randomized Controlled Trial or Controlled Clinical Trial or Pragmatic Clinical Trial or Adaptive Clinical Trial or Equivalence Trial or Clinical Trial, Phase III or Clinical Trial, Phase IV).pt. 114384 63 exp Randomized Controlled Trial (topic)*/ 189427 65 Controlled Clinical Trial (topic)*/ 189427 66 exp Controlled Clinical Trial (topic)*/ 11168 67 "Controlled Clinical Trial (topic)*/ 11168 68 (random* or sham or placebo*).tw,kf,kw. 310537 69 ((singl* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 417514 70 ((tripl* or trebl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 2469 71 ((adaptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. 10688 73 "allocated to*.tw. 10688 74 ((open label or open-label) adj5 (study or studies or trial*).tw,kf,kw. 101220 75 ((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. 1043 77 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 1043 78 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 18628 79 trial.ti,kf,kw. 131029 81 or/61-80 [RCT Filter] 525963	54	Time/	334516
7 "Duration of Therapy"/ use ppez 161 8 Treatment Duration/ use oemezd 235452 9 (duration? or (long* adj term?) or long-term* or longitudinal* or time*).tw,kf,kw. 117211 10 or/52-59 [Long-term Study filter] 127864 61 (Randomized Controlled Trial or Controlled Clinical Trial or Pragmatic Clinical Trial or Adaptive Clinical Trial or Equivalence Trial or Clinical Trial, Phase III or Clinical Trial, Phase IV).pt. 114384 62 Randomized Controlled Trial/ 114384 63 exp Randomized Controlled Trial (topic)"/ 189427 65 Controlled Clinical Trial/ 1559366 66 exp Controlled Clinical Trial (topic)"/ 11168 68 (random* or sham or placebo*).tw,kf,kw. 1168 69 ((sing)* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 117514 70 ((trip)* or treb)*) adj (blind* or dumm* or mask*)).tw,kf,kw. 12469 71 ((adaptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. 10688 73 "allocated to*.tw. 155236 74 ((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw. 101220 75 ((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. 1043 77 ((pragmatic study or pragmatic studies).tw,kf,kw. 1043 78 ((quasi-experimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 1043 77 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 18628 78 trial.tl,kf,kw. 18029 80 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 131029 81 or/61-80 [RCT Filter] 525963	55	Time Factors/ use ppez	1192802
58 Treatment Duration/ use oemezd 59 (duration? or (long* adj term?) or long-term* or longitudinal* or time*),tw,kf,kw. 117211 60 or/52-59 [Long-term Study filter] 127864 61 Randomized Controlled Trial or Controlled Clinical Trial or Pragmatic Clinical Trial or Adaptive Clinical Trial or Equivalence Trial or Clinical Trial, Phase III or Clinical Trial, Phase IV),pt. 62 Randomized Controlled Trial/ 63 exp Randomized Controlled Trials as Topic/ 64 "Randomized Controlled Trials as Topic/ 65 Controlled Clinical Trial/ 66 exp Controlled Clinical Trials as Topic/ 67 "Controlled Clinical Trial (topic)"/ 68 (random* or sham or placebo*),tw,kf,kw. 69 ((singl* or doubl*) adj (blind* or dumm* or mask*)),tw,kf,kw. 70 ((tripl* or trebl*) adj (blind* or dumm* or mask*)),tw,kf,kw. 71 ((adaptive or control* or equivalence) adj3 (study or studies or trial* or group*)),tw,kf,kw. 72 ((usai-random* or quasirandom*),tw,kf,kw. 73 "allocated to*.tw. 74 ((open label or open-label) adj5 (study or studies or trial*)),tw,kf,kw. 75 ((quasi-random* or pagmatic studies),tw,kf,kw. 76 ((quasi-guasic study or pragmatic studies),tw,kf,kw. 77 ((quasi-guasic study or pragmatic studies),tw,kf,kw. 78 ((quasi-guasic study or pragmatic studies),tw,kf,kw. 79 ((quasi-guasic study or pragmatic studies),tw,kf,kw. 79 ((quasi-guasic study or pragmatic studies),tw,kf,kw. 79 ((pragmatic or practical) adj3 trial*),tw,kf,kw. 79 ((pragmatic or practical) adj3 trial*),tw,kf,kw. 79 ((pragmatic or practical) adj3 trial*),tw,kf,kw. 79 ((pragmatic or practical) adj3 (study or studies or trial*)),tw,kf,kw. 79 ((pragmatic or practical) adj3 (study or studies or trial*)),tw,kf,kw. 79 ((pragmatic or practical) adj3 (study or studies or trial*)),tw,kf,kw. 79 ((pragmatic or practical) adj3 (study or studies or trial*)),tw,kf,kw. 79 ((pragmatic or practical) adj3 (study or studies or trial*)),tw,kf,kw. 79 ((pragmatic or practical) adj3 (study or studies or trial*)),tw,kf,kw. 79 ((pragmatic or practical) adj3 (study or studies or trial*)),tw,kf,kw. 79 ((pragmatic or practic	56	Time Factor/ use oemezd	36573
59 (duration? or (long* adj term?) or long-term* or longitudinal* or time*).tw,kf,kw. 117211 60 or/52-59 [Long-term Study filter] 127864 61 (Randomized Controlled Trial or Controlled Clinical Trial or Pragmatic Clinical Trial or Adaptive Clinical Trial or Equivalence Trial or Clinical Trial, Phase III or Clinical Trial, Phase IV).pt. 609009 62 Randomized Controlled Trial 114384 63 exp Randomized Controlled Trial (topic)*/ 329933 64 "Randomized Controlled Trial (topic)*/ 189427 65 Controlled Clinical Trial (topic)*/ 343002 66 exp Controlled Clinical Trial (topic)*/ 11168 67 "Controlled Clinical Trial (topic)*/ 11168 68 (random* or sham or placebo*).tw,kf,kw. 310537 69 ((singl* or doubl*)* adj (blind* or dumm* or mask*)).tw,kf,kw. 417514 70 ((Itipi* or trebl*)* adj (blind* or dumm* or mask*)).tw,kf,kw. 2469 71 ((adaptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. 10688 73 "allocated to*.tw. 155236 74 ((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw. 1043 75 ((equiv	57	"Duration of Therapy"/ use ppez	161
60 or/52-59 [Long-term Study filter] 61 (Randomized Controlled Trial or Controlled Clinical Trial or Pragmatic Clinical Trial or Adaptive Clinical Trial or Equivalence Trial or Clinical Trial, Phase III or Clinical Trial, Phase IV).pt. 62 Randomized Controlled Trial/ 63 exp Randomized Controlled Trial (topic)"/ 64 "Randomized Controlled Trial (topic)"/ 65 Controlled Clinical Trial (topic)"/ 66 exp Controlled Clinical Trial (topic)"/ 67 "Controlled Clinical Trial (topic)"/ 68 (random* or sham or placebo*).tw,kf,kw. 69 ((sing)* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 69 ((tipi)* or trebl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 60 ((daaptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. 60 ((usasi-random* or quasirandom*).tw,kf,kw. 61 ((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw. 61 ((pragmatic study or pragmatic studies).tw,kf,kw. 61 ((pragmatic study or pragmatic studies).tw,kf,kw. 61 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 61 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 61 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 61 ((pragmatic or practical) adj3 (study or studies or trial*)).tw,kf,kw. 61 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 61 ((pragmatic or practical) adj3 (study or studies or trial*)).tw,kf,kw. 61 ((pragmatic or practical) adj3 (study or studies or trial*)).tw,kf,kw. 61 ((pragmatic or practical) adj3 (study or studies or trial*)).tw,kf,kw. 61 ((pragmatic or practical) adj3 (study or studies or trial*)).tw,kf,kw. 61 ((pragmatic or practical) adj3 (study or studies or trial*)).tw,kf,kw. 61 ((pragmatic or practical) adj3 (study or studies or trial*)).tw,kf,kw. 61 ((pragmatic or practical) adj3 (study or studies or trial*)).tw,kf,kw. 61 ((pragmatic or practical) adj3 (study or studies or trial*)).tw,kf,kw. 61 (10 (pragmatic or practical) adj3 (study or studies or trial*)).tw,kf,kw.	58	Treatment Duration/ use oemezd	235452
61 (Randomized Controlled Trial or Controlled Clinical Trial or Pragmatic Clinical Trial or Adaptive Clinical Trial or Equivalence Trial or Clinical Trial, Phase III or Clinical Trial, Phase IV).pt. 62 Randomized Controlled Trial/ 63 exp Randomized Controlled Trials as Topic/ 64 "Randomized Controlled Trial (topic)"/ 65 Controlled Clinical Trial/ 66 exp Controlled Clinical Trials as Topic/ 67 "Controlled Clinical Trial (topic)"/ 68 (random* or sham or placebo*).tw,kf,kw. 69 ((singl* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 70 ((tripl* or trebl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 71 ((adaptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. 73 "allocated to*.tw. 74 ((open label or open-label) adj5 (study or studies or trial*).tw,kf,kw. 75 ((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. 76 ((pragmatic study or pragmatic studies).tw,kf,kw. 77 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 78 ((quasi-xperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 79 (trial*).tw,kf,kw. 80 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 131029 81 (or/61-80 [RCT Filter]	59	(duration? or (long* adj term?) or long-term* or longterm* or longitudinal* or time*).tw,kf,kw.	11721146
Trial or Equivalence Trial or Clinical Trial, Phase III or Clinical Trial, Phase IV).pt. Randomized Controlled Trial/ Randomized Controlled Trials as Topic/ Randomized Controlled Trial (topic)"/ Randomized Controlled Trial (topic)"/ Controlled Clinical Trial/ S59356 Exp Controlled Clinical Trials as Topic/ "Controlled Clinical Trial (topic)"/ 11168 (random* or sham or placebo*).tw,kf,kw. 310537 ((singl* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw. ((dadaptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. ((quasi-random* or quasirandom*).tw,kf,kw. ((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw. ((cquivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. ((pragmatic study or pragmatic studies).tw,kf,kw. ((quasi-random* or practical) adj3 (study or studies or trial*)).tw,kf,kw. ((pragmatic or practical) adj3 trial*).tw,kf,kw. ((pragmatic or practical) adj3 trial*).tw,kf,kw. ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. ((phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 131029 10761-80 [RCT Filter]	60	or/52-59 [Long-term Study filter]	12786464
63 exp Randomized Controlled Trials as Topic/ 64 "Randomized Controlled Trial (topic)"/ 65 Controlled Clinical Trial/ 66 exp Controlled Clinical Trials as Topic/ 67 "Controlled Clinical Trials as Topic/ 68 (random* or sham or placebo*).tw,kf,kw. 69 ((singl* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 70 ((tripl* or trebl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 71 ((adaptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. 72 (quasi-random* or quasirandom*).tw,kf,kw. 73 "allocated to".tw. 74 ((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw. 75 ((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. 76 ((pragmatic study or pragmatic studies).tw,kf,kw. 77 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 78 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 79 trial.ti,kf,kw. 80 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 81029 81 or/61-80 [RCT Filter]	61		
64 "Randomized Controlled Trial (topic)"/ 65 Controlled Clinical Trial/ 66 exp Controlled Clinical Trials as Topic/ 67 "Controlled Clinical Trial (topic)"/ 68 (random* or sham or placebo*).tw,kf,kw. 69 ((singl* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 69 ((tripl* or trebl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 69 ((dadptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. 60 (quasi-random* or quasirandom*).tw,kf,kw. 61 ((dopen label or open-label) adj5 (study or studies or trial*)).tw,kf,kw. 62 ((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. 63 ((equivalence or superiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. 64 ((equivalence or superiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. 65 ((equivalence or superiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. 65 ((equivalence or practical) adj3 trial*).tw,kf,kw. 65 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 65 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 65 ((phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 65 ((phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 65 ((phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw.	62	Randomized Controlled Trial/	1143841
65 Controlled Clinical Trial/ 66 exp Controlled Clinical Trials as Topic/ 67 "Controlled Clinical Trial (topic)"/ 68 (random* or sham or placebo*).tw,kf,kw. 69 ((singl* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 69 ((tripl* or trebl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 69 ((tripl* or trebl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 69 ((dadptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. 69 ((uasi-random* or quasirandom*).tw,kf,kw. 60 (quasi-random* or quasirandom*).tw,kf,kw. 61 ((adaptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. 62 (quasi-random* or quasirandom*).tw,kf,kw. 63 "allocated to".tw. 64 ((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw. 65 ((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. 66 ((pragmatic study or pragmatic studies).tw,kf,kw. 67 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 68 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 68 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 69 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 69 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw.	63	exp Randomized Controlled Trials as Topic/	329993
66 exp Controlled Clinical Trials as Topic/ 7 "Controlled Clinical Trial (topic)"/ 11168 68 (random* or sham or placebo*).tw,kf,kw. 310537 69 ((singl* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 417514 70 ((tripl* or trebl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 2469 71 ((adaptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. 242625 72 (quasi-random* or quasirandom*).tw,kf,kw. 10688 73 "allocated to".tw. 155236 74 ((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw. 101220 75 ((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. 1043 76 ((pragmatic study or pragmatic studies).tw,kf,kw. 1043 77 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 9657 78 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 18628 79 trial.ti,kf,kw. 583819 80 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw.	64	"Randomized Controlled Trial (topic)"/	189427
67 "Controlled Clinical Trial (topic)"/ 68 (random* or sham or placebo*).tw,kf,kw. 69 ((singl* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 70 ((tripl* or trebl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 71 ((adaptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. 72 (quasi-random* or quasirandom*).tw,kf,kw. 73 "allocated to".tw. 74 ((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw. 75 ((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. 76 (pragmatic study or pragmatic studies).tw,kf,kw. 77 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 78 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 79 trial.ti,kf,kw. 80 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 131029 81 or/61-80 [RCT Filter]	65	Controlled Clinical Trial/	559356
68 (random* or sham or placebo*).tw,kf,kw. 69 ((singl* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 70 ((tripl* or trebl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 71 ((adaptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. 72 (quasi-random* or quasirandom*).tw,kf,kw. 73 "allocated to".tw. 74 ((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw. 75 ((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. 76 (pragmatic study or pragmatic studies).tw,kf,kw. 77 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 78 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 80 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 101220 1043 1053 1053 1053 1053 1054 1055 1055 1056 1057 10	66	exp Controlled Clinical Trials as Topic/	343002
69 ((singl* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 70 ((tripl* or trebl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 2469 71 ((adaptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. 242625 72 (quasi-random* or quasirandom*).tw,kf,kw. 10688 73 "allocated to".tw. 105236 74 ((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw. 101220 75 ((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. 20928 76 (pragmatic study or pragmatic studies).tw,kf,kw. 1043 77 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 18628 79 trial.ti,kf,kw. 583819 80 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 131029	67	"Controlled Clinical Trial (topic)"/	11168
70 ((tripl* or trebl*) adj (blind* or dumm* or mask*)).tw,kf,kw. 2469 71 ((adaptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. 242625 72 (quasi-random* or quasirandom*).tw,kf,kw. 10688 73 "allocated to".tw. 155236 74 ((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw. 101220 75 ((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. 20928 76 (pragmatic study or pragmatic studies).tw,kf,kw. 1043 77 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 9657 78 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 18628 79 trial.ti,kf,kw. 583819 80 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 131029 81 or/61-80 [RCT Filter]	68	(random* or sham or placebo*).tw,kf,kw.	3105376
71 ((adaptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw. 72 (quasi-random* or quasirandom*).tw,kf,kw. 73 "allocated to".tw. 74 ((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw. 75 ((equivalence or superiority or non-inferiority) adj3 (study or studies or trial*)).tw,kf,kw. 76 (pragmatic study or pragmatic studies).tw,kf,kw. 77 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 78 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 79 trial.ti,kf,kw. 80 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 131029 81 or/61-80 [RCT Filter]	69	((singl* or doubl*) adj (blind* or dumm* or mask*)).tw,kf,kw.	417514
72 (quasi-random* or quasirandom*).tw,kf,kw. 73 "allocated to".tw. 74 ((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw. 75 ((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. 76 (pragmatic study or pragmatic studies).tw,kf,kw. 77 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 78 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 79 trial.ti,kf,kw. 80 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 81 or/61-80 [RCT Filter] 525963	70	((tripl* or trebl*) adj (blind* or dumm* or mask*)).tw,kf,kw.	2469
73 "allocated to".tw. 155236 74 ((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw. 101220 75 ((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. 20928 76 (pragmatic study or pragmatic studies).tw,kf,kw. 1043 77 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 9657 78 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 18628 79 trial.ti,kf,kw. 583819 80 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 131029 81 or/61-80 [RCT Filter]	71	((adaptive or control* or equivalence) adj3 (study or studies or trial* or group*)).tw,kf,kw.	2426253
74((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw.10122075((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw.2092876(pragmatic study or pragmatic studies).tw,kf,kw.104377((pragmatic or practical) adj3 trial*).tw,kf,kw.965778((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw.1862879trial.ti,kf,kw.58381980(phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw.13102981or/61-80 [RCT Filter]525963	72	(quasi-random* or quasirandom*).tw,kf,kw.	10688
75 ((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw. 20928 76 (pragmatic study or pragmatic studies).tw,kf,kw. 1043 77 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 9657 78 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 18628 79 trial.ti,kf,kw. 583819 80 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 131029 81 or/61-80 [RCT Filter]	73	"allocated to".tw.	155236
76 (pragmatic study or pragmatic studies).tw,kf,kw. 1043 77 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 9657 78 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 18628 79 trial.ti,kf,kw. 583819 80 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 131029 81 or/61-80 [RCT Filter] 525963	74	((open label or open-label) adj5 (study or studies or trial*)).tw,kf,kw.	101220
77 ((pragmatic or practical) adj3 trial*).tw,kf,kw. 9657 78 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 18628 79 trial.ti,kf,kw. 583819 80 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 131029 81 or/61-80 [RCT Filter]	75	((equivalence or superiority or non-inferiority or noninferiority) adj3 (study or studies or trial*)).tw,kf,kw.	20928
78 ((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw. 18628 79 trial.ti,kf,kw. 583819 80 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 131029 81 or/61-80 [RCT Filter] 525963	76		
79 trial.ti,kf,kw. 583819 80 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 131029 81 or/61-80 [RCT Filter] 525963	77		
80 (phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw. 131029 81 or/61-80 [RCT Filter] 525963	78	((quasiexperimental or quasi-experimental) adj3 (study or studies or trial*)).tw,kf,kw.	18628
81 or/61-80 [RCT Filter] 525963	79	trial.ti,kf,kw.	
	80	(phase adj3 (III or "3" or IV or "4") adj3 (study or studies or trial*)).tw,kf,kw.	
92 ava animala/	81	or/61-80 [RCT Filter]	5259637
	82	exp animals/	49787816

83	exp animal experimentation/ or exp animal experiment/	2630293
ļ		
84	exp models animal/	2002835
85	nonhuman/	6362133
86	exp vertebrate/ or exp vertebrates/	48451569
87	or/82-86	51664560
88	exp humans/	40330743
89	exp human experimentation/ or exp human experiment/	
90	or/88-89	
91	87 not 90	
92	81 not 91	
93	27 and 51 and 60 and 92 [Interventions + Populations + LT Studies + RCTs, Human NOT Animals]	7957
94	(case reports.pt. or *Case Report/ or letter.pt.) not ((case reports.pt. or *Case Report/ or letter.pt.) and randomized controlled trial.pt.)	
95	Conference Abstract/	
96	or/94-95 [Publication Types not of Interest]	
97	93 not 96 [RCTs, [Publication Types not of Interest removed]	
98	limit 97 to (english or french or german or italian) [Final results, limited to languages of interest]	7341

Table 22 The Cochrane Library searches for RCTs (from inception 22 October 2020)

Search string | 367 results

exp Physical Therapy Modalities

Cryotherapy

exp Hyperthermia, Induced

exp Massage

exp Ultrasonic Therapy

exp Phototherapy

manual therap* OR physiotherap* OR physio-therap* OR (physic* NEXT therap*) OR CIMT OR mCIMT OR FES OR NMES =ti,ab,kw

(aerobic* OR aquatic* OR balance OR bilateral OR bi-lateral OR breathing OR cardiovascular OR cardio-vascular OR dualtask OR dual-task OR electromechanical assist* OR electromechanical assist* OR endurance OR equine-assisted OR exercise* OR exercising OR fitness OR gait OR horse-back rid* OR horse-back rid* OR lower extremit* OR lower limb* OR mirror* OR mobility OR mobilisation OR mobilization OR motion* OR movement* OR muscle stretch* OR physical OR resistance OR respiratory muscle* OR strength OR strengthening OR taskoriented OR task-oriented OR task specific OR treadmill* OR tread-mill* OR upper extremit* OR upper limb*) NEAR/2 (rehabilitat* OR retraining OR retraining OR program* OR therap* OR training) =ti,ab,kw

ammotherap* OR (biostimulat* NEAR/2 laser*) OR cryotherap* OR cryo-therap* OR cryotherm* OR cryo-therm* OR cryo-therm* OR cryo-treatment* OR ((induc* OR local*) NEXT (hyperthermi* OR hyper-thermi* OR hypothermi* OR hypothermi*)) OR (manual* NEXT (lymph* NEAR/2 drain*)) OR ((lowlevel* laser* OR low-level* laser* OR lowpower* laser*) NEAR/2 (irradiat* OR therap*)) OR massotherap* OR masso-therap* OR photo-therap* OR thermo-therap* OR ((cold OR cryogenic* OR fever* OR heat OR hyperthermia* OR hyper-thermia* OR infra-red OR light* OR massag* OR photobiomodulat* OR photo-biomodulat* OR ultrasound*) NEAR/2 (therap* OR treatment*)) = ti,ab,kw

=ti.ab.kw

(electric* NEAR/3 stimulation) OR electrostimul* OR electro-stimul* OR electrotherap* OR electro-therap* OR galvano-stimulation = ti,ab,kw

aquatherap* OR aqua-therap* OR hydrotherap* OR hydro-therap* OR hippotherap* OR hippotherap* OR hippotherap* OR medical training therap* =ti,ab,kw

exp Exercise

rehabilitat* OR retraining OR re-training OR program* OR therap* OR training = all exercis* NEAR/3 (rehabilitat* OR retraining OR re-training OR program* OR therap* OR training) = .ti

exp Multiple Sclerosis

multiple NEXT (scleros#s OR scleroti*) =.ti

exp Parkinson Disease

(Parkinson* NEXT disease*) OR Primary Parkinsonism OR Paralysis Agitans = .ti

Brain Ischemia

exp Intracranial Hemorrhages

exp Stroke

Stroke Rehabilitation

stroke* OR poststroke* OR post-stroke* OR CVA OR CVAs =.ti

(cerebrovascular* OR cerebro-vascular* OR cerebral vascular*) NEAR/2 (apoplex* OR accident* OR infarct*) =.ti (brain OR cerebral OR intracerebral OR intra-cerebral OR arachnoid OR subarachnoid OR sub-arachnoid OR intracranial* OR cranial* OR cranial*) NEAR/2 (infarct* OR isch*emi* OR h*emorrhag*) =.ti (postacute OR post-acute OR chronic) NEAR/5 (stroke* OR poststroke* OR post-stroke*) =.ti

((postacute OR post-acute OR chronic) NEAR/5 (hemipare* OR paretic OR paresis OR phase* OR stage* OR state* OR condition* OR paraly* OR spastic*)) and (stroke* OR poststroke* OR post-stroke*) = .ti

Longitudinal Studies

Time

Time Factors

duration? OR (long* NEXT term?) OR long-term* OR longterm* OR longitudinal* OR time* =.ti,ab,kf.

Table 23 PEDro searches for RCTs (from inception to 22 October 2020)

#	Searches	Results
1	duration OR long-term OR longiterm OR longitudinal OR time	1056

11.2.1 Supplementary searches for auxiliary domains and grey literature sources

The search strings reported below are not included in the PRISMA flow diagram because they are not considered to be sensitive enough to be classified as a systematic literature search.

Table 24 Search strings for legal considerations (PubMed and Embase) [from inception to 13 November 2020]

Number	Query	PubMed	Embase
1	Personal autonomy [mh]	17,214	14,346
2	Human rights [mh]	144,007	267,735
3	Human rights[tiab]	10,628	9,803
4	(free will)	70,468	14,772
5	(self determination)	31,166	18,639
6	Parental consent [mh]	3,269	5,252
7	Third-party consent [mh]	6,007	18,772
8	Presumed consent [mh]	549	443

Number	Query	PubMed	Embase
9	Informed consent by minors [mh]	137	9100
10	Consent [tiab]	64,638	132,781
11	Privacy [tw]	21,311	19,310
12	Confidentiality [mh]	53,434	33,765
13	Confidentiality[tiab]	11,577	14,195
14	Personally identifiable information [mh]	44	69
15	Health record, personal [mh]	2,007	3,248
16	(personal information)	41,504	2,931
17	Jurisprudence [mh]	205,822	52,736
18	Law enforcement [mh]	3,766	13,821
19	Law[tiab]	92,588	107,851
20	Laws[tiab]	30,612	35,831
21	Legislation as topic [mh]	162,492	118,636
22	Legislation[tiab]	37,600	44,761
23	Civil rights [mh]	24,302	27,242
24	Authority[tiab]	23,365	31,317
25	Legal case [pt]	11,029	4,853
26	Legal guardians [mh]	3,674	1,087
30	Legal [tiab]	92,665	108,549
31	Liability, legal [mh]	15,695	16,744
32	Legal services [mh]	31	366
33	Access to information [mh]	7,664	24,183
34	Social justice [mh]	12,277	11,892
35	Health equity [mh]	1,428	1,658
36	Human rights abuses [mh]	1,399	504
37	Patient rights [mh]	78,478	167543
39	Ownership [mh]	22,754	62,909
40	Intellectual property [mh]	11,581	8,172
41	Intellectual property[tiab]	2,267	3,066
42	Licensure [mh]	17,673	8,710
43	License[tiab]	7,852	12,425
44	Liability, legal [mh]	15,695	6,677
45	Liability [tiab]	19,480	24,866
46	Legislation[mh]	162,492	157,903
47	Legislation as topic [mh]	162,492	98,020
48	Medical device legislation [mh]	249	449
49	Conflict of interest [mh]	10,552	13,087
50	Guaranty[tiab]	126	235
51	Regulation[tiab]	861,687	1,055,636
52	Acquisition	164,250	204,886
53	Conflict of interest[tiab]	4,216	6,227
54	1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 PR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32	1,802,195	2,697,538

Number	Query	PubMed	Embase
	OR 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43 OR 44 OR 45 OR 46 OR 47 OR 48 OR 49 OR 50 OR 51 OR 52 OR 53 OR 54 OR 55 OR 56 OR 57 OR 58		
55	54 AND (((Mutiple sclerosis [MeSH] OR Parkinson disease [MeSH] OR stroke [MeSH]) OR (Multiple sclerosis)) OR (Stroke)) OR (Parkinson's disease)	7,088	50,903
56	55 AND ((Physical Therapy Modalities [MeSH]) OR (Physical therapy)) OR (Physiotherapy)	283	137

Table 25 Search strings for organisational issues (PubMed and Embase) [from inception to 13 November 2020]

Search	Query	PubMed	Embase	
1	Information storage and retrieval [mh]	186,964	1,169	
2	(information management)	365,405	39,527	
3	Health information systems [mh]	1,328	7,971	
4	Health information management [mh]	1,719	21,921	
5	Health information exchange [mh]	901	21,885	
6	Information literacy [mh]	6,307	542	
7	Health equity [mh]	1,428	3,614	
8	(work process)	210,734	422,829	
9	(work flow)	65,466	24,474	
10	Medical Education[mh]	167,137	238,197	
11	Education, professional, retraining [mh]	1,242	32,287	
12	Education, public health professional [mh]	788	345,333	
13	Health information interoperability[mh]	172	321	
14	Communication [mh]	313,409	560,361	
15	Health communication [mh]	2,476	78,120	
16	Quality assurance, health care [mh]	332,438	246,318	
17	Implementation science [mh]	518	1,479	
18	Organization culture [mh]	39,781	1,967	
19	(human skills)	196,826	768,692	
20	Sustainability[tiab]	25,481	154,667	
21	(system structure)	461,170	888	
22	Acceptance[tiab]	71,174	100,879	
23	1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23	2,152,000	1,769,086	
24	23 AND (((Multiple sclerosis [MeSH] OR Parkinson disease [MeSH] OR stroke [MeSH]) OR (Multiple sclerosis)) OR (Stroke)) OR (Parkinson's disease)	391,656	15807	
25	24 AND ((Physical Therapy Modalities [MeSH]) OR (Physical therapy)) OR (Physiotherapy)	794	365	

Table 26 Search strings for ethical considerations (PubMed and Embase) [from inception to 13 November 2020]

Search	Query	PubMed	Ovid
1	Ethics[mh]	147,473	231,837
2	Medical ethics[tiab]	6,439	51,474
3	Ethical theory [mh]	3,395	1,027
4	Bioethics[mh]	11,003	20,555
5	Morals[mh]	170,632	862
6	Morality[tiab]	4,532	43,104
7	Ethical theory[tiab]	302	1,027
8	Principle-based ethics[mh]	29,943	24,454
9	Patient rights [mh]	78,489	14,369
10	Patient autonomy[tiab]	2,393	5,897
11	Personal autonomy [mh]	17,216	14,346
12	Autonomy[tiab]	30,218	51,299
13	Social justice [mh]	12,280	11,892
14	Ethical issues [tiab]	12,180	14,884
15	Normative [tiab]	30,044	39,252
16	1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15	287,812	358,615
17	16 AND (((Multiple sclerosis [MeSH] OR Parkinson disease [MeSH] OR stroke [MeSH]) OR (Multiple sclerosis)) OR (Stroke)) OR (Parkinson's disease)	2,678	6,617
	18 AND ((Physical Therapy Modalities [MeSH]) OR (Physical therapy)) OR (Physiotherapy)	164	153

Table 27 Search string for social considerations (PubMed and Embase) [from inception to 13 November 2020]

Search	Query	PubMed	Embase
1	Patient experience[tiab]	6,495	11,654
2	Quality of life [mh]	199,770	486,701
3	Social aspects of [tiab]	2,389	5,410
4	Medical decision-making process [mh]	10,166	28,374
5	Patient education as topic [mh]	86,063	123,244
6	Patient education[tiab]	19,645	27,640
7	Patient attitude[tiab]	163	206
8	Patient preference [tiab]	4,658	7,048
9	Patient decision[tiab]	1,734	2,690
10	Patient acceptance[tiab]	2,963	4,039
11	Patient satisfaction [tiab]	37,758	53,376
12	Patient-focused [tiab]	1,659	2,363
13	Patient-centred [tiab]	6,450	8,299
14	Patient advocacy [tiab]	1,442	2,076

Search	Query	PubMed	Embase
15	Consumer satisfaction [tiab]	779	900
16	Consumer participation [tiab]	401	407
17	Consumer preference [tiab]	433	407
18	Consumer attitude[tiab]	51	51
19	Self-perception	153,179	98,033
20	Self-care	199,125	68,568
21	Self-efficacy	65,382	107,348
22	Attitude to health	550,627	117,989
23	Health education	731,148	351,412
24	Health knowledge	335,543	119,987
25	Informed choice	51,123	112,313
26	Shared decision making	12,970	15,104
27	Empowerment	13,467	19,741
28	Quality of Life	414,116	618,854
29	Adaptation, psychological	136,317	61,157
30	Coping	167,261	103,241
31	1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30	2,016,054	1,450,858
32	Focus group	121,456	264,368
33	verbal communication	30,365	17,014
34	qualitative	301,688	348,887
35	survey	1,502,714	1,418,325
36	32 OR 33 OR 34 OR 35	1,857,896	1,957,915
37	31 AND 36	610,540	251,464
38	37 AND (((Multiple sclerosis [MeSH] OR Parkinson disease [MeSH] OR stroke [MeSH]) OR (Multiple sclerosis)) OR (Stroke)) OR (Parkinson's disease)	13,472	7,863
39	38 AND ((Physical Therapy Modalities [MeSH]) OR (Physical therapy)) OR (Physiotherapy)	1,841	280

Table 28 Specialty websites literature search (18 November 2020)

Society	Website	Search term: Physiotherapy or Physical therapy	Total Relevant			
Stroke						
American Academy of Neurology	https://www.aan.com/	11	0			
American Stroke Association	https://www.stroke.org/	58	0			
European Academy of Neurology	https://www.ean.org/	3	0			
Stroke Association	https://www.stroke.org.uk/	13	0			
Stroke Society of Australasia	http://www.strokesociety.com.au/	1	0			
World Federation of Neurology	https://wfneurology.org/	1	0			
World Stroke Organization	https://www.world-stroke.org/	0	0			
Multiple sclerosis						

	I	_	1 .
European Committee for Treatment and Research in Multiple Sclerosis	https://www.ectrims.eu/	0	0
European Multiple Sclerosis Platform	http://www.emsp.org/	2	0
Italian Multiple Sclerosis Society	https://www.aism.it/	1	0
MS Research Australia	https://msra.org.au/	0	0
Multiple Sclerosis Society UK	https://www.mssociety.org.uk/	2	0
MS International Federation	https://www.msif.org/	0	0
National Multiple Sclerosis Society	https://www.nationalmssociety.org/	5	0
Parkinson's disease			
American Academy of Neurology	https://www.aan.com/	3	0
American Parkinson Disease Association	https://www.apdaparkinson.org/research/	0	0
European Parkinson's Disease Association	https://www.epda.eu.com/	9	0
Parkinson's Australia	https://www.parkinsons.org.au/	0	0
Parkinson Canada	https://www.parkinson.ca/	0	0
Parkinson's Foundation	https://www.parkinson.org/	0	0
Parkinson's UK	https://www.parkinsons.org.uk/research	3	0
The Michael J. Fox Foundation for Parkinson's Research	https://www.michaeljfox.org/	0	0

Table 29 HTA agency websites literature search (18 November 2020)

Society	Website	Search terms: Physiotherapy or Physical therapy AND		Total relevant	
		Stroke	MS	PD	
International					
National Information Centre of Health Services Research and Health Care Technology (NICHSR)	https://www.nlm.nih.gov/hsrph.html	154	97	95	0
National Library of Medicine Health Services/Technology Assessment Texts (HSTAT)	https://www.ncbi.nlm.nih.gov/books/NBK16710/	125	62	65	0
Australia					
National Health and Medical Research Council	https://www.nhmrc.gov.au/	3	0	0	0
Australian Safety and Efficacy Register of New Interventional Procedures— Surgical (ASERNIP-S)	https://www.surgeons.org/research- audit/research-evaluation-inc-asernips	0	0	0	0
Austria					
Institute of Technology Assessment / HTA unit	https://www.oeaw.ac.at/ita/publikationen/	0	2	0	0
Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA)	https://hta.lbg.ac.at/page/publikationen/en	2	0	0	0

Society	Website	Search t Physioth Physical AND	Total relevant		
		Stroke	MS	PD	
Belgium		1	1		1
Scientific Institute of Public Health (IPH)	https://www.wiv-isp.be/en	0	0	0	0
Belgian Health Care Knowledge Centre (KCE)	http://kce.fgov.be	3	0	0	0
Canada					
Institute of Health Economics (IHE)	http://www.ihe.ca	0	0	0	0
Institut National d'Excellence en Santé et en Services (INESSS)	https://www.inesss.qc.ca/en/home.html	0	0	0	0
The Canadian Agency for Drugs and Technologies in Health (CADTH)	3	2	0	0	
Denmark					
Danish National Institute of Public Health	https://www.sdu.dk/en/sif/forskning	0	0	0	0
Finland		-			•
National Institute for Health and Welfare (THL)	https://www.thl.fi	0	0	0	0
Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	https://www.ppshp.fi/Tutkimus-ja- opetus/FinCCHTA/Sivut/HTA-julkaisuja.aspx	0	0	0	0
France					
French National Authority for Health (Haute Autorité de Santé; HAS)	http://www.has-sante.fr/	0	0	0	0
Germany					
Institute for Quality and Efficiency in Health Care (IQWiG)	http://www.iqwig.de	1	0	0	0
Ireland					
Health Information and Quality Authority (HIQA)	http://www.hiqa.ie	0	0	0	0
Norway				•	•
The Norwegian Institute of Public Health (NIPHNO)	http://www.fhi.no/	2	0	0	0
Sweden		ı	•	•	·
Swedish Council on Technology Assessment in Health Care (SBU)	http://www.sbu.se/en/	2	0	0	0
Switzerland		•	•	•	•
Swiss Federal Office of Public Health (FOPH)	http://www.bag.admin.ch/hta	0	0	0	0

Society	Website	Search to Physioth Physical AND	Total relevant		
		Stroke	MS	PD	
Swiss Network on Health Technology Assessment (SNHTA)	http://www.snhta.ch/	-	-	-	-
United Kingdom					
Healthcare Improvement Scotland (HIS)	http://www.healthcareimprovementscotland.org	0	0	0	0
National Health Service Health Technology Assessment (UK) / National Coordinating Centre for Health Technology Assessment (NCCHTA)	https://www.nihr.ac.uk/	0	0	0	0
National Institute for Clinical Excellence (NICE)	http://www.nice.org.uk/	7	0	5	0
National Institute for Health Research (NIHR), including HTA programme	http://www.nets.nihr.ac.uk/programmes/hta	0	0	0	0
United States					
Institute for Clinical and Economic Review (ICER)	http://www.icer-review.org/	0	0	0	0

12 Appendix B: Characteristics of included trials

12.1 Efficacy studies

Table 30 List of included systematic reviews for effectiveness outcomes

Author; year	Number of studies (country of studies); sample size	Inclusion and exclusion criteria	Intervention; Comparator	Treatment duration	Relevant outcomes			
Stroke								
Ferrarello 2011 ¹⁵²	RCT = 15 (Canada x3, Taiwan x3, USA x2, UK x2, Brazil x1, Australia x1, Sweden x1, Hong Kong x1, New Zealand x1) N = 700	RCT performed at least 6 months after stroke onset, enrolling 5 or more adults in each group, randomised to an active physiotherapy intervention aimed either at improving mobility and ADL independence or at controlling treatment (placebo or no intervention) Interventions that represent standard practice in stroke rehabilitation Exclusion criteria Physiotherapy prescribed <6 months from stroke event Interventions that are highly innovative or uncommonly used in practice	Motor rehabilitation and physiotherapy interventions; Placebo or no intervention	10 to 120 min, 1 to 5 times per week from 4 to 26 weeks	Mobility ADL independence			
Hakkennes 2005 ¹⁵³	RCT = 14 (USA x9, UK x1, Thailand x1, Saudi Arabia x1, Canada x1, The Netherlands x1) N = 292	Inclusion criteria: Trial participants >18 years old reduced functional use of an upper extremity due to stroke study design either RCT or quasi-RCT including cross-over designs or a systematic review of RCTs	Constrained- induced muscle treatment; No treatment	12 days to 10 weeks	 ADL Patient satisfaction QoL 			

Author; year	Number of studies (country of studies); sample size	Inclusion and exclusion criteria	Intervention; Comparator	Treatment duration	Relevant outcomes
Howlett 2015 ¹⁵⁴	RCT = 18 (Finland x3, UK x2, USA x2, Denmark x2, Australia x1, Slovenia x1, Taiwan x1, Japan x1, Korea x1, Switzerland x1, Saudi Arabia x1, Hong Kong x1, India x1) N = 168	 Inclusion criteria: Adults 18+ Moderate- to high-quality (PEDro >4) randomised or controlled trials of adults with stroke using FES 	FES; Placebo/nil	2 to 12 weeks, with the total dose ranging from 5 to 90 hours	Measures of activity limitation
Pomeroy 2006 ¹⁵⁵	RCT and quasi RCT = 24 (USA x10, UK x4, Sweden x2, Slovenia x1, Australia x1, Italy x1, China x1, Denmark x1, Turkey x1, Hong Kong x1, could not determine x1) N = 888	Participants with diagnosis of either ischaemic stroke or haemorrhagic stroke at any time after stroke Exclusion criteria Trials which investigated an experimental condition that differed from the control condition by combining electrostimulation with other interventions (e.g. splints)	Electrostimulati on; Placebo, no treatment	Up to three months	 Functional motor ability Ability to undertake ADL Motor impairment Normality of movement (voluntary movement control)

Author; year	Number of studies (country of studies); sample size	Inclusion and exclusion criteria	Intervention; Comparator	Treatment duration	Relevant outcomes
Saunders 2020 ¹⁶³	RCT = 75 (USA x9, UK x9, Korea x9, China x8, Australia x6, Ireland x4, Canada x4, Sweden x3, The Netherlands x3, Belgium x3, Turkey x2, Japan x2, Israel x2, Portugal x1, Brazil x1, Iran x1, Norway x1, France x1, Germany x1, Italy x1, Switzerland x1, Jamaica x1, South Africa x1, Norway x1, New Zealand x1) N = 3617	All studies described as RCTs that examined the effects of cardiorespiratory, resistance or mixed training Studies in which controls were exposed to either physical activity occurring during usual care or no training or usual care Full text reports of published and unpublished studies	Cardiorespirato ry training, resistance training, mixed training; Usual care, no intervention	12 weeks or less	 Death Dependence Disability Adverse events Vascular risk factors Physical fitness, mobility Physical function Health status and QoL Mood Cognitive function
States 2009 ¹⁵⁶	RCT = 9 (Canada x4, Taiwan x3, UK x2) N = 499	Inclusion criteria Adults (>18 years) who had a stroke and mobility deficits at least 6 months prior to inclusion in study Exclusion criteria Studies that only used treadmill training, only used technologically demanding forms of gait training like body weight-supported treadmill training, only used progressive resistance training without gait-oriented exercises, or only included home-care programmes	Overground physical therapy; No intervention or control intervention (other rehabilitative techniques that do not include gait training)	1 to 3 sessions per week for 4 to 19 weeks	Gait function

Author; year	Number of studies (country of studies); sample size	Inclusion and exclusion criteria	Intervention; Comparator	Treatment duration	Relevant outcomes
Stewart 2019 ¹⁵⁷	RCT = 28 (for nerve stimulation 2 studies) (UK x1, Australia x4, Sweden x3, Canada x3, USA x2, Norway x1, Holland x1, Brazil x1, Taiwan x1, and Italy x1) N = 326	 Inclusion criteria Participants ≥65 years of age, or mean age of participants ≥65 years of age All aetiologies, types and severity of stroke/stroke symptoms 	Nerve stimulation (TENS), physiotherapy interventions; Sham, acupuncture, other physiotherapy interventions	30 min, 2x a week for 10 weeks	• QoL
van der Lee 2001 ¹⁵⁸	RCT = 13 (USA x7, The Netherlands x2, UK x2, Belgium x1, Canada x1) N = 939	Inclusion criteria Studies concerning exercise therapy aimed at amelioration of motor function of hemiparetic/hemiplegic arm in stroke patients Studies designed and reported as RCTs Outcomes measured at impairment and/or disability level Separate results presented for affected arm Published full-length articles English, German, French or Dutch language Published after 1966. Exclusion criteria Studies concerning pharmacological interventions, biofeedback techniques or electrical stimulation	Exercise therapy; Other rehabilitation intervention, usual care, no treatment	5 to 2 hours/day; 3 to 6 times a week; for 2 to 20 weeks	Arm function

Author; year	Number of studies (country of studies); sample size	Inclusion and exclusion criteria	Intervention; Comparator	Treatment duration	Relevant outcomes
Veldema 2020 ¹⁵⁹	RCT = 28 (Korea x8, China x3, Canada x2, Israel x2, Italy x2, Denmark x2, USA x2, Taiwan x2, Egypt x1, Ireland x1, Australia x1, Germany x1, The Netherlands x1) N = 1,115	Inclusion criteria Human studies Prospective studies English language	Ergometer training; No intervention	Between 15 and 365 intervention sessions with follow-up over 8 weeks and 12 months in 2 studies	Cardiorespirator y fitness Motor function and muscle force of lower limbs Independence in ADLs Glucose metabolism Predictive force accuracy Cognitive abilities Walking abilities Balance ability Postural control Health relevant physiological indicators Multidimensiona I stroke outcome Health related QoL
Yang 2019 ¹⁶⁰	RCT = 59 (USA x14, UK x6, Korea x6, Japan x5, Turkey x5, China x4, Taiwan x3, Brazil x2, Canada x2, The Netherlands x2, Italy x2, Germany x2, Egypt x1, Spain x1, Thailand x1, Sweden x1, Hong Kong x1, Australia x1)	 Inclusion criteria RCTs reporting the effects of ES on arm function after stroke Exclusion criteria Articles with only protocols, conference papers or animal studies RCTs that investigated the effect of a combined treatment, where the effects of electrical stimulation cannot be isolated Crossover studies with no isolated outcomes before the crossover 	ES; Placebo	20 minutes to 12 hours; treatment frequency of 3 times per week to 3 times per day; treatment duration of 1 day to 5 months	Primary outcome Body function Secondary outcome Activity assessment
Daylein a a v ! a	N=1,712				
Parkinson's	Disease				

Author; year	Number of studies (country of studies); sample size	Inclusion and exclusion criteria	Intervention; Comparator	Treatment duration	Relevant outcomes
Shen 2016 ¹⁶¹	RCT = 25 (USA x5, Australia x4, Italy x3, Germany, x2, Hong Kong x2, Taiwan x2, UK x2, Canada x1, China x1, The Netherlands x1, Sweden x1, USA & The Netherlands x1) N = 1,181	RCTs for PD with outcomes related to balance, gait and/or falls Exclusion criteria Interventions did not involve any gait, balance or strengthening exercises Control group had balance, gait or strengthening exercises for the LE Low-quality studies	Exercise (balance, gait, strength training); Control group that did not receive any intervention or placebo training that did not include balance, gait, or strengthening exercises	2 to 24 weeks	FallsBalanceGait Ability
Tomlinson 2013 ¹⁶²	RCT = 76 RCTs from 39 studies (USA x9, could not determine x8, Canada x4, UK x4, Australia x2, India x2, The Netherlands x2, Turkey x2, Austria x1, Germany x1, Hong Kong x1, Iran x1, Poland x1, USA & Netherlands x1) N = 1,827	RCTs comparing physiotherapy intervention with no physiotherapy intervention including placebo control Participants of any age, duration of PD, drug therapy and any duration of physiotherapy treatment	Physiotherapy intervention; No physiotherapy intervention (including placebo control); trials in which the no-intervention arm used an active or credible placebo, as long as no physiotherapy was delivered to this group	4 weeks to 12 months	Gait Functional mobility and balance Falls Clinician-rated impairment and disability Patient rated QoL Adverse events Compliance Economic analysis

Abbreviations: **ADL** = activities of daily living, **ES** = electrical stimulation, **FES** = functional electrical stimulation, **LE** = lower extremity, **Min** = minutes, **PEDro** = Physiotherapy Evidence Database, **PD** = Parkinson's disease, **QoL** = quality of life, **RCT** = randomised controlled trials, **TENS** = transcutaneous electrical nerve stimulation, **UK** = United Kingdom, **USA** = United States of America.

12.2 Safety studies

Table 31 List of included systematic reviews for safety outcomes

Abbreviations: PD = Parkinson's disease, RCT = randomised control trial, UK = United Kingdom, USA = United States of America.

13 Appendix C: Economic evaluation study extraction

Table 32 Evidence table for included studies on health economic evaluations

Study	Country	Treatment regimen, duration	Costing Year	Model time horizon	Study Perspective	Patients	Approach	Health State Costs and sources	Sensitivity Analysis	Discount rate	Source	QoL Measure	Evaluation Outcome
Stroke													
Beech et al 1999 ¹⁶⁴	UK	-Community-based rehabilitation for stroke -Conventional care -Planned program for 3 months	1997	12 months	Government	Early stroke discharge	Cost analysis	Physician, GP and social service costs obtained using a questionnaire	Overhead rate	Nil	RCT	NR	Average annual cost per patient
Chan 2015 ¹⁶⁵	Canada	- Higher-intensity physiotherapy for stroke rehabilitation (23 hours) -Lower intensity (9.2 hours)	2014	Lifelong	Government	Recent stroke patients	Markov model	Times spent by physiotherapists were multiplied by federal wages. Average bed costs and rehabilitation time from literature	-Duration of effect -Physiotherapist wage -Physiotherapy assistant -Mortality rate -Discount rate -Utility value -Inpatient stay	5%	Literature review	EQ-5D	Cost per QALY

Study	Country	Treatment regimen, duration	Costing Year	Model time horizon	Study Perspective	Patients	Approach	Health State Costs and sources	Sensitivity Analysis	Discount rate	Source	QoL Measure	Evaluation Outcome
Collins et al 2018 ¹⁶⁸	UK	-Fitness programme (3 times/week for 12 weeks) Each class 1 hour and 15 minutes -Relaxation	2014	7 months	Societal	Stroke	Decision model	Costs provided by local community group fitness provider	Comparing to usual care, classes for 12 months, less than 7 attendees per class	Nil	Previous RCT	SF-36	Cost per QALY
Faulkner et al 2017 ¹⁷⁰	NZ	-Short-term exercise and education -Usual care	2015	3·5 years	Hospital	Transient ischemic attack or minor stroke	Costing model	Hospital costs estimated using unit costs based on disease groupings	Nil	Nil	Hospital records	Nil	Cost per patient
Harrington et al 2010 ¹⁷¹	UK	-16 sessions (1 hour exercise and 1 hour education) for 8 weeks -Standard care	2004	1 year	Societal	Stroke	Cost comparison	Resource use collected prospectively using diaries. Intervention costs included venue hire, staff costs, transport, and disposable items	Nil	Nil	RCT	WHO QOL Index	Cost per patient

Study	Country	Treatment regimen, duration	Costing Year	Model time horizon	Study Perspective	Patients	Approach	Health State Costs and sources	Sensitivity Analysis	Discount rate	Source	QoL Measure	Evaluation Outcome
Hunter et al 2018 ¹⁶⁷	UK	- Conventional physical therapy plus functional strength training for upper limb for 90 min/day, 5 days/week for 6 weeks - Conventional physical therapy plus movement performance therapy for 60 min/day, 5 days/week	2015	6 months	Health system	Stroke	Trial based cost utility analysis	A log of equipment, and training costs was used to cost the intervention. Patients were asked to provide details of health service use at follow-up which were valued using reference costs.	Including carer cost and excluding training costs	Nil	RCT	EQ-5D	Cost per QALY
PD													
Clarke et al 2016 ¹⁶⁶	UK	-Physiotherapy & occupational therapy tailored to individual patient requirements. Median therapy dose 4 sessions of 58 minutes over 8 weeks -No therapy	2012	15 months	Government	Mild to moderate PD	Trial based cost utility analysis	GP and practice nurse visits, hospital inpatient stays, outpatient visits and accident attendances costed using a resource-utilisation questionnaire	Missing values	Nil	RCT	EQ-5D	Cost per QALY

Study	Country	Treatment regimen, duration	Costing Year	Model time horizon	Study Perspective	Patients	Approach	Health State Costs and sources	Sensitivity Analysis	Discount rate	Source	QoL Measure	Evaluation Outcome
Farag et al 2016 ¹⁶⁹	Australia	-Monthly exercise class & 2–4 home visits from physical therapist over 6 months -Usual care	2012	6 months	Health system	PD	Trial-based cost utility analysis	Implementation costs from records of service delivery and travel. Monthly calendars used for health service utilisation	Nil	Nil	RCT	SF-6D	Cost per QALY
Fletcher et al 2012 ¹⁷²	UK	-10-week group exercise programme with supplementary home exercises -Usual care	2008	20 weeks	Societal	PD and self-reported history of 2 or more falls in preceding 12 months	Trial based cost-utility analysis	Physiotherapist time input was recorded by research team. Reference costs used for valuing services	Nil	Nil	RCT	EQ-5D	Cost per QALY
Gage et al 2006 ¹⁷³	UK	-1 day/week for 6 consecutive weeks, 2 hours exercise	2000	6 weeks	Societal	PD	Cost comparison	Costs derived from protocol and hospital financial managers	Nil	Nil	Cohort analysis	Nil	Cost analysis
Joseph et al 2019 ¹⁷⁴	Sweden	-10-week (3 times/week), group-based, progressive balance training program, led by 2 physical therapists -Usual care	2013	10 weeks	Societal	Mild to moderate PD	Trial based cost utility analysis	Costs included physiotherapist education, participants' and therapists' costs during assessments, and facilities use. Mean wages applied to retrospective data	Nil	Nil	RCT	SF-36	Cost per QALY

Study	Country	Treatment regimen, duration	Costing Year	Model time horizon	Study Perspective	Patients	Approach	Health State Costs and sources	Sensitivity Analysis	Discount rate	Source	QoL Measure	Evaluation Outcome
Xin et al 2020 ¹⁷⁵	UK	-12 x 1-hour sessions of physiotherapist- delivered fall prevention programme -Usual care	2016	12 months	Government	PD, history of fall	Trial based cost utility analysis	Questionnaires used by participants to collect resource use for primary, hospital, medicines and social services	Time horizon, physiotherapist visits and numbers of sessions	Nil	RCT	EQ-5D	Cost per QALY
MS													
Tosh et al 2014 ¹⁷⁶	UK	-18 supervised and 18 home exercise sessions over 12 weeks -Usual care	2011	6 months	Health system	MS	Trial-based cost-utility analysis	Questionnaires used to cost health services	Private gyms or by third-party providers. Personal costs and time off work	Nil	RCT	EQ-5D	Cost per QALY

Abbreviations: EQ-5D = EuroQol-5D, **GP**= general practitioner, **MS** = multiple sclerosis, **NR** = not reported, **NZ** = New Zealand, **PD** = Parkinson's disease, **RCT** = randomised control trial, **QALY** = quality-adjusted life year, **QoL** = quality of life, **SF-6D/-36** = short form-6D/-36, **UK** = United Kingdom, **WHO** = World Health Organisation

14 Appendix D: List of excluded trials at full text

14.1 Wrong study design

- Ashburn A, Pickering R, McIntosh E, et al. Exercise-and strategy-based physiotherapy-delivered intervention for preventing repeat falls in people with parkinson's: The PDSAFE RCT. 2019;23(36):1-147.
- 2. Bega D, Gonzalez-Latapi P, Zadikoff C, et al. A Review of the Clinical Evidence for Complementary and Alternative Therapies in Parkinson's Disease. Current Treatment Options in Neurology 2014;16(10)
- **3.** Capato TTC, Fen CH, Barbosa ER. Classification and recommendation of nonpharmacological therapies for Parkinson's disease. Movement Disorders 2016;31:S690.
- **4.** Claflin S, Claflin SB, Van Der Mei I, et al. Complementary and alternative treatments of multiple sclerosis: A review of the evidence from 2001-2016. Multiple Sclerosis 2017;23:NP13.
- 5. Clarke CE, Patel S, Ives N, et al. Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson's disease: a large pragmatic randomised controlled trial (PD REHAB). Health technology assessment (Winchester, England) 2016;20(63):1-96.
- **6.** Coleman ER, Moudgal R, Lang K, et al. Early Rehabilitation After Stroke: a Narrative Review. Current Atherosclerosis Reports 2017;19(12).
- **7.** Coupar F, Pollock A, Legg LA, et al. Home-based therapy programmes for upper limb functional recovery following stroke. 2012;5:CD006755.
- **8.** Domingos JMM, Ferreira JJ. Criteria for referral to rehabilitation services in Parkinson's disease. Movement Disorders 2011;26:S188.
- **9.** English C, Hillier S, Lynch E. Circuit class therapy improves walking ability and may reduce length of stay after stroke. An updated cochrane review. International Journal of Stroke 2017;12:13.
- **10.** Everton LF, Benfield JK, Hedstrom A, et al. Psychometric assessment and validation of the dysphagia severity rating scale in stroke patients. Scientific reports 2020;10(1):7268.
- **11.** Galvin R, Lennon S, Murphy Brendan T, et al. Additional exercise therapy for the recovery of function after stroke. Cochrane Database of Systematic Reviews: Reviews 2012.

- **12.** Glanz M, Klawansky S, Chalmers T. Biofeedback therapy in stroke rehabilitation: a review. Journal of the Royal Society of Medicine 1997 Jan;90(1):33-39 1997
- **13.** Hartley P, Pomeroy V, Wellwood I. The rationale for and methods of dose selection in trials of intensity of physical therapy to enhance recovery after stroke. International Journal of Stroke 2015;10:171-72.
- **14.** Hegarty D, Mockler D, Stokes E, et al. The impact of high intensity exercise on outcome in people with Parkinson's disease: A systematic review. Journal of Parkinson's Disease 2013;1:145.
- **15.** Kanase Suraj B, Varadharajulu G, Salunkhe PV, et al. Role of physiotherapy on quality of life in stroke survivors a systematic review. Indian Journal of Forensic Medicine and Toxicology 2020;14(2):226-30.
- **16.** Li Y, Li R, Xiao J, et al. Medicine effectiveness comparisons of different physicotherapeutics for stroke patients with dysphagia: A protocol for systematic review and network meta-analysis. Medicine 2020;99(38):e22183.
- **17.** Medical Advisory Secretariat HQO. Constraint-induced movement therapy for rehabilitation of arm dysfunction after stroke in adults: an evidence-based analysis. Ontario Health Technology Assessment Series 2011;11(6):1-58.
- **18.** Miles A, Allen JE. Management of oropharyngeal neurogenic dysphagia in adults. Current Opinion in Otolaryngology and Head and Neck Surgery 2015;23(6):433-39.
- **19.** Monti S, Bellini C, Medri E, et al. Physiotherapy and the prevention of falls in Parkinson's disease: scientific evidences in literature. Scienza Riabilitativa 2011 Aug;13(3):28-35 2011.
- **20.** Nedeljkovic U, Dubljanin Raspopovic E, Ilic N, et al. Endurance and resistance training in rehabilitation of patients with multiple sclerosis. Vojnosanitetski Pregled 2014;71(10):963-68.
- **21.** Pilutti LA, Platta ME, Motl RW, et al. The safety of exercise training in multiple sclerosis: A systematic review. Journal of the Neurological Sciences 2014;343(1):3-7.
- **22.** Qin W, Wang Z, Zhong Y, et al. Comparative efficacy of nonpharmaceutical therapy in the treatment of dysphagia after stroke: A protocol for systematic review. Medicine (United States) 2020;99(9).
- **23.** Ransmayr G. Physical, occupational, speech and swallowing therapies and physical exercise in Parkinson's disease. Journal of Neural Transmission 2011;118(5):773-81.
- **24.** Regan J, Murphy A, Chiang M, et al. Botulinum toxin for upper oesophageal sphincter dysfunction in neurological swallowing disorders. Cochrane Database of Systematic Reviews 2014(5).

- **25.** Shaw L, Rodgers H, Price C, et al. BoTULS: A multicentre randomized controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technology Assessment 2010;14(26):i-141.
- **26.** Sosnoff JJ, Sung J. Reducing falls and improving mobility in multiple sclerosis [with consumer summary]. Expert Review of Neurotherapeutics 2015 Jun;15(6):655-666 2015.
- **27.** Thieme H, Mehrholz J, Pohl M, et al. Mirror therapy for improving motor function after stroke. Stroke 2013;44(1):e1-2.
- **28.** Whitehead L. Constraint-Induced Movement Therapy for Hemiparesis Following Stroke. The American journal of nursing 2016;116(8):63.
- **29.** Zhang JH, Wang D, Liu M. Overview of systematic reviews and meta-analyses of acupuncture for stroke. Neuroepidemiology 2014;42(1):50-58 2014

14.2 Wrong population

- 1. Connors MH, Quinto L, McKeith I, et al. Non-pharmacological interventions for Lewy body dementia: a systematic review. Psychological medicine 2018;48(11):1749-58.
- 2. Kazachkov M, Palma JA, Norcliffe-Kaufmann L, et al. Respiratory care in familial dysautonomia: Systematic review and expert consensus recommendations. Respiratory Medicine 2018;141:37-46.
- 3. Lennon O, Galvin R, Smith K, et al. Lifestyle interventions for secondary disease prevention in stroke and transient ischaemic attack: A systematic review. European Journal of Preventive Cardiology 2014;21(8):1026-39.
- **4.** McLean SM, Burton M, Bradley L, et al. Interventions for enhancing adherence with physiotherapy: a systematic review. Manual Therapy 2010;15(6):514-21.
- 5. Neill J, Belan I, Ried K. Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: A systematic review. Journal of Advanced Nursing 2006;56(6):617-35.
- **6.** Oremus M, Santaguida P, Walker K, et al. Studies of stroke rehabilitation therapies should report blinding and rationalize use of outcome measurement instruments. Journal of Clinical Epidemiology 2012;65(4):368-74.
- **7.** Pollock A, Hazelton C, Rowe FJ, et al. Interventions for visual field defects in people with stroke. Cochrane Database of Systematic Reviews 2019(5).

- **8.** Tan C, Liu Y, Li W, et al. Transcutaneous neuromuscular electrical stimulation can improve swallowing function in patients with dysphagia caused by non-stroke diseases: A meta-analysis. Journal of Oral Rehabilitation 2013;40(6):472-80.
- **9.** Wakabayashi H, Sakuma K. Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management. Journal of Cachexia, Sarcopenia and Muscle 2014;5(4):269-77.
- **10.** Wu F, Liu Y, Ye G, et al. Respiratory muscle training improves strength and decreases the risk of respiratory complications in stroke survivors: a systematic review and meta-analysis. Archives of physical medicine and rehabilitation 2020;20.

14.3 Wrong intervention

- Abbasian S, Rastegar MM. Is the Intensity or Duration of Treadmill Training Important for Stroke Patients? A Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases 2018;27(1):32-43.
- 2. Adie, K., C. Schofield, M. Berrow, C. Pritchard, J. Freeman, J. Humfryes and J. Wingham (2014).
 "Does the use of Nintendo Wii SportsTM improve arm function and is it acceptable to patients after stroke? Publication of the Protocol of the Trial of WiiTM in Stroke TWIST." International Journal of General Medicine 7: 475-481.
- Asano M, Finlayson ML. Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: Exercise, education, and medication. Multiple Sclerosis International 2014;2014
- **4.** Ashford J, McCabe D, Wheeler-Hegland K, et al. Evidence-based systematic review: Oropharyngeal dysphagia behavioral treatments. Part III--impact of dysphagia treatments on populations with neurological disorders. Journal of Rehabilitation Research & Development 2009;46(2):195-204.
- 5. Blikman LJ, Huisstede BM, Kooijmans H, et al. Effectiveness of energy conservation treatment in reducing fatigue in multiple sclerosis: a systematic review and meta-analysis. Archives of Physical Medicine & Rehabilitation 2013;94(7):1360-76.
- **6.** Bouca-Machado R, Rosario A, Caldeira D, et al. Physical Activity, Exercise, and Physiotherapy in Parkinson's Disease: Defining the Concepts. Movement Disorders Clinical Practice 2020;7(1):7-15.
- Brefel-Courbon, C., K. Desboeuf, C. Thalamas, M. Galitzky, J. M. Senard, O. Rascol and J. L. Montastruc (2003). "Clinical and economic analysis of spa therapy in Parkinson's disease."
 Movement Disorders 18(5): 578-584.

- 8. Chae, S. H., Y. Kim, K. S. Lee and H. S. Park (2020). "Development and Clinical Evaluation of a Web-Based Upper Limb Home Rehabilitation System Using a Smartwatch and Machine Learning Model for Chronic Stroke Survivors: Prospective Comparative Study." JMIR mHealth and uHealth 8(7): e17216.
- **9.** Chung CSY, Pollock A, Campbell T, et al. Cognitive rehabilitation for executive dysfunction in adults with stroke or other adult non-progressive acquired brain damage. Cochrane Database of Systematic Reviews 2013(4).
- **10.** Corcos D, Robichaud J, David F, et al. 24 months of exercise improves the motor symptoms in Parkinson's disease. Neurology Conference: 64th American Academy of Neurology Annual Meeting New Orleans, LA United States Conference Publication: 2012;78(1)
- **11.** Crotty, M., M. Van Den Berg, E. Liu, Kaambwa, W. E. Van and G. Kwakkel (2016). "Cost-effectiveness of caregiver-mediated exercises combined with e-health services after stroke." Cerebrovascular Diseases 42: 156.
- **12.** das Nair R, Cogger H, Worthington E, et al. Cognitive rehabilitation for memory deficits after stroke. Cochrane Database of Systematic Reviews 2016(9).
- **13.** das Nair R, Martin KJ, Lincoln NB. Memory rehabilitation for people with multiple sclerosis. Cochrane Database of Systematic Reviews 2016(3).
- **14.** Deane K, Whurr R, Clarke CE, et al. Non-pharmacological therapies for dysphagia in Parkinson's disease. Cochrane Database of Systematic Reviews 2001(1).
- **15.** Demetrios M, Khan F, Turner-Stokes L, et al. Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post-stroke spasticity. The Cochrane database of systematic reviews 2013;6:CD009689.
- 16. Diekmann, S., L. Horster, S. Evers, M. Hiligsmann, G. Gelbrich, K. Groschel, R. Wachter, G. F. Hamann, P. Kermer, J. Liman, M. Weber-Kruger, J. Wasem and A. Neumann (2019). "Economic evaluation of prolonged and enhanced ECG Holter monitoring in acute ischemic stroke patients." Current Medical Research and Opinion 35(11): 1859-1866.
- 17. Dominguez-Romero JG, Molina-Aroca A, Moral-Munoz JA, et al. Effectiveness of mechanical horseriding simulators on postural balance in neurological rehabilitation: Systematic review and metaanalysis. International Journal of Environmental Research and Public Health 2020;17(1).
- **18.** Dorstyn D, Roberts R, Kneebone I, et al. Systematic review of leisure therapy and its effectiveness in managing functional outcomes in stroke rehabilitation. Topics in Stroke Rehabilitation 2014;21(1):40-51 2014.

- **19.** Ensari I, Motl RW, Pilutti LA. Exercise training improves depressive symptoms in people with multiple sclerosis: Results of a meta-analysis. Journal of Psychosomatic Research 2014;76(6):465-71.
- **20.** Foley N, Teasell R, Salter K, et al. Dysphagia treatment post stroke: a systematic review of randomised controlled trials [with consumer summary]. Age and Ageing 2008 May;37(3):258-264 2008.
- **21.** Fryer CE, Luker JA, McDonnell MN, et al. Self management programmes for quality of life in people with stroke (Cochrane review) [with consumer summary]. 2016.
- **22.** Gage H, Storey L. Rehabilitation for Parkinson's disease: A systematic review of available evidence. Clinical Rehabilitation 2004;18(5):463-82.
- **23.** Gebruers N, Vanroy C, Truijen S, et al. Monitoring of physical activity after stroke: a systematic review of accelerometry-based measures. Archives of Physical Medicine & Rehabilitation 2010;91(2):288-97.
- 24. Gomes-Neto M, Saquetto MB, Silva CM, et al. Effects of Respiratory Muscle Training on Respiratory Function, Respiratory Muscle Strength, and Exercise Tolerance in Patients Poststroke: A Systematic Review With Meta-Analysis. Archives of Physical Medicine and Rehabilitation 2016;97(11):1994-2001.
- **25.** Gras, A. and J. Broughton (2016). "A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis." Expert Review of Pharmacoeconomics and Outcomes Research 16(6): 771-779.
- **26.** Hesse, S., R. Buschfort, A. Hess, N. Kabbert and C. Werner (2014). "Effect on arm function and cost of robot-assisted group therapy in subacute patients with stroke and a moderately to severely affected arm: A randomized controlled trial. [German]." Neurologie und Rehabilitation 20(2): 67-73.
- **27.** Hooper, J. and I. R. Whittle (2003). "Costs of thalamic deep brain stimulation for movement disorders in patients with multiple sclerosis." British Journal of Neurosurgery 17(1): 40-45.
- **28.** Jones F, Riazi A. Self-efficacy and self-management after stroke: a systematic review. Disability and Rehabilitation 2011;33(10):797-810 2011.
- **29.** Juckes, F. M., G. Marceniuk, C. Seary and V. L. Stevenson (2019). "A cohort study of functional electrical stimulation in people with multiple sclerosis demonstrating improvements in quality of life and cost-effectiveness." Clinical rehabilitation 33(7): 1163-1170.
- **30.** Kacsir AP, Braun T, Pinter M. Der effekt von rhythmisch-auditorischer stimulation auf das gehen bei Parkinson-patienten -- applizierte frequenzen und langzeiteffekte (Rhythmic-auditory stimulation in

- Parkinson's disease -- effectiveness, applied frequencies and long-term effects) [German]. Neurologie und Rehabilitation 2014;20(1):5-16 2014.
- **31.** Kashiwagi F, Gomaa H, Gawish N, et al. Non-invasive brain stimulations for unilateral spatial neglect after stroke-a systematic review and meta-analysis of randomized and non-randomized controlled trials. Cerebrovascular Diseases 2017;43:82.
- **32.** Kolovos, S., A. P. Finch, H. P. Van Der Ploeg, F. Van Nassau, H. M. Broulikova, A. Baka, S. Treweek, C. M. Gray, J. G. M. Jelsma, C. Bunn, G. C. Roberts, M. N. Silva, J. M. R. Gill, O. Roynesdal, W. Van Mechelen, E. Andersen, K. Hunt, S. Wyke and J. E. Bosmans (2020). "Five-year cost-effectiveness analysis of the European Fans in Training (EuroFIT) physical activity intervention for men versus no intervention." International Journal of Behavioral Nutrition and Physical Activity 17(1).
- **33.** Li, F. and P. Harmer (2015). "Economic Evaluation of a Tai Ji Quan Intervention to Reduce Falls in People With Parkinson Disease, Oregon, 2008-2011." Preventing chronic disease 12: E120.
- **34.** Light, K. (2015). "Constraint-induced movement therapy: Home-training is beneficial and cost effective." Physiotherapy (United Kingdom) 101: eS873-eS874.
- **35.** Llorens, R., E. Noe, C. Colomer and M. Alcaniz (2015). "Effectiveness, usability, and cost-benefit of a virtual reality-based telerehabilitation program for balance recovery after stroke: A randomized controlled trial." Archives of Physical Medicine and Rehabilitation 96(3): 418-425.e412.
- **36.** Long YB, Wu XP. A meta-analysis of the efficacy of acupuncture in treating dysphagia in patients with a stroke [with consumer summary]. Acupuncture in Medicine 2012 Dec;30(4):291-297 2012.
- **37.** Morris JH, Macgillivray S, Macfarlane S. Interventions to promote long-term participation in physical activity after stroke: a systematic review of the literature. Archives of Physical Medicine and Rehabilitation 2014;95(5):956-67.
- **38.** Roderick, P., J. Low, R. Day, T. Peasgood, M. A. Mullee, J. C. Turnbull, T. Villar and J. Raftery (2001). "Stroke rehabilitation after hospital discharge: A randomized trial comparing domiciliary and day-hospital care." Age and Ageing 30(4): 303-310.
- 39. Seymour, K. C., S. E. Lamb, A. Ashburn, K. Seymour, H. C. Roberts, R. M. Pickering, S. Lamb, C. Ballinger, V. A. Goodwin, L. Rochester, A. Nieuwboer, E. McIntosh, D. Kunkel, S. Hulbert, C. Fitton, I. Marian, Y. Xin, A. Rowsell and R. Summer (2020). "Cost-effectiveness of the PDSAFE personalised physiotherapy intervention for fall prevention in Parkinson's: An economic evaluation alongside a randomised controlled trial." BMC Neurology 20(1).

- **40.** Shackley, P., L. Shaw, C. Price, F. van Wijck, M. Barnes, L. Graham, G. A. Ford, N. Steen and H. Rodgers (2012). "Cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type a: Results from the botulinum toxin for the upper limb after stroke (BoTULS) trial." Toxins 4(12): 1415-1426.
- 41. Sheppard, L., H. Dewey, J. Bernhardt, J. M. Collier, F. Ellery, L. Churilov, K. Tay-Teo, O. Wu, M. Moodie and A. T. C. Group (2016). "Economic Evaluation Plan (EEP) for A Very Early Rehabilitation Trial (AVERT): An international trial to compare the costs and cost-effectiveness of commencing out of bed standing and walking training (very early mobilization) within 24 h of stroke onset with usual stroke unit care." International Journal of Stroke 11(4): 492-494.
- **42.** Slof, J. and A. Gras (2012). "Sativex in multiple sclerosis spasticity: a cost-effectiveness model." Expert review of pharmacoeconomics & outcomes research 12(4): 439-441.
- **43.** van de Port, I. G. L., L. Wevers, H. Roelse, L. van Kats, E. Lindeman and G. Kwakkel (2009). "Cost-effectiveness of a structured progressive task-oriented circuit class training programme to enhance walking competency after stroke: The protocol of the FIT-Stroke trial." BMC Neurology 9.
- **44.** Veldema J, Jansen P. Resistance training in stroke rehabilitation: systematic review and metaanalysis. Clinical rehabilitation 2020;34(9):1173-97.
- **45.** Von Koch, L., J. De Pedro-Cuesta, V. Kostulas, J. Almazan and L. Widen Holmqvist (2001). "Randomized controlled trial of rehabilitation at home after stroke: One-year follow-up of patient outcome, resource use and cost." Cerebrovascular Diseases 12(2): 131-138.
- 46. Wagner, T. H., A. C. Lo, P. Peduzzi, D. M. Bravata, G. D. Huang, H. I. Krebs, R. J. Ringer, D. G. Federman, L. G. Richards, J. K. Haselkorn, G. F. Wittenberg, B. T. Volpe, C. T. Bever, P. W. Duncan, A. Siroka and P. D. Guarino (2011). "An economic analysis of robot-assisted therapy for long-term upper-limb impairment after stroke." Stroke 42(9): 2630-2632.
- **47.** Wong ISY, Ng KF, Tsang HWH. Acupuncture for dysphagia following stroke: A systematic review. European Journal of Integrative Medicine 2012;4(2):e141-e50.
- **48.** Wu S, Kutlubaev MA, Chun HYY, et al. Interventions for post-stroke fatigue. Cochrane Database of Systematic Reviews 2015;2015(7)
- **49.** Xie Y, Wang L, He J, et al. Acupuncture for dysphagia in acute stroke. Cochrane Database of Systematic Reviews 2008(3).
- **50.** Ye Q, Xie Y, Shi J, et al. Systematic review on acupuncture for treatment of dysphagia after stroke. Evidence-Based Complementary and Alternative Medicine 2017;(6421852):Epub 2017

51. Young, J. and A. Forster (1993). "Day hospital and home physiotherapy for stroke patients: a comparative cost-effectiveness study." Journal of the Royal College of Physicians of London 27(3): 252-258.

14.4 Wrong comparator

- 1. Aguiar LT, Nadeau S, Martins JC, et al. Efficacy of interventions aimed at improving physical activity in individuals with stroke: a systematic review. Disability and rehabilitation 2020;42(7):902-17.
- Alamer A, Getie K, Melese H, et al. Effectiveness of body awareness therapy in stroke survivors: A
 systematic review of randomized controlled trials. Open Access Journal of Clinical Trials
 2020;12:23-32.
- **3.** Ali RM, Siddiqui MA, Mail QJ. Role of increased exercise therapy time in stroke rehabilitation. Journal of Medicine (Bangladesh) 2015;16(2):103-04.
- **4.** Alphonsus KB, Su Y, D'Arcy C. The effect of exercise, yoga and physiotherapy on the quality of life of people with multiple sclerosis: Systematic review and meta-analysis. Complementary Therapies in Medicine 2019;43:188-95.
- **5.** Alves Da Rocha P, McClelland J, Morris ME. Complementary physical therapies for movement disorders in Parkinson's disease: a systematic review. European journal of physical and rehabilitation medicine 2015;51(6):693-704.
- **6.** Ambrosini E, Parati M, Ferriero G, et al. Does cycling induced by functional electrical stimulation enhance motor recovery in the subacute phase after stroke? A systematic review and meta-analysis. Clinical rehabilitation 2020:269215520938423.
- 7. Amedoro A, Berardi A, Conte A, et al. The effect of aquatic physical therapy on patients with multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders 2020;41.
- **8.** Bjorklund A, Fecht A. The effectiveness of constraint-induced therapy as a stroke intervention: A meta-analysis. Occupational Therapy in Health Care 2006;20(2):31-49.
- **9.** Brazzelli M, Saunders DH, Greig CA, et al. Physical Fitness Training for Stroke Patients: A systematic review of the evidence. International Journal of Stroke 2011;6:11.
- 10. Bronson C, Brewerton K, Ong J, et al. Does hippotherapy improve balance in persons with multiple sclerosis: A systematic review. European Journal of Physical and Rehabilitation Medicine 2010;46(3):347-53.

- **11.** Busk H, Stausholm MB, Lykke L, et al. Electrical Stimulation in Lower Limb During Exercise to Improve Gait Speed and Functional Motor Ability 6 Months Poststroke. A Review with Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases 2020;29(3).
- **12.** Byrnes KL, Whillier S. Effects of Nonpharmaceutical Treatments on Symptom Management in Adults With Mild or Moderate Multiple Sclerosis: A Meta-analysis. Journal of Manipulative and Physiological Therapeutics 2019;42(7):514-31.
- **13.** Campbell E, Coulter EH, Mattison PG, et al. Physiotherapy rehabilitation for people with progressive multiple sclerosis: A systematic review. Archives of Physical Medicine and Rehabilitation 2016;97(1):141-51.e3.
- **14.** Carroll LM, Morris ME, O'Connor WT, et al. Is Aquatic Therapy Optimally Prescribed for Parkinson's Disease? A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease 2020;10(1):59-76.
- **15.** Chae CS, Jun JH, Im S, et al. Effectiveness of Hydrotherapy on Balance and Paretic Knee Strength in Patients With Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. American journal of physical medicine & rehabilitation 2020;99(5):409-19.
- **16.** Choi HY, Cho KH, Jin C, et al. Exercise Therapies for Parkinson's Disease: A Systematic Review and Meta-Analysis. Parkinsons Disease 2020;2565320.
- **17.** Cooke EV, Mares K, Clark A, et al. The effects of increased dose of exercise-based therapies to enhance motor recovery after stroke: A systematic review and meta-analysis. BMC Medicine 2010;8.
- **18.** Cugusi L, Manca A, Bergamin M, et al. Aquatic exercise improves motor impairments in people with Parkinson's disease, with similar or greater benefits than land-based exercise: a systematic review. Journal of physiotherapy 2019;65(2):65-74.
- **19.** Cusso ME, Donald KJ, Khoo TK. The Impact of Physical Activity on Non-Motor Symptoms in Parkinson's Disease: A Systematic Review. Frontiers in Medicine 2016;3:35.
- 20. Dennett R, Madsen LT, Connolly L, et al. Adherence and drop-out in randomized controlled trials of exercise interventions in people with multiple sclerosis: A systematic review and meta-analyses. Multiple Sclerosis and Related Disorders 2020;43.
- **21.** Diaz-Arribas MJ, Martin-Casas P, Cano-de-la-Cuerda R, et al. Effectiveness of the Bobath concept in the treatment of stroke: a systematic review. Disability and rehabilitation 2020;42(12):1636-49.

- **22.** Eraifej J, Clark W, France B, et al. Effectiveness of upper limb functional electrical stimulation after stroke for the improvement of activities of daily living and motor function: A systematic review and meta-analysis. Systematic Reviews 2017;6(1).
- 23. Etoom M, Hawamdeh M, Hawamdeh Z, et al. Constraint-induced movement therapy as a rehabilitation intervention for upper extremity in stroke patients: systematic review and meta-analysis. International journal of rehabilitation research 2016(3):197-210.
- **24.** Flynn A, Allen NE, Dennis S, et al. Home-based prescribed exercise improves balance-related activities in people with Parkinson's disease and has benefits similar to centre-based exercise: a systematic review. Journal of physiotherapy 2019;65(4):189-99.
- **25.** Galvin R, Murphy B, Cusack T, et al. The impact of increased duration of exercise therapy on functional recovery following stroke What is the evidence? Topics in Stroke Rehabilitation 2008;15(4):365-77.
- **26.** Garcia-Rudolph A, Laxe S, Sauri J, et al. Evidence of chronic stroke rehabilitation interventions in activities and participation outcomes: systematic review of meta-analyses of randomized controlled trials. European journal of physical and rehabilitation medicine 2019;55(6):695-709.
- **27.** Giuriati S, Servadio A, Temperoni G, et al. The effect of aquatic physical therapy in patients with stroke: A systematic review and meta-analysis. Topics in Stroke Rehabilitation 2020.
- **28.** Grant VM, Gibson A, Shields N. Somatosensory stimulation to improve hand and upper limb function after stroke-a systematic review with meta-analyses. Topics in Stroke Rehabilitation 2018;25(2):150-60.
- **29.** Greisberger A, Aviv H, Garbade SF, et al. Clinical relevance of the effects of reach-to-grasp training using trunk restraint in individuals with hemiparesis poststroke: A systematic review. Journal of rehabilitation medicine 2016;48(5):405-16.
- **30.** Hayes S, Galvin R, Kennedy C, et al. Interventions for preventing falls in people with multiple sclerosis. Cochrane Database of Systematic Reviews 2019;2019(11).
- **31.** Hayward KS, Kramer SF, Thijs V, et al. A systematic review protocol of timing, efficacy and cost effectiveness of upper limb therapy for motor recovery post-stroke. Systematic Reviews 2019;8(1).
- **32.** Hidalgo-Agudo RD, Lucena-Anton D, Luque-Moreno C, et al. Additional physical interventions to conventional physical therapy in parkinson's disease: A systematic review and meta-analysis of randomized clinical trials. Journal of Clinical Medicine 2020;9(4).
- **33.** Hindle JV, Petrelli A, Clare L, et al. Nonpharmacological enhancement of cognitive function in Parkinson's disease: A systematic review. 2013;28(8):1034-49.

- **34.** Hiraoka K. Rehabilitation effort to improve upper extremity function in post-stroke patients: a metaanalysis. Journal of Physical Therapy Science 2001 Jun;13(1):5-9 2001
- **35.** Hong Z, Sui M, Zhuang Z, et al. Effectiveness of Neuromuscular Electrical Stimulation on Lower Limbs of Patients With Hemiplegia After Chronic Stroke: A Systematic Review. 2018;99(5):1011-22.e1.
- **36.** Iliescu AM, McIntyre A, Wiener J, et al. Evaluating the effectiveness of aquatic therapy on mobility, balance, and level of functional independence in stroke rehabilitation: a systematic review and meta-analysis. Clinical rehabilitation 2020;34(1):56-68.
- **37.** Jambeau M, Chauviere C, Cordier JP. [Treadmill training to improve Parkinsonian gait]. Kinesitherapie la Revue 2011;11(113):35-45.
- **38.** Jia G, Ma J, Wang S, et al. Long-term Effects of Extracorporeal Shock Wave Therapy on Poststroke Spasticity: A Meta-analysis of Randomized Controlled Trials. Journal of Stroke & Cerebrovascular Diseases 2020;29(3):104591.
- **39.** Kendall BJ, Gothe NP. Effect of Aerobic Exercise Interventions on Mobility among Stroke Patients: A Systematic Review. American journal of physical medicine & rehabilitation / Association of Academic Physiatrists 2016;95(3):214-24.
- **40.** Khadke S, Siddique T. Diverse mechanisms and treatment strategies to confront fatigue in multiple sclerosis: A systematic review. F1000Research 2019;8.
- **41.** Khan F, Amatya B. Rehabilitation in Multiple Sclerosis: A Systematic Review of Systematic Reviews. Archives of Physical Medicine and Rehabilitation 2017;98(2):353-67.
- **42.** Ko DS, Jung DI, Bae SY. Effect of lumbar stabilization exercises on the balance ability of patients with stroke: a systematic review. Journal of Physical Therapy Science 2014;26(12):1993-96.
- **43.** Latimer-Cheung AE, Pilutti LA, Hicks AL, et al. Effects of exercise training on fitness, mobility, fatigue, and health-related quality of life among adults with multiple sclerosis: A systematic review to inform guideline development. Archives of Physical Medicine and Rehabilitation 2013;94(9):1800-28.
- **44.** Lawrence M, Celestino Junior FT, Matozinho HHS, et al. Yoga for stroke rehabilitation (Cochrane review) [with consumer summary]. Cochrane Database of Systematic Reviews 2017; Issue 12 2017.
- **45.** Learmonth YC, Ensari I, Motl RW. Physiotherapy and walking outcomes in adults with multiple sclerosis: systematic review and meta-analysis. Physical Therapy Reviews 2016;21(3-6):160-172 2016.

- **46.** Lee J, Stone AJ. Combined Aerobic and Resistance Training for Cardiorespiratory Fitness, Muscle Strength, and Walking Capacity after Stroke: A Systematic Review and Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases 2020;29(1).
- **47.** Li Z, Wang T, Liu H, et al. Dual-task training on gait, motor symptoms, and balance in patients with Parkinson's disease: a systematic review and meta-analysis. Clinical rehabilitation 2020:269215520941142.
- **48.** Lloyd M, Skelton DA, Mead GE, et al. Physical fitness interventions for nonambulatory stroke survivors: A mixed-methods systematic review and meta-analysis. Brain and Behavior 2018;8(7).
- **49.** Lu R, Lloyd-Randolfi D, Jones H, et al. Assessing adherence to physical activity programs poststroke at home: A systematic review of randomized controlled trials. Topics in Stroke Rehabilitation 2020.
- **50.** Lubetzky-Vilnai A, Kartin D. The effect of balance training on balance performance in individuals poststroke: A systematic review. Journal of Neurologic Physical Therapy 2010;34(3):127-37.
- **51.** Luo L, Meng H, Wang Z, et al. Effect of high-intensity exercise on cardiorespiratory fitness in stroke survivors: A systematic review and meta-analysis. Annals of Physical and Rehabilitation Medicine 2020;63(1):59-68.
- **52.** Mahmood A, Veluswamy SK, Hombali A, et al. Effect of Transcutaneous Electrical Nerve Stimulation on Spasticity in Adults With Stroke: A Systematic Review and Meta-analysis. Archives of Physical Medicine and Rehabilitation 2019;100(4):751-68.
- **53.** Manning CD, Pomeroy VM. Effectiveness of treadmill retraining on gait of hemiparetic stroke patients: Systematic review of current evidence. Physiotherapy 2003;89(6):337-45.
- **54.** Marsden DL, Dunn A, Callister R, et al. Characteristics of exercise training interventions to improve cardiorespiratory fitness after stroke: A systematic review with meta-analysis. Neurorehabilitation and Neural Repair 2013;27(9):775-88.
- **55.** McIntyre A, Viana R, Janzen S, et al. Systematic review and meta-analysis of constraint-induced movement therapy in the hemiparetic upper extremity more than six months post stroke. Topics in Stroke Rehabilitation 2012;19(6):499-513.
- **56.** Mehrholz J, Kugler J, Storch A, et al. Treadmill training for patients with Parkinson Disease. An abridged version of a Cochrane Review. European journal of physical and rehabilitation medicine 2016;52(5):704-13.

- **57.** Methajarunon P, Eitivipart C, Diver CJ, et al. Systematic review of published studies on aquatic exercise for balance in patients with multiple sclerosis, Parkinson's disease, and hemiplegia. Hong Kong Physiotherapy Journal 2016;35:12-20.
- **58.** Mills RJ, Yap L, Young CA. Treatment for ataxia in multiple sclerosis. Cochrane Database of Systematic Reviews 2007(1):CD005029.
- **59.** Moritz TA, Snowdon DA, Peiris CL. Combining aquatic physiotherapy with usual care physiotherapy for people with neurological conditions: A systematic review. Physiotherapy research international: the journal for researchers and clinicians in physical therapy 2020;25(1):e1813.
- **60.** Mulla SM, Wang L, Khokhar R, et al. Management of central poststroke pain: systematic review of randomized controlled trials. Stroke 2015 Oct;46(10):2853-2860 2015.
- **61.** Nayak P, Mahmood A, Natarajan M, et al. Effect of aquatic therapy on balance and gait in stroke survivors: A systematic review and meta-analysis. Complementary therapies in clinical practice 2020;39:101110.
- **62.** Outpatient Service Trialists. Therapy-based rehabilitation services for stroke patients at home. Cochrane database of systematic reviews (Online) 2003(1):CD002925.
- **63.** Pereira S, Mehta S, McIntyre A, et al. Functional electrical stimulation for improving gait in persons with chronic stroke. Topics in Stroke Rehabilitation 2012;19(6):491-98.
- **64.** Pollock A, Baer GD, Langhorne P, et al. Physiotherapy treatment approaches for stroke. Stroke 2008;39(2):519-20.
- **65.** Pulman J, Buckley E. Assessing the efficacy of different upper limb hemiparesis interventions on improving health-related quality of life in stroke patients: A systematic review. Topics in Stroke Rehabilitation 2013;20(2):171-88.
- **66.** Rae-Grant AD, Turner AP, Sloan A, et al. Self-management in neurological disorders: Systematic review of the literature and potential interventions in multiple sclerosis care. Journal of Rehabilitation Research and Development 2011;48(9):1087-100.
- **67.** Roeder L, Costello JT, Smith SS, et al. Effects of resistance training on measures of muscular strength in people with Parkinson's Disease: A systematic review and meta-analysis. PLoS ONE 2015;10(7).
- **68.** Rietberg MB, Veerbeek JM, Gosselink R, et al. Respiratory muscle training for multiple sclerosis. Cochrane Database of Systematic Reviews 2017;2017(12).

- **69.** Rutz DG, Benninger DH. Physical Therapy for Freezing of Gait and Gait Impairments in Parkinson Disease: A Systematic Review. PM and R 2020.
- **70.** Salazar AP, Pinto C, Ruschel M, et al. Effectiveness of static stretching positioning on post-stroke upper-limb spasticity and mobility: systematic review with meta-analysis. Annals of Physical and Rehabilitation Medicine 2019 Jul;62(4):274-282 2019.
- **71.** Silva Borges CA, Castao KC, Souto PA, et al. Effect of resisted exercise on muscular strength, spasticity and functionality in chronic hemiparetic subjects: a systematic review. Journal of Applied Research 2009;9(4):147-58.
- **72.** Stanton R, Ada L, Dean CM, et al. Biofeedback improves activities of the lower limb after stroke: A systematic review. Journal of Physiotherapy 2011;57(3):145-55.
- **73.** Thayabaranathan T, Andrew NE, Immink MA, et al. Determining the potential benefits of yoga in chronic stroke care: A systematic review and meta-analysis. Topics in Stroke Rehabilitation 2017;24(4):279-87.
- **74.** Terrens AF, Soh SE, Morgan PE. The efficacy and feasibility of aquatic physiotherapy for people with Parkinson's disease: a systematic review. Disability and rehabilitation 2018;40(24):2847-56.
- **75.** Vafadar AK, Cote JN, Archambault PS. Effectiveness of functional electrical stimulation in improving clinical outcomes in the upper arm following stroke: A systematic review and meta-analysis. BioMed Research International 2015;2015.
- **76.** Van Criekinge T, Truijen S, Schroder J, et al. The effectiveness of trunk training on trunk control, sitting and standing balance and mobility post-stroke: a systematic review and meta-analysis. Clinical rehabilitation 2019;33(6):992-1002.
- 77. Viana R, Pereira S, Mehta S, et al. Evidence for therapeutic interventions for hemiplegic shoulder pain during the chronic stage of stroke: A review. Topics in Stroke Rehabilitation 2012;19(6):514-22.
- **78.** Woodford H, Price C. EMG biofeedback for the recovery of motor function after stroke. Cochrane Database of Systematic Reviews 2007.
- **79.** Wu T, Li JH, Song HX, et al. Effectiveness of botulinum toxin for lower limbs spasticity after stroke: A Systematic review and meta-analysis. Topics in Stroke Rehabilitation 2016;23(3):217-23.

14.5 Wrong outcome

 Bhalsing, K. S., M. M. Abbas and L. C. S. Tan (2018). "Role of physical activity in Parkinson's disease." Annals of Indian Academy of Neurology 21(4): 242-249.

- 2. Bjorkdahl, A. and K. S. Sunnerhagen (2007). "Process skill rather than motor skill seems to be a predictor of costs for rehabilitation after a stroke in working age; a longitudinal study with a 1 year follow up post discharge." BMC Health Services Research 7: 209.
- 3. Bloem, B. R., L. Rompen, N. M. de Vries, A. Klink, M. Munneke and P. Jeurissen (2017).
 "ParkinsonNet: A low-cost health care innovation with a systems approach from the Netherlands."
 Health Affairs 36(11): 1987-1996.
- **4.** Bryant, N. H., L. Candland and R. Loewenstein (1974). "Comparison of care and cost outcomes for stroke patients with and without home care." Stroke 5(1): 54-59.
- 5. Burridge, J. H., A. C. W. Lee, R. Turk, M. Stokes, J. Whitall, R. Vaidyanathan, P. Clatworthy, A. M. Hughes, C. Meagher, E. Franco and L. Yardley (2017). "Telehealth, Wearable Sensors, and the Internet: Will They Improve Stroke Outcomes Through Increased Intensity of Therapy, Motivation, and Adherence to Rehabilitation Programs?" Journal of neurologic physical therapy: JNPT 41: S32-S38.
- **6.** Butler, A., S. Housley, D. Wu, K. Richards, A. Garlow, K. Ducote, A. Howard and T. Thomas (2017). "Effect of home-based rehabilitation on access to cost effective therapy for rural veteran stroke survivors." Archives of Physical Medicine and Rehabilitation 98: e58-e59.
- 7. Canning, C. G., I. Farag, C. Sherrington, S. R. Lord, J. C. T. Close, K. Howard, S. Heritier, G. Z. Heller, A. Hayes, N. E. Allen, M. D. Latt, S. M. Murray, S. D. O'Rourke, S. S. Paul, J. Song and V. S. C. Fung (2015). "Minimally-supervised exercise is effective and cost-saving in reducing falls in people with mild, but not more severe parkinson's disease." Physiotherapy (United Kingdom) 101: eS199.
- **8.** Franceschini, M., A. Rampello, F. Bovolenta, M. Aiello, P. Tzani and A. Chetta (2010). "Cost of walking, exertional dyspnoea and fatigue in individuals with multiple sclerosis not requiring assistive devices." Journal of rehabilitation medicine: official journal of the UEMS European Board of Physical and Rehabilitation Medicine 42(8): 719-723.
- **9.** Gittins, M., D. G. Lugo-Palacios, L. Paley, B. Bray, A. Bowen, A. Vail, B. Gannon and S. Tyson (2020). "How do patients pass through stroke services? Identifying stroke care pathways using national audit data." Clinical rehabilitation 34(5): 698-709.
- **10.** Langhorne, P., O. Wu, H. Rodgers, A. Ashburn and J. Bernhardt (2017). "A very early rehabilitation trial after stroke (AVERT): a Phase III, multicentre, randomised controlled trial." Health Technology Assessment 21(54): 1-119.

- **11.** Learmonth, Y. C., B. C. Adamson, D. Kinnett-Hopkins, M. Bohri and R. W. Motl (2017). "Results of a feasibility randomised controlled study of the guidelines for exercise in multiple sclerosis project." Contemporary Clinical Trials 54: 84-97.
- **12.** Levy T, Laver K, Killington M, et al. A systematic review of measures of adherence to physical exercise recommendations in people with stroke. Clinical rehabilitation 2019;33(3):535-45.
- **13.** Li Z, Wang T, Liu H, et al. Dual-task training on gait, motor symptoms, and balance in patients with Parkinson's disease: a systematic review and meta-analysis. Clinical rehabilitation 2020:269215520941142.
- **14.** Manning CD, Pomeroy VM. Effectiveness of treadmill retraining on gait of hemiparetic stroke patients: Systematic review of current evidence. Physiotherapy 2003;89(6):337-45.
- **15.** Mills RJ, Yap L, Young CA. Treatment for ataxia in multiple sclerosis. Cochrane Database of Systematic Reviews 2007(1):CD005029.
- **16.** Mulla SM, Wang L, Khokhar R, et al. Management of central poststroke pain: systematic review of randomized controlled trials. Stroke 2015 Oct;46(10):2853-2860 2015.
- **17.** Neill J, Belan I, Ried K. Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: A systematic review. Journal of Advanced Nursing 2006;56(6):617-35.
- **18.** Orgeta V, McDonald KR, Poliakoff E, et al. Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's disease. Cochrane Database of Systematic Reviews 2020;2020(2).
- **19.** Pang MYC, Charlesworth SA, Lau RWK, et al. Using aerobic exercise to improve health outcomes and quality of life in stroke: Evidence-based exercise prescription recommendations. Cerebrovascular Diseases 2013;35(1):7-22.
- **20.** Pinto C, Salazar AP, Marchese RR, et al. The effects of hydrotherapy on balance, functional mobility, motor status, and quality of life in patients with Parkinson disease: A systematic review and meta-analysis. PM and R 2019;11(3):278-91.
- **21.** Sa MJ. Exercise therapy and multiple sclerosis: a systematic review. Journal of Neurology 2013:1-11.
- **22.** Young, J. and A. Forster (1993). "Day hospital and home physiotherapy for stroke patients: a comparative cost-effectiveness study." Journal of the Royal College of Physicians of London 27(3): 252-258.

14.6 Wrong intervention/comparator treatment duration

- Adeyemo BO, Simis M, Macea DD, et al. Systematic review of parameters of stimulation, clinical trial design characteristics, and motor outcomes in non-invasive brain stimulation in stroke. Frontiers in Psychiatry 2012;3
- 2. Alali D, Ballard K, Bogaardt H. Treatment Effects for Dysphagia in Adults with Multiple Sclerosis: A Systematic Review. Dysphagia 2016;31(5):610-18.
- **3.** Alamer A, Melese H, Nigussie F. Effectiveness of neuromuscular electrical stimulation on post-stroke dysphagia: A systematic review of randomized controlled trials. Clinical Interventions in Aging 2020;15:1521-31.
- **4.** Alingh JF, Groen BE, Van Asseldonk EHF, et al. Effectiveness of rehabilitation interventions to improve paretic propulsion in individuals with stroke A systematic review. Clinical Biomechanics 2020;71:176-88.
- **5.** Allen NE, Sherrington C, Paul SS, et al. Balance and falls in Parkinson's disease: A meta-analysis of the effect of exercise and motor training. Movement Disorders 2011;26(9):1605-15.
- **6.** Allen NE, Sherrington C, Suriyarachchi GD, et al. Exercise and motor training in people with parkinson's disease: A systematic review of participant characteristics, intervention delivery, retention rates, adherence, and adverse events in clinical trials. Parkinson's Disease 2012.
- 7. Amatya B, Khan F, La Mantia L, et al. Non pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database of Systematic Reviews 2013;2013(2).
- 8. Amatya B, Young J, Khan F. Non-pharmacological interventions for chronic pain in multiple sclerosis. Cochrane Database of Systematic Reviews 2018;2018(12)
- **9.** Bath PM, Lee HS, Everton LF. Swallowing therapy for dysphagia in acute and subacute stroke. Cochrane Database of Systematic Reviews 2018;2018(10).
- 10. Beretta VS, Conceicao NR, Nobrega-Sousa P, et al. Transcranial direct current stimulation combined with physical or cognitive training in people with Parkinson's disease: A systematic review. Journal of NeuroEngineering and Rehabilitation 2020;17(1)
- **11.** Bogaardt H, Kalf H, Fokkens W. The use of surface-EMG as biofeedback in the treatment of stroke patients with dysphagia: A systematic review. Dysphagia 2009;24:468.
- **12.** Borges L, Fernandes A, Melo LP, et al. Action observation for upper limb rehabilitation after stroke. Cochrane Database of Systematic Reviews 2018(10).

- **13.** Bornheim S, Thibaut A, Beaudart C, et al. Evaluating the effects of tDCS in stroke patients using functional outcomes: a systematic review. Disability and rehabilitation 2020:1-11.
- **14.** Bowen A, Hazelton C, Pollock A, et al. Cognitive rehabilitation for spatial neglect following stroke. Cochrane Database of Systematic Reviews 2013(7).
- **15.** Broderick P, Horgan F, Blake C, et al. Mirror therapy for improving lower limb motor function and mobility after stroke: A systematic review and meta-analysis. Gait and Posture 2018;63:208-20.
- **16.** Byrnes K, Wu PJ, Whillier S. Is Pilates an effective rehabilitation tool? A systematic review. 2018;22(1):192-202.
- **17.** Castelli E, Corbetta D. Mirror therapy for upper extremities recovery after stroke: a systematic review. Italian Journal of Physiotherapy 2011 Sep;1(3):80-86 2011.
- **18.** Cauraugh JH, Naik SK, Lodha N, et al. Long-term rehabilitation for chronic stroke arm movements: a randomized controlled trial. Clinical Rehabilitation 2011;25(12):1086-96.
- **19.** Chen YW, Chang KH, Chen HC, et al. The effects of surface neuromuscular electrical stimulation on post-stroke dysphagia: a systemic review and meta-analysis. Clinical rehabilitation 2016;30(1):24-35.
- 20. Chen K, Tan Y, Lu Y, et al. Effect of exercise on quality of life in Parkinson's disease: a systematic review and meta-analysis. Parkinson's Disease 2020 Jul 9;(3257623):Epub 2020
- **21.** Chiang CF, Lin MT, Hsiao MY, et al. Comparative Efficacy of Noninvasive Neurostimulation Therapies for Acute and Subacute Poststroke Dysphagia: A Systematic Review and Network Meta-analysis. Archives of Physical Medicine and Rehabilitation 2019;100(4):739-50.e4.
- **22.** Chung LH, Thilarajah S, Tan D. Effectiveness of resistance training on muscle strength and physical function in people with Parkinson's disease: A systematic review and meta-analysis. Movement Disorders 2013;28:S140-S41.
- 23. Cosentino C, Baccini M, Putzolu M, et al. Effectiveness of Physiotherapy on Freezing of Gait in Parkinson's Disease: A Systematic Review and Meta-Analyses. Movement Disorders 2020;35(4):523-36.
- **24.** Cramer H, Lauche R, Azizi H, et al. Yoga for multiple sclerosis: A systematic review and metaanalysis. PLoS ONE 2014;9(11).
- **25.** De Almeida PMD, Santo A, Dias B, et al. Hands-on physiotherapy interventions and stroke and International Classification of Functionality, Disability and Health outcomes: A systematic review. European Journal of Physiotherapy 2015;17(3):100-15.

- **26.** Denissen S, Staring W, Kunkel D, et al. Interventions for preventing falls in people after stroke. Cochrane Database of Systematic Reviews 2019(10).
- **27.** De Paz RH, Serrano-Munoz D, Perez-Nombela S, et al. Combining transcranial direct-current stimulation with gait training in patients with neurological disorders: A systematic review. Journal of NeuroEngineering and Rehabilitation 2019;16(1).
- **28.** de Sousa DG, Harvey LA, Dorsch S, et al. Interventions involving repetitive practice improve strength after stroke: a systematic review. Journal of physiotherapy 2018;64(4):210-21.
- **29.** Dieguez-Perez I, Leiros-Rodriguez R. Effectiveness of different application parameters of neuromuscular electrical stimulation for the treatment of dysphagia after a stroke: A systematic review. Journal of Clinical Medicine 2020;9(8):1-19.
- **30.** Dorsch S, Ada L, Alloggia D. Progressive resistance training increases strength after stroke but this may not carry over to activity: a systematic review. Journal of physiotherapy 2018;64(2):84-90.
- **31.** Doyle S, Bennett S, Fasoli SE, et al. Interventions for sensory impairment in the upper limb after stroke. Cochrane database of systematic reviews (Online) 2010;6:CD006331.
- **32.** Duncan PW, Sullivan KJ, Behrman AL, et al. Body-weight Supported treadmill rehabilitation after stroke. New England Journal of Medicine 2011;364(21):2026-36.
- **33.** Fernandez-Tenorio E, Serrano-Munoz D, Avendano-Coy J, et al. Transcutaneous electrical nerve stimulation for spasticity: A systematic review. Neurologia 2019;34(7):451-60.
- **34.** French B, Thomas L, Leathley M, et al. Does repetitive task training improve functional activity after stroke? A Cochrane systematic review and meta-analysis. Journal of rehabilitation medicine: official journal of the UEMS European Board of Physical and Rehabilitation Medicine 2010;42(1):9-14.
- **35.** Gandhi DBC, Sterba A, Khatter H, et al. Mirror therapy in stroke rehabilitation: Current perspectives. Therapeutics and Clinical Risk Management 2020;16:75-85.
- **36.** Garcia-Munoz C, Cortes-Vega MD, Heredia-Rizo AM, et al. Effectiveness of vestibular training for balance and dizziness rehabilitation in people with multiple sclerosis: A systematic review and meta-analysis. Journal of Clinical Medicine 2020;9(2).
- **37.** Garcia-Rudolph A, Sanchez-Pinsach D, Salleras EO, et al. Subacute stroke physical rehabilitation evidence in activities of daily living outcomes: A systematic review of meta-analyses of randomized controlled trials. Medicine 2019;98(8):e14501.
- **38.** Garrett M, Coote S. Multiple sclerosis and exercise in people with minimal gait impairment: a review. Physical Therapy Reviews 2009;14(3):169-80.

- **39.** Geeganage C, Beavan J, Ellender S, et al. Interventions for dysphagia and nutritional support in acute and subacute stroke. Cochrane database of systematic reviews (Online) 2012;10:CD000323.
- **40.** Gunn H, Markevics S, Haas B, et al. Systematic Review: The Effectiveness of Interventions to Reduce Falls and Improve Balance in Adults with Multiple Sclerosis. Archives of Physical Medicine and Rehabilitation 2015;96(10):1898-912.
- **41.** Hatem SM, Saussez G, della Faille M, et al. Rehabilitation of motor function after stroke: A multiple systematic review focused on techniques to stimulate upper extremity recovery. Frontiers in Human Neuroscience 2016;10
- **42.** Heine M, van de Port I, Rietberg MB, et al. Exercise therapy for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews 2015;2015(9).
- **43.** Hollands KL, Pelton TA, Tyson SF, et al. Interventions for coordination of walking following stroke: systematic review. Gait and Posture 2012;35(3):349-59.
- **44.** Hoyer E, Jahnsen R, Stanghelle JK, et al. Body weight supported treadmill training versus traditional training in patients dependent on walking assistance after stroke: a randomized controlled trial. Disability & Rehabilitation 2012;34(3):210-9.
- **45.** Hugues A, Marco JD, Ribault S, et al. Limited evidence of physical therapy on balance after stroke: A systematic review and meta-analysis. PLoS ONE 2019;14(8).
- **46.** Huntley A, Ernst E. Complementary and alternative therapies for treating multiple sclerosis symptoms: A systematic review. Complementary Therapies in Medicine 2000;8(2):97-105.
- **47.** Iyigun, Yildirim GA, Snowdon S. Is physiotherapy effective in improving balance and gait in patients with multiple sclerosis? A systematic review. Turkiye Klinikleri Journal of Medical Sciences 2010;30(2):482-93.
- **48.** Janssen S, Cotoi A, Mehta S, et al. The effects of transcutaneous electrical nerve stimulation (TENS) on post-stroke spasticity of the upper and lower limbs: A systematic review. International Journal of Stroke 2017;12:56.
- **49.** Khan F, Amatya B, Galea M. Management of fatigue in persons with multiple sclerosis. Frontiers in Neurology 2014;5
- **50.** Klamroth S, Steib S, Devan S, et al. Effects of Exercise Therapy on Postural Instability in Parkinson Disease: A Meta-analysis. Journal of neurologic physical therapy: JNPT 2016;40(1):3-14.

- **51.** Kwok JYY, Choi KC, Chan HYL. Effects of mind-body exercises on the physiological and psychosocial well-being of individuals with Parkinson's disease: A systematic review and meta-analysis. Complementary Therapies in Medicine 2016;29:121-31.
- **52.** Kwong PW, Ng GY, Chung RC, et al. Transcutaneous electrical nerve stimulation improves walking capacity and reduces spasticity in stroke survivors: a systematic review and meta-analysis. Clinical rehabilitation 2018;32(9):1203-19.
- **53.** Lecharte T, Gross R, Nordez A, et al. Effect of chronic stretching interventions on the mechanical properties of muscles in patients with stroke: A systematic review. Annals of Physical and Rehabilitation Medicine 2020;63(3):222-29.
- **54.** Lee J, Choi M, Yoo Y. A Meta-Analysis of Nonpharmacological Interventions for People With Parkinson's Disease. Clinical nursing research 2017;26(5):608-31.
- **55.** Li LX, Deng K, Qu Y. Acupuncture treatment for post-stroke dysphagia: an update meta-analysis of randomized controlled trials. Chinese Journal of Integrative Medicine 2018 Sep;24(9):686-695 2018.
- **56.** Li LX, Deng K, Qu Y. Acupuncture treatment for post-stroke dysphagia: an update meta-analysis of randomized controlled trials. Chinese Journal of Integrative Medicine 2018 Sep;24(9):686-695 2018.
- **57.** Lin IH, Tsai HT, Wang CY, et al. Effectiveness and Superiority of Rehabilitative Treatments in Enhancing Motor Recovery Within 6 Months Poststroke: A Systemic Review. Archives of Physical Medicine and Rehabilitation 2019;100(2):366-78.
- **58.** Lin S, Sun Q, Wang H, et al. Influence of transcutaneous electrical nerve stimulation on spasticity, balance, and walking speed in stroke patients: A systematic review and meta-analysis. Journal of rehabilitation medicine 2018;50(1):3-7.
- **59.** Lindley RI, Dean C, Ada L. Can treadmill training improve walking in the chronic phase of stroke? The AMBULATE Randomised Controlled Trial. Cerebrovascular Diseases 2012;33:61.
- **60.** Lopez-Liria R, Parra-Egeda J, Vega-Ramirez FA, et al. Treatment of dysphagia in parkinson's disease: A systematic review. International Journal of Environmental Research and Public Health 2020;17(11):1-13.
- **61.** Louie DR, Lim SB, Eng JJ. The Efficacy of Lower Extremity Mirror Therapy for Improving Balance, Gait, and Motor Function Poststroke: A Systematic Review and Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases 2019;28(1):107-20.
- **62.** Marchina S, Pisegna JM, Massaro JM, et al. Transcranial direct current stimulation for post-stroke dysphagia: a systematic review and meta-analysis of randomized controlled trials. Journal of Neurology 2020.

- **63.** Martin-Valero R, De La Casa Almeida M, Casuso-Holgado MJ, et al. Systematic review of inspiratory muscle training after cerebrovascular accident. Respiratory Care 2015;60(11):1652-59.
- **64.** Mehrholz J, Kugler J, Pohl M. Water-based exercises for improving activities of daily living after stroke. 2011;1:CD008186.
- **65.** Mehrholz J, Kugler J, Pohl M. Water-based exercises for improving activities of daily living after stroke. Cochrane database of systematic reviews (Online) 2011;1:CD008186.
- **66.** Meilink A, Hemmen B, Seelen HAM, et al. Impact of EMG-triggered neuromuscular stimulation of the wrist and finger extensors of the paretic hand after stroke: A systematic review of the literature. Clinical Rehabilitation 2008;22(4):291-305.
- **67.** Menezes KK, Nascimento LR, Ada L, et al. Respiratory muscle training increases respiratory muscle strength and reduces respiratory complications after stroke: a systematic review. Journal of physiotherapy 2016;62(3):138-44.
- **68.** Nadeau SE, Wu SS, Dobkin BH, et al. Effects of task-specific and impairment-based training compared with usual care on functional walking ability after inpatient stroke rehabilitation: LEAPS Trial. Neurorehabilitation & Neural Repair 2013;27(4):370-80.
- **69.** Nascimento LR, Flores LC, de Menezes KKP, et al. Water-based exercises for improving walking speed, balance, and strength after stroke: a systematic review with meta-analyses of randomized trials. Physiotherapy (United Kingdom) 2020;107:100-10.
- 70. Pilutti LA, Motl RW. Functional electrical stimulation cycling exercise for people with multiple sclerosis. Current Treatment Options in Neurology 2019 Nov;21(11):54 2019
- **71.** Pisegna JM, Kaneoka A, Pearson WG, Jr., et al. Effects of non-invasive brain stimulation on post-stroke dysphagia: A systematic review and meta-analysis of randomized controlled trials. Clinical Neurophysiology 2016;127(1):956-68.
- **72.** Pollock A, Farmer SE, Brady MC, et al. Interventions for improving upper limb function after stroke. Cochrane Database of Systematic Reviews 2014(11).
- 73. Pozuelo-Carrascosa DP, Carmona-Torres JM, Laredo-Aguillera JA, et al. Effectiveness of respiratory muscle training for pulmonary function and walking ability in patients with stroke: A systematic review with meta-analysis. International Journal of Environmental Research and Public Health 2020;17(15):1-22.
- **74.** Qureshi AR, Rana AQ, Malik SH, et al. Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology 2018;51(3):190-206.

- **75.** Radder DLM, Ligia Silva de Lima A, Domingos J, et al. Physiotherapy in Parkinson's Disease: A Meta-Analysis of Present Treatment Modalities. Neurorehabilitation and Neural Repair 2020.
- **76.** Rietberg MB, Brooks D, Uitdehaag BMJ, et al. Exercise therapy for multiple sclerosis. Cochrane Database of Systematic Reviews 2009.
- 77. Roche A, O'Laighin G, Coote S. Surface-applied functional electrical stimulation for orthotic and therapeutic treatment of drop-foot after stroke: a systematic review. Physical Therapy Reviews 2009;14(2):63-80.
- **78.** Salter K, Musovic A, Taylor NF. In the first 3 months after stroke is progressive resistance training safe and does it improve activity? A systematic review. Topics in Stroke Rehabilitation 2016;23(5):366-75.
- 79. Scutt P, Lee HS, Hamdy S, et al. Pharyngeal Electrical Stimulation for Treatment of Poststroke Dysphagia: Individual Patient Data Meta-Analysis of Randomised Controlled Trials. Stroke Research and Treatment 2015;2015.
- **80.** Shohani M, Kazemi F, Rahmati S, et al. The effect of yoga on the quality of life and fatigue in patients with multiple sclerosis: A systematic review and meta-analysis of randomized clinical trials. Complementary therapies in clinical practice 2020;39:101087.
- **81.** Stein C, Fritsch CG, Robinson C, et al. Effects of Electrical Stimulation in Spastic Muscles After Stroke: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Stroke; a journal of cerebral circulation 2015;46(8):2197-205.
- **82.** Thieme H, Morkisch N, Mehrholz J, et al. Mirror therapy for improving motor function after stroke. Cochrane Database of Systematic Reviews 2018(7).
- **83.** van Hooren MRA, Baijens LWJ, Voskuilen S, et al. Treatment effects for dysphagia in Parkinson's disease: A systematic review. Parkinsonism and Related Disorders 2014;20(8):800-07.
- **84.** Xiao Y, Luo M, Wang J, et al. Inspiratory muscle training for the recovery of function after stroke. Cochrane database of systematic reviews (Online) 2012;5:CD009360.
- **85.** Yitayeh A, Teshome A. The effectiveness of physiotherapy treatment on balance dysfunction and postural instability in persons with Parkinson's disease: A systematic review and meta-analysis. BMC Sports Science, Medicine and Rehabilitation 2016;8(1)

14.7 Others (could not be retrieved, other language, wrong publication type, old report version)

- Afentou, N., J. Jarl, U. G. Gerdtham and S. Saha (2019). "Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review." Movement Disorders Clinical Practice 6(4): 282-290
- 2. Amatya, B., F. Khan and M. Galea (2019). "Rehabilitation for people with multiple sclerosis: An overview of Cochrane Reviews." Cochrane Database of Systematic Reviews 2019(1).
- **3.** Amatya, B., M. P. Galea, J. Kesselring and F. Khan (2015). "Effectiveness of telerehabilitation interventions in persons with multiple sclerosis: A systematic review." Multiple Sclerosis and Related Disorders 4(4): 358-369.
- **4.** Arienti C, Lazzarini SG, Pollock A, et al. Rehabilitation interventions for improving balance following stroke: An overview of systematic reviews. PLoS ONE 2019;14(7).
- 5. Barros AFS, Santos SG, Medeiros GFR, et al. Analise de intervencoes fisioterapeuticas na qualidade de vida de pacientes Pos-AVC (Analysis of physical therapy interventions on quality of life of patients after stroke) [Portuguese]. Revista Neurociencias 2014;22(2):308-314 2014
- **6.** Bath PMW, Lee HS. Acute stroke management cochrane systematic review of interventions for dysphagia in acute stroke. International Journal of Stroke 2014;9:74.
- 7. Bernhardt J, Godecke E, Johnson L, et al. Early rehabilitation after stroke. Current Opinion in Neurology 2017;30(1):48-54.
- 8. Branas, P., R. Jordan, A. Fry-Smith, A. Burls and C. Hyde (2000). "Treatments for fatigue in multiple sclerosis: A rapid and systematic review." Health Technology Assessment 4(27): i-iv+1-52.
- 9. Canning, C. G., C. Sherrington, S. R. Lord, V. S. C. Fung, J. C. T. Close, M. D. Latt, K. Howard, N. E. Allen, S. D. O'Rourke and S. M. Murray (2009). "Exercise therapy for prevention of falls in people with Parkinson's disease: A protocol for a randomised controlled trial and economic evaluation." BMC Neurology 9.
- **10.** Capato TTC, Fen CH, Barbosa ER. Classification and recommendation of nonpharmacological therapies for Parkinson's disease. Movement Disorders 2016;31:S690.
- 11. Cascaes da Silva F, lop Rda R, Domingos Dos Santos P, et al. Effects of Physical-Exercise-Based Rehabilitation Programs on the Quality of Life of Patients With Parkinson's Disease: A Systematic Review of Randomized Controlled Trials. Journal of aging and physical activity 2016;24(3):484-96.

- **12.** Castellano-del Castillo MA, Lacasa-Andrade ME, Hijos-Bitrian E, et al. Efectividad de la rehabilitacion en la esclerosis multiple (Effectiveness of rehabilitation in multiple sclerosis) [Spanish]. Rehabilitacion [Rehabilitation] 2014 Jan-Mar;48(1):46-53 2014.
- **13.** Castelli E, Corbetta D. Mirror therapy for upper extremities recovery after stroke: a systematic review. Italian Journal of Physiotherapy 2011 Sep;1(3):80-86 2011.
- 14. Clarke CE, Moore AP. Parkinson's disease. Clinical Evidence 2007;1:01.
- **15.** Cola PC, Dantas RO, da Silva RG. Neuromuscular electrical stimulation in rehabilitation of neurogenic oropharyngeal dysphagia. Revista Neurociencias 2012;20(2):285-93.
- **16.** Cooke E, Mares K, Clark A, et al. Does providing more exercise-based therapy enhance motor recovery after stroke? A systematic review and meta-analysis. Archives of Physical Medicine and Rehabilitation 2010;91:e25-e26.
- 17. Costa Queiroz L, Parreiras de Menezes KK, Avelino PR. Efeitos do treino de equilibrio na velocidade de marcha, mobilidade e qualidade de vida de individuos pos acidente vascular encefalico (Effects of the balance training on walking speed, mobility and quality of life of stroke survivors) [Portuguese]. Fisioterapia Brasil [Physical Therapy Brazil] 2020;21(1):114-123 2020.
- **18.** Crocker T, Brown L, Hall J, et al. A systematic overview of Cochrane reviews of interventions feasible for stroke survivors and carers in the community beyond 6 months. International Journal of Stroke 2015;10:58.
- **19.** Da Silva R, Moore SA, Price CIM. A systematic review of self-directed therapy programmes for upper limb rehabilitation after stroke. International Journal of Stroke 2017;12:29.
- **20.** Danicic J, Williams K, Semciw A, et al. The efficacy of vestibular rehabilitation in people reporting dizziness with multiple sclerosis: A systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry 2017;88(5):e16.
- 21. Dowling, F. P., C. Rick, C. Sackley, N. Ives, S. Patel, G. L. Yao, K. Wheatley and C. E. Clarke (2012). "Parkinson's disease REHAB: Randomised controlled trial to study the effectiveness and cost-effectiveness of physiotherapy and occupational therapy for people with PD." Movement Disorders 27: S115.
- 22. Duyff R. Evidence for physical therapy after stroke. Nederlands Tijdschrift voor Geneeskunde 2014
- 23. Fernandez-Gomez E, Sanchez-Cabeza A. Imagineria motora: revision sistematica de su efectividad en la rehabilitacion de la extremidad superior tras un ictus (Motor imagery: a systematic review of its effectiveness in the rehabilitation of the upper limb following a stroke) [Spanish]. Revista de Neurologia 2018 Mar 1-15;66(5):137-146 2018.

- **24.** Fletcher, E., V. A. Goodwin, S. H. Richards, J. L. Campbell and R. S. Taylor (2013). "An exercise intervention to prevent falls in Parkinson's disease: An economic evaluation." Movement Disorders 28: S139.
- **25.** Freeman, J. A., W. Hendrie, S. Creanor, L. Jarrett, A. Barton, C. Green, J. Marsden, E. Rogers and J. Zajicek (2016). "Standing up in multiple sclerosis (SUMS): Protocol for a multi-centre randomised controlled trial evaluating the clinical and cost effectiveness of a home-based self-management standing frame programme in people with progressive multiple sclerosis." BMC Neurology 16(1).
- **26.** French B, Thomas LH, Leathley MJ, et al. Repetitive task training for improving functional ability after stroke. Cochrane Database of Systematic Reviews 2007
- 27. French, B., M. Leathley, C. Sutton, J. McAdam, L. Thomas, A. Forster, P. Langhorne, C. Price, A. Walker and C. Watkins (2008). "A systematic review of repetitive functional task practice with modelling of resource use, costs and effectiveness." Health Technology Assessment (Winchester, England) 12(30): iii, ix-x, 1-117.
- **28.** Geeganage C, Beavan J, Bath PMW. Interventions for dysphagia after stroke: A Cochrane systematic review. International Journal of Stroke 2012;7:40.
- **29.** Gelaw AY, Teshome A. The effectiveness of physiotherapy treatment on balance dysfunction and postural instability in persons with Parkinson's disease: A systematic review and meta-analysis. Journal of the Neurological Sciences 2017;381:597-98.
- **30.** Gomes Neto M, Pontes SS, Almeida LO, et al. Effects of water-based exercise on functioning and quality of life in people with Parkinson's disease: a systematic review and meta-analysis. Clinical rehabilitation 2020:269215520943660.
- **31.** Gopaul U, Van Vliet P. Progressive resistance training improves muscle strength of paretic lower limb in chronic stroke patients: A systematic review. Physiotherapy (United Kingdom) 2015;101:eS465-eS66.
- **32.** Gross T, Wells C, Vincent M. Does pilates exercise improve balance and walking in people with multiple sclerosis? A systematic review. Archives of Physical Medicine and Rehabilitation 2016;97:e39.
- **33.** Hamdy S, Bath P, Scutt P. Electrical pharyngeal stimulation for post stroke dysphagia: A metaanalysis of individual patient data from randomised controlled trials. International Journal of Stroke 2014;9:22.

- **34.** Han C, Zhao C, Wang X, et al. (A network meta-analysis of the effect of 13 interventions on dysphagia in stroke patients) [Chinese simplified characters]. Huli Yanjiu [Chinese Nursing Research] 2020 Jun;34(11):1869-1877 2020.
- **35.** Hayward, K. S., S. F. Kramer, V. Thijs, J. Ratcliffe, N. S. Ward, L. Churilov, L. Jolliffe, D. Corbett, G. Cloud, T. Kaffenberger, A. Brodtmann, J. Bernhardt and N. A. Lannin (2019). "A systematic review protocol of timing, efficacy and cost effectiveness of upper limb therapy for motor recovery post-stroke." Systematic Reviews 8(1).
- **36.** Kalron A, Zeilig G. Efficacy of exercise intervention programs on cognition in people suffering from multiple sclerosis, stroke and Parkinson's disease: A systematic review and meta-analysis of current evidence. NeuroRehabilitation 2015;37(2):273-89.
- **37.** Khan, F. and B. Amatya (2017). "Rehabilitation in Multiple Sclerosis: A Systematic Review of Systematic Reviews." Archives of Physical Medicine and Rehabilitation 98(2): 353-367.
- **38.** Kohler M, Mayer H, Battocletti M, et al. Effectiveness of non-pharmacological interventions to promote urinary continence in stroke survivors a systematic literature review. Pflege 2016;29(5):235-45
- 39. Koolstra M, Veerbeek JM, van Wegen EE, et al. Het effect van additionele oefentherapie op het lopen en aan lopen gerelateerde activiteiten in de eerste 6 maanden na een beroerte; een meta-analyse (Effects of augmented exercise therapy on outcome of gait and gait-related activities in the first six months after stroke: a meta-analysis) [Dutch]. Nederlands Tijdschrift voor Fysiotherapie [Dutch Journal of Physical Therapy] 2012 Oct;122(3):116-122 2012.
- **40.** Kwakkel, G., C. J. T. de Goede and E. E. H. van Wegen (2007). "Impact of physical therapy for Parkinson's disease: A critical review of the literature." Parkinsonism and Related Disorders 13: S478-S487.
- **41.** Lee H, Bath P. Cochrane systematic review of interventions for dysphagia in acute stroke. International Journal of Stroke 2014;9:22.
- **42.** Legg, L. (2004). "Rehabilitation therapy services for stroke patients living at home: Systematic review of randomised trials." Lancet 363(9406): 352-356.
- 43. Leistner, S., G. Michelson, I. Laumeier, M. Ahmadi, M. Smyth, G. Nieweler, W. Doehner, J. Sobesky, J. B. Fiebach, P. Marx, O. Busse, F. Kohler, H. Poppert, M. L. J. Wimmer, T. Knoll, P. Von Weitzel-Mudersbach and H. J. Audebert (2013). "Intensified secondary prevention intending a reduction of recurrent events in TIA and minor stroke patients (INSPiRE-TMS): A protocol for a randomised controlled trial." BMC Neurology 13.

- **44.** Liepert J. Evidence-based methods in motor rehabilitation after stroke. [German]. Fortschritte der Neurologie Psychiatrie 2012;80(7):388-93.
- **45.** Lin YH, Lien YS, Tsai CY, et al. Effect of dual-task training on gait speed in individuals with stroke-a systematic review and meta analysis. Cerebrovascular Diseases 2017;43:81-82.
- **46.** Lindsay MP, Foley N, Green T, et al. Post-stroke fatigue: An under-diagnosed effect of stroke with a large impact on recovery. Cerebrovascular Diseases 2014;37:433.
- **47.** Lisa LP, Jughters A, Kerckhofs E. The effectiveness of different treatment modalities for the rehabilitation of unilateral neglect in stroke patients: A systematic review. NeuroRehabilitation 2013;33(4):611-20.
- **48.** Lloyd, M., D. A. Skelton, G. E. Mead, B. Williams and F. van Wijck (2018). "Physical fitness interventions for nonambulatory stroke survivors: A mixed-methods systematic review and meta-analysis." Brain and Behavior 8(7).
- **49.** Lo, K., M. Stephenson and C. Lockwood (2019). "The economic cost of robotic rehabilitation for adult stroke patients: A systematic review." JBI Database of Systematic Reviews and Implementation Reports 17(4): 520-547.
- **50.** Mahmood A, Kumar S, Solomon MJ, et al. Effect of transcutaneous electrical nerve stimulation (TENS) on spasticity in adults with stroke: A systematic review and metaanalysis. International Journal of Stroke 2016;11:158.
- 51. Markle-Reid, M., R. Valaitis, A. Bartholomew, K. Fisher, R. Fleck, J. Ploeg and J. Salerno (2020).
 "An integrated hospital-to-home transitional care intervention for older adults with stroke and multimorbidity: A feasibility study." Journal of Comorbidity 10: 2235042X19900451.
- **52.** Marquez J, Chambers L. Rehabilitative benefits of hippotherapy in adults with stroke: A systematic review. European Stroke Journal 2016;1:565-66.
- **53.** Marsden DL, Dunn A, Callister R, et al. Exercise training interventions that are aerobic or include an aerobic component can improve cardiorespiratory fitness after stroke: A systematic review with meta-analysis. Cerebrovascular Diseases 2013;35:820.
- **54.** Marsden DL, Dunn A, Callister R, et al. Improving cardiorespiratory fitness after stroke by using exercise interventions that are aerobic or include an aerobic component: A systematic review with meta-analysis. International Journal of Stroke 2013;8:12.
- **55.** Miller KJ, Suarez-Iglesias D, Seijo-Martinez M, et al. Fisioterapia para la congelacion de la marcha en la enfermedad de Parkinson: revision sistematica y metaanalisis (Physiotherapy for freezing of

- gait in Parkinson's disease: a systematic review and meta-analysis) [Spanish]. Revista de Neurologia 2020 Mar 1-15;70(5):161-170 2020.
- **56.** Miller KJ, Suarez-Iglesias D, Seijo-Martinez M, et al. Physiotherapy for freezing of gait in Parkinson's disease: A systematic review and meta-analysis. Revista de Neurologia 2019;70(4):161-69.
- **57.** Monte-Silva K, Piscitelli D, Norouzi-Gheidari N, et al. Electromyogram-Related Neuromuscular Electrical Stimulation for Restoring Wrist and Hand Movement in Poststroke Hemiplegia: A Systematic Review and Meta-Analysis. Neurorehabilitation and Neural Repair 2019;33(2):96-111.
- **58.** Mulla SM, Wang L, Khokhar R, et al. Management of central poststroke pain: systematic review of randomized controlled trials. Stroke 2015 Oct;46(10):2853-2860 2015.
- **59.** Nicholas R, Chataway J. Multiple sclerosis. Clinical Evidence 2007;15:15.
- **60.** Norouzi-Gheidari, N., P. S. Archambault and J. Fung (2012). "Effects of robot-assisted therapy on stroke rehabilitation in upper limbs: Systematic review and meta-analysis of the literature." Journal of Rehabilitation Research and Development 49(4): 479-496.
- **61.** Parry, A., M. Deverill and K. Ricci (1997). "Evaluation of a therapist-led community-based stroke service: Economic considerations." Physiotherapy 83(7): 351.
- **62.** Pereira S, Foley N, Lobo L, et al. Neuromuscular electrical stimulation (NMES) in chronic stroke: A systematic review of upper extremity outcomes. Archives of Physical Medicine and Rehabilitation 2012;93:E35.
- **63.** Peters, C., M. Currin, S. Tyson, A. Rogers, S. Healy, S. McPhail, S. G. Brauer, K. Heathcote and T. Comans (2012). "A randomized controlled trial of an enhanced interdisciplinary community based group program for people with Parkinson's disease: study rationale and protocol." Neurology International 4(1): e3.
- **64.** Polese JC, Ada L, Dean CM, et al. Treadmill training is effective for ambulatory adults with stroke: A systematic review. Journal of Physiotherapy 2013;59(2):73-80.
- **65.** Pollock A, Baer G, Campbell P, et al. Physical rehabilitation approaches for the recovery of function and mobility following stroke. Cochrane Database of Systematic Reviews 2014;2014(4).
- **66.** Pollock A, Campbell P, Morris J, et al. Physiotherapy treatment approaches following stroke: Major update of Cochrane systematic review of evidence. International Journal of Stroke 2013;8:67.
- **67.** Pollock A, Gray C, Culham E, et al. Interventions for improving sit-to-stand ability following stroke. Cochrane Database of Systematic Reviews 2014;2014(5)

- **68.** Pollock R, Rafferty G, Moxham J, et al. A systematic review of respiratory muscle training in stroke and neurological diseases. Stroke Conference 2012;43(2).
- **69.** Pritchard MO, Laster JV, Rogers LJ, et al. The effects of aquatic therapy on gait, balance, and quality of life in patients with Parkinson's disease. Journal of Aquatic Physical Therapy 2019 Winter;27(2):10-24 2019.
- **70.** Radder D, De Vries N, Faber M, et al. Treadmill training, tai chi, dance and more: A meta-analysis on the effectiveness of different physiotherapy modalities in Parkinson's disease. Movement Disorders 2017;32:461.
- **71.** Raluy-Callado, M., A. Cox, S. MacLachlan, A. M. Bakheit, A. P. Moore, J. Dinet and S. Gabriel (2018). "A retrospective study to assess resource utilization and costs in patients with post-stroke spasticity in the United Kingdom." Current Medical Research and Opinion 34(7): 1317-1324.
- 72. Ramos-Valero L, Meseguer-Henarejos AB. Tratamientos fisioterapicos para pacientes con hombro doloroso tras un accidente cerebrovascular. Revision sistematica (Physiotherapy treatments for patients with shoulder pain after stroke. A systematic review) [Spanish]. Fisioterapia 2013 Sep-Oct;35(5):214-223 2013.
- **73.** Rick, C., C. Clarke, C. Sackley, M. Walker, N. Ives, P. Smitaa, M. Charmaine, Y. Guiqing and W. Keith (2010). "PD REHAB: Randomized controlled trial to study the effectiveness and cost-effectiveness of physiotherapy and Occupational therapy for people with PD." Movement Disorders 25: S717.
- **74.** Sa MJ. Exercise therapy and multiple sclerosis: a systematic review. Journal of Neurology 2013:1-11.
- **75.** Sackley C, Patel S, Natalie I, et al. Systematic overview of randomised trials of physiotherapy in parkinson's disease. Physiotherapy (United Kingdom) 2011;97:eS1080.
- **76.** Saltychev M, Barlund E, Paltamaa J, et al. Progressive resistance training in Parkinson's disease: A systematic review and meta-analysis. BMJ Open 2016;6(1)
- 77. Schroder, J., T. van Criekinge, E. Embrechts, X. Celis, J. Van Schuppen, S. Truijen and W. Saeys (2019). "Combining the benefits of tele-rehabilitation and virtual reality-based balance training: a systematic review on feasibility and effectiveness." Disability and rehabilitation(1): 2-11.
- 78. Simpson, K. N., A. N. Simpson, P. D. Mauldin, Y. Y. Palesch, S. D. Yeatts, D. Kleindorfer, T. A. Tomsick, L. D. Foster, A. M. Demchuk, P. Khatri, M. D. Hill, E. C. Jauch, T. G. Jovin, B. Yan, R. Kummer, C. A. Molina, M. Goyal, W. J. Schonewille, M. Mazighi, S. T. Engelter, C. Anderson, J. Spilker, J. Carrozzella, K. J. Ryckborst, L. S. Janis and J. P. Broderick (2017). "Observed cost and

- variations in short term cost-effectiveness of therapy for ischemic stroke in Interventional Management of Stroke (IMS) III." Journal of the American Heart Association 6(5).
- **79.** Sorinola IO, Fergusson M, Skevington-Postles L. The effect of rehabilitation interventions on long term upper limb function in chronic stroke patients: A meta-analysis. Physiotherapy 2016;102:e23-e24.
- **80.** Thieme H, Mehrholz J, Pohl M, et al. Mirror Therapy for improving motor function after stroke-a systematic review carried out using Cochrane methodology. Neurorehabilitation and Neural Repair 2012;26:434.
- **81.** Thomas LH, Barrett J, Cross S, et al. Prevention and treatment of urinary incontinence after stroke in adults. Stroke 2006;37(3):929-30.
- **82.** Thomas LH, Coupe J, Cross LD, et al. Interventions for treating urinary incontinence after stroke in adults (Cochrane review) [with consumer summary]. Cochrane Database of Systematic Reviews 2019;Issue 2 2019.
- **83.** Thrane G, Friborg O, Anke A, et al. A meta-analysis of constraint-induced movement therapy after stroke. Journal of rehabilitation medicine 2014;46(9):833-42.
- **84.** Tillman A, Muthalib M, Hendy AM, et al. Lower limb progressive resistance training improves leg strength but not gait speed or balance in Parkinson's disease: A systematic review and meta-analysis. Frontiers in Aging Neuroscience 2015;7.
- **85.** Tillman A, Muthalib M, Hendy AM, et al. Lower limb progressive resistance training improves leg strength but not gait speed or balance in Parkinson's disease: A systematic review and meta-analysis. 2015;7.
- **86.** Tomlinson CL, Patel S, Meek C, et al. Physiotherapy intervention in Parkinson's disease: Systematic review and meta-analysis. BMJ (Online) 2012;345(7872).
- Tomlinson, C. L., C. P. Herd, C. E. Clarke, C. Meek, S. Patel, R. Stowe, K. H. O. Deane, L. Shah,
 M. Sackley, K. Wheatley and N. Ives (2014). "Physiotherapy for parkinson's disease: A comparison of techniques." Cochrane Database of Systematic Reviews 2014(6): 1-119.
- **88.** Veerbeek, J. M., E. van Wegen, R. van Peppen, P. J. van der Wees, E. Hendriks, M. Rietberg and G. Kwakkel (2014). "What Is the Evidence for Physical Therapy Poststroke? A Systematic Review and Meta-Analysis.(Research Article)." PLoS ONE 9(2): e87987.
- **89.** Vloothuis JDM, Mulder M, Veerbeek JM, et al. Caregiver-mediated exercises for improving outcomes after stroke (Cochrane review) [with consumer summary]. Cochrane Database of Systematic Reviews 2016;Issue 12 2016.

- **90.** Wang LP, Xie Y. (Systematic evaluation on acupuncture and moxibustion for treatment of dysphagia after stroke) [Chinese simplified characters]. Zhongguo Zhen Jiu [Chinese Acupuncture & Moxibustion] 2006 Feb;26(2):141-146 2006.
- **91.** Wang QS, Liu Y, Zou XN, et al. Evaluating the Efficacy of Massage Intervention for the Treatment of Poststroke Constipation: A Meta-Analysis. 2020;2020.
- **92.** Wang QS, Liu Y, Zou XN, et al. Evaluating the Efficacy of Massage Intervention for the Treatment of Poststroke Constipation: A Meta-Analysis. Evidence-based Complementary and Alternative Medicine 2020;2020
- 93. Watts, J. J., J. L. McGinley, F. Huxham, H. B. Menz, R. Iansek, A. T. Murphy, E. R. Waller and M. E. Morris (2008). "Cost effectiveness of preventing falls and improving mobility in people with Parkinson disease: Protocol for an economic evaluation alongside a clinical trial." BMC Geriatrics 8.
- **94.** Widen Holmqvist, L., L. Von Koch, V. Kostulas, M. Holm, G. Widsell, H. Tegler, K. Johansson, J. Almazan and J. De Pedro-Cuesta (1998). "A randomized controlled trial of rehabilitation at home after stroke in southwest Stockholm." Stroke 29(3): 591-597.
- **95.** Winser, S. J., L. F. Paul, L. K. L. Magnus, S. Yan, T. P. Shenug, Y. M. Sing and G. Cheing (2019). "Economic evaluation of exercise-based fall prevention programs for people with Parkinson's disease: A systematic review." Journal of Alternative and Complementary Medicine 25(12): 1225-1237.
- **96.** Winser, S., S. H. Lee, H. S. Law, H. Y. Leung, U. M. Bello and P. Kannan (2020). "Economic evaluations of physiotherapy interventions for neurological disorders: a systematic review." Disability and rehabilitation 42(7): 892-901.
- **97.** Wong-Yu ISK, Mak MKY. Long-term effects of the hopeful outdoor Parkinson's exercise (HOPE) program on enhancing the dynamic balance and gait performance in people with Parkinson's disease. Movement Disorders 2014;29:S274-S75.
- **98.** Wynne D, Rickhart E, Cooper K. Investigating adherence and quality of life in relation to group based exercise among individuals with multiple sclerosis: A systematic review. Physiotherapy (United Kingdom) 2017;103:e50-e51.
- **99.** Zhang, Q., M. Schwade, Y. Smith, R. Wood and L. Young (2020). "Exercise-based interventions for post-stroke social participation: A systematic review and network meta-analysis." International journal of nursing studies 111: 103738.

100. Zhong X, Liu X, Wang J, et al. Effects of core muscles group training on balance and walking function in patients with stroke:a systematic review. Huli Yanjiu [Chinese Nursing Research] 2019 Dec;33(24):4221-4226 2019.